MEDICAL INTELLIGENCE UNIT 31
Gary L. Buchschacher, Jr.
Lentiviral Vector Systems for Gene Transfer
MEDICAL INTELLIGE...
109 downloads
1181 Views
2MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
MEDICAL INTELLIGENCE UNIT 31
Gary L. Buchschacher, Jr.
Lentiviral Vector Systems for Gene Transfer
MEDICAL INTELLIGENCE UNIT 31
Lentiviral Vector Systems for Gene Transfer Gary L. Buchschacher, Jr., M.D., Ph.D. Division of Hematology/Oncology Department of Medicine University of California-San Diego La Jolla, California, U.S.A.
EUREKAH.COM GEORGETOWN, TEXAS U.S.A.
LENTIVIRAL VECTOR SYSTEMS FOR GENE TRANSFER Medical Intelligence Unit 31 Eurekah.com Landes Bioscience Designed by Jesse Kelly-Landes Georgetown, Texas, U.S.A. Copyright ©2003 Eurekah.com All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Printed in the U.S.A. Please address all inquiries to the Publishers: Eurekah.com / Landes Bioscience, 810 South Church Street, Georgetown, Texas, U.S.A. 78626 Phone: 512/ 863 7762; FAX: 512/ 863 0081 ISBN: 1-58706-094-9 While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.
Library of Congress Cataloging-in-Publication Data Lentiviral vector systems for gene transfer / [edited by] Gary L. Buchschacher, Jr. p. ; cm. -- (Medical intelligence unit ; 31) Includes bibliographical references and index. ISBN 1-58706-094-9 (hardcover) -- ISBN 1-58076-095-7 (softcover) 1. Genetic vectors. 2. Lentiviruses. 3. Genetic transformation. [DNLM: 1. Gene Transfer Techniques. 2. Gene Therapy. 3. Genetic Vectors. 4. Lentivirus. QZ 50 L574 2001] I. Buchschacher, Gary L. II. Series. QH442.2 .L46 2001 571.9'648--dc21
in memoria di mia nonna Elisabetta Michelotti Mattaini n. 11 aprile 1902 Fiano, Italia m. 7 agosto 2000 Bessemer, Michigan e mio nonno Pietro Luigi Mattaini n. 23 luglio 1897 Sesona di Vergiate, Italia m. 17 giugno 1976 Bessemer, Michigan
—GB
CONTENTS Preface ................................................................................................. vii 1. Introduction to Retroviruses and Retroviral Vectors .............................. 1 Gary L. Buchschacher, Jr. Abstract ....................................................................................................... 1 Introduction ................................................................................................ 1 General Background and Classification of Retroviruses ................................ 1 The Retrovirus Genome and Virion Structure ............................................. 2 The Retrovirus Replication Cycle ................................................................ 3 Elements of Retroviral Vector Systems ......................................................... 6 Summary ..................................................................................................... 9 Acknowledgements .................................................................................... 10
2. HIV-1 Replication................................................................................ 13 Eric O. Freed Introduction .............................................................................................. 13 The HIV-1 Replication Cycle .................................................................... 14 Role of the HIV Accessory Proteins in Virus Replication ........................... 28 Concluding Remarks ................................................................................. 30
3. Determinants for Lentiviral Infection of Non-Dividing Cells ............... 35 Marie A. Vodicka Abstract ..................................................................................................... 35 Introduction .............................................................................................. 35 Nuclear Transport ..................................................................................... 36 Transit of Non-Retroviral Particles ............................................................ 36 Retroviral Preintegration Complexes .......................................................... 39 Assays for Infection of Non-Dividing Cells ................................................ 40 Viral Protein Determinants for HIV-1 Infection of Non-Dividing Cells ........................................................................... 40 Viral Genome Structural Determinants ..................................................... 43 Cellular Transport Pathways and the Cytoskeleton .................................... 45 Summary and Conclusions ........................................................................ 45
4. HIV-1 Vector Systems .......................................................................... 51 Narasimhachar Srinivasakumar Abstract ..................................................................................................... 51 Introduction .............................................................................................. 51 HIV-1 Vector System Development .......................................................... 53 Clinical Applications of HIV-1 Vectors ..................................................... 68 Anticipated Developments in HIV-1 Based Packaging Systems and Possible Confounding Factors ......................................................... 69 Conclusions ............................................................................................... 72 Acknowledgements .................................................................................... 72
5. HIV-2 and SIV Vector Systems ............................................................ 83 James R. Gilbert and Flossie Wong-Staal Abstract ..................................................................................................... 83
Introduction .............................................................................................. 83 Classification and Distribution .................................................................. 84 Pathology and Viral Replication ................................................................ 85 Genome Organization and Regulation ....................................................... 87 Vector Systems .......................................................................................... 91 Requiem and Prospectus ............................................................................ 94
6. FIV Vector Systems .............................................................................. 99 Sybille L. Sauter and Mehdi Gasmi Abstract ..................................................................................................... 99 Epidemiology and Pathogenesis of FIV Infection ....................................... 99 Development of FIV-Based Vectors ......................................................... 107 Acknowledgements .................................................................................. 118
7. EIAV, CAEV and Other Lentivirus Vector Systems ........................... 131 John C. Olsen Abstract ................................................................................................... 131 Introduction ............................................................................................ 131 Biological Similarities and Differences of Lentiviruses .............................. 131 Recent Vector Developments ................................................................... 134
8. Safety Considerations in Vector Development ................................... 147 John C. Kappes and Xiaoyun Wu Abstract ................................................................................................... 147 Introduction ............................................................................................ 147 Current Safety Design ............................................................................. 149 Advancing Lentiviral Vectors Toward the Clinic ..................................... 154
9. Prospects for Gene Therapy Using HIV-Based Vectors ...................... 159 Jiing-Kuan Yee and John A. Zaia Abstract ................................................................................................... 159 Advantages of HIV Vectors Support Development .................................. 159 Attempts to Engineer Biosafety into HIV Vectors.................................... 160 Potential Clinical Applications of HIV Vectors........................................ 163 Regulatory Issues ..................................................................................... 166 Acknowledgements .................................................................................. 168
10. Ethical Considerations in the Use of Lentiviral Vectors for Genetic Transfer ........................................................................... 175 Ina Roy Abstract ................................................................................................... 175 Introduction ............................................................................................ 175 Gene Therapy: Potentially Problematic Types of Application .................. 176 General Ethical Considerations: Research and Clinical Settings ............... 182 Summary ................................................................................................. 190
Index .................................................................................................. 193
EDITOR Gary L. Buchschacher, Jr., M.D., Ph.D. Division of Hematology/Oncology Department of Medicine University of California-San Diego La Jolla, California, U.S.A. Chapter 1
CONTRIBUTORS Eric O. Freed Laboratory of Molecular Microbiology NIAID, NIH Bethesda, Maryland, U.S.A Chapter 2 Mehdi Gasmi University of California-San Diego La Jolla, California, U.S.A. Chapter 6 James R. Gilbert University of California-San Diego La Jolla, California, U.S.A. Chapter 5 John C. Kappes Department of Medicine University of Alabama at Birmingham Birmingham, Alabama, U.S.A. Chapter 8 John C. Olsen Cystic Fibrosis/Pulmonary Research and Treatment Center University of North Carolina Chapel Hill, North Carolina, U.S.A. Chapter 7 Ina Roy Center for Bioethics University of Pennsylvania Philadelphia, Pennsylvania, U.S.A. Chapter 10 Sybille L. Sauter GenStar Therapeutics San Diego, California, U.S.A. Chapter 6
Narasimhachar Srinivasakumar Division of Hematology/Oncology Department of Medicine Vanderbilt University Nashville, Tennessee, U.S.A. Chapter 4 Marie A. Vodicka Human Biology Fred Hutchinson Cancer Research Center Seattle, Washington, U.S.A. Chapter 3 Flossie Wong-Staal University of California-San Diego La Jolla, California, U.S.A. Chapter 5 Xiaoyun Wu Department of Medicine University of Alabama at Birmingham Birmingham, Alabama, U.S.A. Chapter 8 Jiing-Kuan Yee Department of Virology Beckman Research Institute City of Hope Duarte, California, U.S.A. Chapter 9 John A. Zaia Department of Virology Beckman Research Institute City of Hope Duarte, California, U.S.A. Chapter 9
PREFACE
T
his volume is designed to summarize recent progress in the development of lentiviral vectors for in vitro gene transfer studies and for subsequent animal and human clinical studies. Although lentiviral vector systems may offer some advantage over previously studied viral vector systems for use in potential gene therapy applications, such vectors also present technological hurdles that must be overcome and raise unique concerns that must be addressed as the vector systems are developed and potentially applied to clinical gene transfer studies. Applied gene transfer studies using viral vector systems are being undertaken by more and more people. For this reason, the first chapter presented here is designed to assist those interested primarily in the application of lentiviral vectors for gene transfer, but who may lack a background in basic retrovirology, by presenting some general information about retroviral replication and retroviral vector systems that will provide a basis for the topics that are discussed in detail in the remainder of the book. The final section of this book, discussing ethical considerations relevant to lentiviral vector systems, is important for those studying either vector development or potential clinical gene transfer applications; it is recommended that this chapter be read first, so that topics discussed in other chapters can be thought of with these ethical considerations in mind. Because the various lentiviruses share many features of replication and because human immunodeficiency virus type 1 (HIV-1) is the most thoroughly studied of the lentiviruses, one chapter is devoted to a discussion of HIV-1 replication. The following chapter discusses in detail the feature that makes lentiviral vectors attractive as gene transfer vehicles—the ability of lentiviruses to efficiently infect non-dividing cells. Subsequent chapters discuss progress in development of vector systems based on a variety of lentiviruses—HIV-1, HIV-2, SIV, FIV, EIAV and so on. Potential approaches to and issues regarding some clinical applications of the vector systems are then presented, along with discussions dealing with various safety issues that are raised when developing and considering these systems for clinical use. It is hoped that the contents of the book will leave readers, either those involved in the study of basic virology or vector system development or those involved in gene transfer applications, with an understanding of both the current status of lentiviral vector technology and the issues which must be addressed as these systems are further developed and used. Clearly, regardless of how the various vector systems eventually might or might not be used for clinical applications, the value of study of the vector systems is evident by the amount of information on the basic science of viral replication, cell biology and gene transfer that continues to be obtained. Gary L. Buchschacher, Jr., M.D., Ph.D.
CHAPTER 1
Introduction to Retroviruses and Retroviral Vectors Gary L. Buchschacher, Jr.
Abstract
A
s various viral vector systems for gene transfer are developed, interest in using such systems in applied settings continues to grow. This Chapter is designed to provide background information for readers interested in learning about lentiviral vector systems for gene transfer applications but who lack a background in retrovirology. To assist those readers who are unfamiliar with retroviral vector systems, basic outlines of the retroviral replication cycle and of characteristics of retroviral vector systems are introduced here in order to present and define concepts and terms that are discussed in subsequent Chapters.
Introduction The development of vector systems derived from the lentivirus genus of retroviruses has potential for possible clinical gene transfer applications.1 Retroviral vector systems used previously in gene transfer applications have been derived from the oncogenic retrovirus genus. The oncoretroviruses, sometimes (though not necessarily correctly) referred to as “simpler” retroviruses in comparison to lentiviruses, had been studied for years and knowledge gained from those studies enabled development of vector systems based on the parent viruses. The concepts governing development of oncoretrovirus-derived vector systems also guide the development of lentiviral vector systems. Therefore, an understanding of the retroviral replication cycle and of the basic features of retroviral vector systems based on oncogenic retroviruses is necessary in order to fully understand the complexities and issues associated with the development of lentiviral vector systems discussed later in this book. In this first Chapter, the retroviral replication cycle and concepts related to development of retroviral vector systems are outlined. Since a comprehensive review of the various retroviruses and vectors derived from them is obviously beyond the scope of this section, the information presented will describe generic features shared by retroviruses and vector systems in general, rather than focus on one or more particular viruses. Readers who are familiar with these concepts are advised to skip this introductory Chapter and to move on to Chapter 2.
General Background and Classification of Retroviruses Retroviruses are single-stranded RNA viruses that replicate through a double-stranded DNA intermediate.2 Various retroviruses have been found that infect a number of organisms, including humans and many other mammals. The earliest retroviruses studied were isolated from mice and birds. Examples of such retroviruses include murine leukemia virus (MLV) and Lentiviral Vector Systems for Gene Transfer, edited by Gary L. Buchschacher, Jr. ©2003 Eurekah.com.
2
Lentiviral Vector Systems for Gene Transfer
mouse mammary tumor virus (MMTV), and the avian pathogens Rous sarcoma virus (RSV), spleen necrosis virus (SNV), and avian leukosis virus (ALV). These viruses were discovered and were of interest because of their association with the development of tumors in their host organisms. Study of these viruses eventually led to the discovery and development of the oncogene theory of tumorigenesis: some of the viruses actually contained oncogenes within their genomes, while others interacted with oncogenes in either a direct or indirect way to contribute to tumor formation.3,4 Over time, other retroviruses that had in common with the previously isolated viruses many features of their genome organization and overall replication strategy were discovered. Historically, because of their pattern of pathogenicity, these viruses were grouped into three subfamilies: 1) the acutely oncogenic retroviruses, or oncoretroviruses (such as those described above); 2) the lentiviruses (associated with “slow” diseases or those with long latent periods); 3) the spumaviruses (“foamy” viruses, named because of the pathogenic changes observed in infected cells). Viruses were also grouped (Types A-D) according to the electron microscopic appearance of their nucleocapsid structures.5 Further study of these viruses enabled detailed comparison of their genome structures and nucleic acid sequences, which resulted in a further refinement of the retrovirus classification system.6 This led to a revised classification of the Retroviridae family into seven genera: mammalian type B retroviruses, mammalian type C retroviruses, avian type C retroviruses, mammalian type D retroviruses, HTLV/BLV type retroviruses, lentiviruses, and spumaviruses. The remainder of this Chapter will focus on describing general features of the retrovirus replication cycle and retroviral vector systems, focusing on “simple” oncoretroviruses. Although vector systems derived from MLV are the most commonly used retroviral-based systems in gene transfer applications, this discussion will not focus on MLV per se, but will describe prototypical features characteristic of the retroviruses in general.
The Retrovirus Genome and Virion Structure Genome Structure The retrovirus genome contained within viral particles consists of two identical singlestranded RNA molecules (for this reason, retroviruses are referred to as being “pseudodiploid”) of positive polarity that are replicated through a double-stranded DNA intermediate (reviewed in refs. 7, 8). The organization of the RNA and DNA forms of the genome are shown in Figure 1. The 5’ end of the genomic RNA begins with the “r” (for repeat) and “u5” (for unique 5’ region) segments, followed by the viral genes gag, pol, and env. The 3’ end of the genomic RNA terminates with the u3 (for unique 3’ region) and r (identical to the 5’ r region) regions and a polyA tail. Following reverse transcription of the RNA genome into a double-stranded DNA molecule, the DNA form of the viral genome is integrated into the host cell chromosomal DNA, where it is thereafter referred to as a “provirus.” Because of the mechanism used for reading and utilizing the viral RNA template during reverse transcription,8-10 the u3 and u5 regions are duplicated such that the 5’ and 3’ ends of the proviral genome differ in structure from the ends of the RNA genome (Fig. 1). Each end of the proviral genome is made up of regions called long terminal repeats (LTRs) which contain the proviral U3, R, and U5 regions. This rearrangement of both termini of the viral genome enables appropriate expression of the viral genes. The U3 region of the 5’ LTR (copied from the u3 region at the 3’ end of the RNA genome) contains the viral promoter and enhancers responsible for initiation of transcription of the viral genome at the 5’ U3/R junction. The viral gag and pol genes are expressed from an unspliced transcript while the env gene is expressed from a spliced transcript (the splice donor is located between the 3’ end of the 5’ LTR and the 5’ end of the gag gene, with the splice acceptor located at the 5’ end of the env gene). The 3’ end of the genome contains the transcription termination signal, with the
Introduction to Retroviruses and Retroviral Vectors
3
Fig. 1. Genome structure of a prototypical retrovirus. The genomic viral RNA, represented by a single black line, is shown at the top of the figure, with the structure of the resulting provirus after reverse transcription below. The locations of the open reading frames gag, pol, and env are shown. Reverse transcription of the RNA results in rearrangement of the termini of the genome, resulting in the structures of the LTRs (long terminal repeats) as indicated. Cis-acting sequences of the viral genome are shown in more detail in Figure 3.
polyadenylation signal located in the 3’ LTR. The gag gene encodes viral core structural proteins: matrix (MA), capsid (CA), and nucleocapsid (NC). Some retroviruses also encode various other small proteins or peptides within the gag open reading frame. The pol gene encodes the viral replication enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). The env gene encodes the envelope glycoprotein (Env) which is processed into transmembrane (TM) and surface (SU) subunits.
Virion Structure Retrovirus particles consist of the viral protein core and the surrounding viral envelope that is made up of a cellular membrane-derived lipid bilayer and viral-encoded envelope glycoproteins. The structural core of the virion contains the two RNA molecules (associated as a dimer) in association with the nucleocapsid protein that, in turn, is surrounded by a shell of capsid protein. The matrix protein is located outside of the viral capsid and appears to interface with the inner part of the viral envelope that surrounds the core. The viral-encoded replication enzymes, including reverse transcriptase and integrase, are located within the viral core.
The Retrovirus Replication Cycle The retroviral replication cycle (Fig. 2) commences when a virion begins to infect a cell via the interaction of the envelope surface glycoprotein with a specific cellular receptor (or receptors). A subsequent conformational change in the viral envelope surface glycoprotein results in exposure of a fusion domain contained within the envelope transmembrane glycoprotein. Subsequent fusion of the viral envelope with the cellular membrane occurs, which results in release of the virus core into the cytoplasm of the cell.7 In most retroviruses, this membrane fusion occurs directly at the cell surface, but in some retroviruses the virion, after binding to the cellular receptor, is internalized via endocytosis; fusion of the viral envelope with the endosome then results in release of the viral core into the cytoplasm. Exactly how the next series of steps occur in relation to each other is not completely clear. However, it is known that the viral genome is uncoated, reverse transcribed into double-stranded DNA, and integrated into the genome of the host cell where it resides permanently as the provirus. The provirus is then passed on to daughter cells following cellular division, just like a cellular gene would be. A brief description of the general steps of retroviral reverse transcription will be given here; the steps of reverse transcription of the HIV-1 genome are discussed in detail in Chapter 2 (refs. 7,8). Viral reverse transcriptase, in order to initiate minus strand DNA synthesis using the RNA genome as a template, utilizes as a primer a cellular tRNA molecule that is bound to the primer binding site (pbs) located just downstream of the 5’ LTR. The identical r regions of the
4
Lentiviral Vector Systems for Gene Transfer
Fig. 2. The retrovirus replication cycle. Following recognition of a specific cellular receptor by the viral envelope glycoprotein and adsorption of the virion to the cell surface, fusion of viral and cellular membranes results in release of the viral core into the cell cytoplasm (usually at the cell surface, but for some retroviruses this occurs following endocytosis of virions). The viral RNA is uncoated and reverse transcribed into a double-stranded DNA copy. Following breakdown of the nuclear envelope, the DNA copy is integrated into a chromosome where it resides as the provirus. Transcription of the provirus results in production of copies of viral genomic RNA, which can either be translated to produce viral proteins or packaged by viral proteins to form new core particles. Cores form and mature while budding from the cell surface, during which time they obtain their envelopes consisting of cellular membrane and viral envelope glycoproteins (modified from ref. 1).
viral RNA genome facilitate a strand transfer of the reverse transcriptase and nascent minus strand DNA that is necessary for DNA synthesis to continue.9 Utilization of the polypurine tract (ppt) located near the 3’ end of the genome to initiate synthesis of the DNA plus strand followed by a second strand-switching event results in the completion of reverse transcription and the existence of a full-length double-stranded DNA copy of the viral genome containing LTRs at each end. This genome is integrated, in an apparent random fashion, into a chromosome of the host cell where it resides as the provirus. The integration reaction11,12,13 is mediated by the viral integrase protein; the termini of the DNA genome are processed (two nucleotides on each end are removed), there is a break in and a short duplication made of the cellular DNA sequence, the viral DNA is inserted, and DNA repair enzymes complete the integration process. Because oncoretroviruses, unlike lentiviruses, lack a nuclear transport function to move the proviral preintegration complex into an intact nucleus, the integration process occurs only in cells where the nuclear envelope has broken down as a part of the mitotic process.14
Introduction to Retroviruses and Retroviral Vectors
5
Once integration of the viral genome is complete, the provirus is maintained in the cell just like any cellular gene. A cellular RNA polymerase uses the viral promoter/enhancer in the 5’ LTR to initiate transcription of proviral DNA. RNA transcripts are polyadenylated and transported from the nucleus for translation as any cellular mRNA would be. The viral Gag and Pol proteins are translated from a full-length unspliced RNA that extends from the 5’ LTR to the 3’ LTR. Usually, during translation of the retroviral RNA, translation terminates after reading of the gag open reading frame by the ribosomal complexes, resulting in significant Gag production. However, about 5% of the time there is production of a Gag-Pol fusion polyprotein precursor [some studies have indicated that the stoichiometry of Gag and Pol production appears to be important for efficient and correct virion assembly15,16]. The mechanism of production of the Gag-Pol precursor varies among the different retroviruses: in some retroviruses, production of Gag-Pol during translation is a result of a ribosomal frameshift event that puts the pol gene into the same reading frame as the gag gene;17 in other retroviruses, Gag-Pol production results from a readthrough event mediated by a suppressor tRNA that prevents termination of translation at the end of the gag gene.18 The envelope protein is expressed from a spliced message. This protein precursor undergoes post-translational modification including extensive glycosylation and processing by a cellular protease to generate the two TM and SU glycoprotein subunits that make up the functional Env protein. Full-length transcripts of the viral genome, in addition to being translated into viral proteins, also can be incorporated into newly forming viral particles.19 This “packaging” (or “encapsidation”) of the viral genome into newly forming capsids is mediated by an RNA packaging (encapsidation) signal located on full-length viral transcripts. This predominate packaging signal, sometimes referred to as “ψ” or “E,” is generally located near the 5’ end of the genome between the splice donor and the gag start codon (Fig. 3). Because it is typically located within an intron, the packaging signal is removed during splicing, insuring that only fulllength viral transcripts and not spliced transcripts (containing only env) are incorporated into progeny virions. Although the locations of retroviral packaging sequences are generally thought to be as described above, further study of the packaging signals of various retroviruses has revealed that the actual situation is, not surprisingly, more complex.20,21 In some cases, sequences upstream of the splice donor have been shown to be important in RNA packaging. In other cases, sequences extending past the gag start codon have been shown to increase efficiency of RNA encapsidation (these “extended” packaging signals are oftentimes referred to as “ψ+” or “E+”). Still, in other cases, sequences distant from the major packaging signal have been suggested to affect encapsidation of viral RNA. It is generally believed that the secondary structure of the RNA within the packaging signal, and not the primary RNA sequence itself, plays the more important role in RNA encapsidation. The process and relative timing of many events of virus particle assembly are not understood completely. Newly synthesized Gag proteins recognize RNA that is to be packaged into virions and incorporate the RNA into capsids formed of multimers of Gag molecules. Recognition of the viral encapsidation sequence is thought to be mediated primarily by the NC portion of the Gag protein precursor. Viral core formation is thought to be driven by intermolecular Gag-Gag interactions, with the Pol protein being incorporated into the forming virion via Gag molecules interacting with the Gag portion of the Gag-Pol precursor. Viral core assembly and processing of the Gag and Gag-Pol protein precursors to form mature, infectious virions appears to occur during and just after budding of virus particles from the cell.22 The viralencoded protease (PR, encoded by pol) self-cleaves the Gag-Pol precursor and also further processes Gag into the MA, CA, and NC proteins and Pol into the RT and IN proteins. The
6
Lentiviral Vector Systems for Gene Transfer
Fig. 3. Retroviral vector cis-acting elements. In this example of a “typical” retroviral vector, the viral genes have been removed and replaced with a foreign gene of interest. The viral sequences that remain as part of the vector construct are necessary in cis during various steps of the retroviral replication cycle. These sequences are necessary for vector production and for successful reverse transcription and integration of the vector genome, followed by expression of the foreign gene. Although in the example shown the foreign gene is expressed directly from the LTR, other strategies for expressing foreign genes exist and are illustrated in Figure 4. att, attachment site; pbs, primer binding site; ppt, polypurine tract. Modified from ref. 1.
virion envelope, made up of cellular membrane and viral envelope glycoproteins, is obtained during budding of the virus from the cell.
Elements of Retroviral Vector Systems General Concepts Retroviral vectors are derivatives of viruses that have been engineered to carry a foreign gene of interest into a target cell. Generally, for studies involving gene transfer or examination of the basic viral replication cycle, the vectors are engineered to be replication-defective, being able to complete only a single round of the retroviral replication cycle (though in some instances vectors capable of continued self-propagation might be used; ref. 23). Because of the way replication-defective retroviral vectors are designed, virus particles containing vector genomes can be produced and can be used to infect target cells. The vector genome then undergoes reverse transcription and integration into the cell’s genome, where it can express the foreign gene(s) of interest, but is unable to be replicated an additional time and spread to other cells; the vectors can undergo only a single round of replication. For studies of basic viral biology, this property enables researchers to study in detail many aspects of the replication cycle; for gene transfer studies, it enables foreign genes to be permanently introduced into cells without exposing them to replicating virus. Building a replication-defective vector from the parental retrovirus necessitates separating the cis- and trans-acting sequences of the viral genome. In a practical sense, this entails removal of the trans-acting gag, pol, and env genes from the virus (and replacing them with a foreign gene of interest), leaving on the genome only those cis-acting regions that are recognized by viral and cellular proteins during the various stages of the viral replication cycle—reverse transcription, integration, transcription, encapsidation—as reviewed above. These cis-acting regions are shown in Figure 3. Obviously, necessary viral proteins that make up the physical structure of the virion and that perform enzymatic functions need to be provided in order to produce infectious vector
Introduction to Retroviruses and Retroviral Vectors
7
virus. This requirement can be satisfied by expression of the gag, pol, and env genes, removed from the parental virus during vector construction, in cells that also express the vector construct. In this way, Gag, Pol, and Env can be provided in trans but the gag, pol, and env genes will not be carried along with the vector when it is harvested and used to infect target cells. Various strategies24 for expression of vector constructs and viral genes and for production of vector virus are discussed below. Vector virus that is produced by this trans-complementation can then be used to transduce (infect and express a foreign gene in) target cells. For experiments using vectors to study a single round of viral replication, the foreign gene is generally some type of marker gene that can be used to screen for transduction and to quantify the vector virus that is produced; typical markers used to titer vector produced include lacz or genes encoding GFP or a molecule conferring antibiotic resistance.
Design of Vectors Once the basic vector backbone has been constructed (Fig. 3), there are several different ways in which to express a foreign gene (Fig. 4). In the simplest case, the foreign gene is expressed directly from the promoter located in the 5’ LTR of the vector construct. Two or more genes can be expressed from the LTR if the second gene is expressed from a spliced message or if the second gene is translated using an internal ribosome entry site (IRES) (ref. 25). Although using the vector LTR to drive expression of the foreign gene(s) is useful in a number of settings, at times other strategies are used in order to attempt to control or to increase the level of gene expression. By designing vectors that contain internal, heterologous promoters, oftentimes foreign gene expression can be increased greatly compared to levels that could be obtained using the promoter in the vector LTR (this is attributable to low LTR promoter activity in the target cell, which typically is not the natural target cell of the parental virus). Frequently, the heterologous promoter is another viral promoter, such as cytomegalovirus (CMV), or it may be a tissue-specific promoter. Of course, the years of experience with retroviral vector development have made it clear that the design of vectors to deliver and express foreign genes in cells is often not as simple as one might think from the description above. For example, sustained expression of the foreign genes has been a great problem that can have many possible etiologies. For instance, although use of a heterologous promoter can increase foreign gene expression, addition of an additional promoter on the vector sometimes can actually decrease gene expression. This phenomenon, termed “promoter interference,” is incompletely understood and not always predictable: often it can be affected by the precise or relative location of the promoters or even by the foreign gene itself.26,27 Efforts to overcome promoter interference have included attempts to express the foreign gene from a heterologous promoter/foreign gene cassette placed on the vector in an anti-sense orientation relative to the LTRs. This strategy has had mixed success, probably since the same number of promoters are still present on the vector and possibly because the production of anti-sense transcripts may interfere with vector production or gene expression. The development of self-inactivating (SIN) vectors may decrease the problem of promoter interference and also offers a potential safety advantage over traditional retroviral vectors. SIN vectors are named as such because they are engineered to generate, following reverse transcription of the vector RNA into the DNA form, a defective, and thus inactive, promoter in the 5’ LTR. This is accomplished by engineering constructs that have a defective u3 region at the 3’ end of the viral RNA form of the genome (this defective u3 is duplicated as a defective U3 of the 5’ LTR during reverse transcription; see above and Chapter 2). In this scenario, there would be no active promoter in the proviral 5’ LTR to interfere with internal, heterologous promoters. It also, in theory, offers additional safety advantages in that it would be more difficult to re-generate a wild-type parental retrovirus via recombination and also it may decrease
8
Lentiviral Vector Systems for Gene Transfer
Fig. 4. Vector design strategies for expression of foreign genes. Examples of various strategies for expression of foreign genes delivered by retroviral vectors are illustrated. Other combinations of the strategies shown here also can be used. A. The foreign gene is expressed directly from the promoter located in the vector LTR. B. Expression of two or more foreign genes might be expressed using the promoter in the vector LTR by utilizing a spliced message to express the second gene. C. A foreign gene can be expressed from a heterologous promoter located in the middle of the vector; sometimes this promoter/foreign gene cassette is placed in the anti-sense orientation relative to the vector LTR. D. An internal ribosome entry site (IRES) can be utilized to express a second foreign gene. LTR, long terminal repeat; S.D., splice donor; S.A., splice acceptor; Pr, promoter. Arrows indicate the location and direction of transcription initiation.
the chances of insertional mutagenesis by a promoter insertion mechanism after the provirus is integrated into the cell’s genome.
Design of Packaging Systems There are three basic strategies for expressing viral proteins for trans-complementation of a replication-defective vector. These include co-infection of vector-producing cells with wildtype virus (“helper virus”), transient transfection of cells with plasmids expressing vector and protein-coding constructs (“packaging plasmids”), and the use of cells (“packaging cells” or “helper cells”) that stably express viral proteins. If cells containing a vector genome are infected with replication competent wild-type virus, the wild-type virus will complete the viral replication cycle as described above. The viral proteins produced as part of this process, however, also will recognize the vector RNA and will incorporate vector RNA genomes into virus particles. Both wild-type virus and vector virus will be released from cells. This vector virus can be harvested and used to infect target cells; however, because these preparations would be contaminated with wild-type virus, any target cells transduced with the vector would also be infected with wild-type virus. Therefore, continued replication and spread of the vector to other cells would occur. In certain experimental situations this could be a useful phenomenon, but in most cases a mixture of vector virus and wild-type virus would confound experimental results and make them difficult or impossible to interpret. Obviously, the presence of wild-type virus in vector preparations would make them unacceptable for clinical gene transfer studies. In order to limit vector replication to a single round, separate viral protein-coding constructs can be used to trans-complement the vector. The gag, pol, and env genes are removed from the virus and expressed on separate plasmids using heterologous promoters. These packaging and vector plasmids can be co-transfected into cells. The viral proteins produced will
Introduction to Retroviruses and Retroviral Vectors
9
package vector RNA, and vector virus that is released from these transfected cells can be harvested for transduction of target cells. Because the helper packaging plasmids do not contain the cis-acting sequences necessary for propagation (see above), they will not be packaged or transferred to the target cells; therefore, there will be only a single round of vector replication and the foreign gene can be introduced into target cells in a relatively predictable manner. In order to decrease the chances of the re-generation of wild-type virus (replication-competent retrovirus, RCR) during vector production via recombination between vector and packaging constructs, use of a “split genome” approach to expressing viral proteins generally has been adopted. In such an approach, the vector is expressed on one construct, the gag and pol genes on another, and the env gene on yet another. Separate expression of the env gene also enables the use of Env from heterologus viruses in place of the native Env. The use of Env from heterologous viruses, termed pseudotyping, is extremely valuable because it allows the cellular tropism of the vector virus to be different from that of the parental virus from which the vector was derived. In addition, different envelope proteins have different physical properties that can be an advantage during vector preparation.28,29 The split genome approach decreases the frequency of RCR generation, given that multiple recombination events would need to take place. However, it does not reduce it to zero, especially when using transient transfection of cells, an inherently recombinagenic procedure, to produce vector virus. For this reason, packaging cell lines often are used to generate vector virus. Packaging cells are cell lines that have been engineered to stably maintain viral genes and to express viral proteins.30 The viral genes are expressed from heterologous promoters and there are no cis-acting sequences associated with the viral genes, just as when packaging plasmids are used in transient transfections as described above; usually the split genome approach is used to express gag, pol, and env. When a vector construct is introduced into the packaging cells, usually by transfection, vector virus is produced and can be harvested (Fig. 5). Generally, the use of packaging cells was thought to be preferential to the use of a transient transfection protocol for vector production: packaging cells can be well characterized and it was thought that the chances of RCR formation through recombination was less than during a transient co-transfection of vector and packaging plamsids. The use of packaging cells was generally a more direct way to produce vector virus and yielded higher vector titers than those obtained from transient transfections; however, improvements in protocols for vector production have made this factor less of a concern. One final word on vector production and design of packaging systems: the biggest safety concern31 during vector production is that RCR might inadvertently be generated.32 Therefore, improvements designed to reduce the amount of sequence homology among constructs used in vector and packaging systems has remained a priority. Still, all vector preparations used need to be extensively tested for the presence of RCR.
Summary Vector systems based on oncoretroviruses have been important tools for understanding basic retroviral replication and for applied studies involving gene transfer. Development of these vector systems enabled detailed study of the basic biology of the parent retrovirus from which they were derived and vice versa, enabling advances in vector systems and gene transfer technology to be made. Use of retroviral vectors for gene transfer has been limited for a number of years by several problems including low vector titers, inability to achieve sustained foreign gene expression in target cells, inability to target vector virus to transduce the desired cell type, the theoretical possibility of insertional mutagenesis by the vector upon integration, and the possibility of the re-generation wild-type virus during vector production. Over time, advances in the understanding of retroviral vector design and gene transfer have occurred and progress has been made in overcoming what had been identified as system limitations.
Lentiviral Vector Systems for Gene Transfer
10
Fig. 5. Vector production using a packaging cell line. Packaging cells are cell lines that have been engineered to stably express viral proteins from heterologous promoters; these viral protein-coding sequences lack cisacting sequences that are necessary for propagation and are therefore not transmitted to other cells. Following introduction of a vector into the packaging cell, usually by transfection, vector RNA is produced and packaged into vector virus particles that are then released from the packaging cell. These vector virus particles can be harvested and used to infect fresh target cells. Following reverse transcription and integration of the vector genome, the foreign gene is expressed in the target cells. Because viral proteins are not produced in the target cells, further vector production and propagation does not occur (1).
Recently, vector systems derived from several different lentiviruses, which could offer some advantages over oncoretroviral vector systems, have been under development. At least some of these systems are anticipated to have use in future clinical gene transfer applications. Certainly, the immense experience obtained with oncoretroviral vector systems and the basic tenets that guided their development has benefited and will continue to benefit the development of lentiviral vector systems which, because of their more complex genome and their potential to be human pathogens, raise technical, practical, and ethical issues that must be addressed.
Acknowledgements I thank Kathleen Boris-Lawrie of the Ohio State University for comments on the manuscript and Scott Buchschacher for preparation of figures.
References 1. Buchschacher GL, Jr., Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000; 9:2499-2504. 2. Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970; 226:1211-1213. 3. Poeschla EM, Buchschacher GL, Jr., Wong-Staal F. Etiology of cancer: RNA viruses. In: DeVita VT, Jr., Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2000:149-158. 4. Fearon ER. Oncogenes and tumor suppressor genes. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology. 2nd ed. Philadelphia: Churchill Livingstone, 2000:77-118.
Introduction to Retroviruses and Retroviral Vectors
11
5. Nermut MV, Hockley DJ. Comparitive morphology and structural classification of retroviruses. New Biol 1992; 4:1-24. 6. Coffin JM. Structure and classification of retroviruses. In: Levy JA, ed. The Retroviridae. New York: Plenum Press, 1992:19-50. 7. Coffin JM. Retroviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM et al, eds. Fundamental Virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996:763-843. 8. Flint SJ, Enquist LW, Krug RM et al. Reverse transcription and integration: Hallmarks of the retroid viruses. In: Principles of Virology-Molecular Biology, Pathogenesis, and Control. Washington DC: ASM Press, 2000:199-234. 9. Panganiban AT, Fiore D. Ordered interstrand and intrastrand DNA transfer during reverse transcription. Science 1988; 241:1064-1069. 10. Hu Wei-Shau, Temin HM. Retroviral recombination and reverse transcription. Science 1990; 250:1227-1233. 11. Grandgenett DP, Mumm SR. Unraveling retrovirus integration. Cell 1990; 60:3-4. 12. Panganiban AT. Retroviral reverse transcription and integration. 1990; 1:187-194. 13. Skalka AM. Retroviral integration. In: Advances in virus research. Maramorosch K, Murphy FA, Shatkin AJ, eds. Seminars in Virology: Retroviral DNA Integration. Vol 52. New York: Academic Press, 1999. 14. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68:510-516. 15. Schwartzberg P, Colicelli J, Gordon ML, Goff SP. Mutations in the gag gene of Moloney murine leukemia virus: Effects on production of virions and reverse transcriptase. J Virol 1984; 49:918-924. 16. Felsenstein KM, Goff S. Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J Virol 1988; 62:2179-2182. 17. Jacks T, Power FR, Masiarz PA et al. Characterization of ribosomal frameshifting in HIV-1 gagpol expression. Nature 1988; 331:280-283. 18. Weaver TA, Talbot KJ, Panganiban AT. Spleen necrosis virus gag polyprotein is necessary for particle assembly and release but not for proteolytic processing. J Virol 1990; 64:2642-2652. 19. Butsch M, Boris-Lawrie K. Translation is not required to generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells. J Virol 2000; 74:11531-11537. 20. McBride MS, Panganiban AT. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. J Virol 1996; 70:2963-2973. 21. Jewell NA, Mansky LM. In the beginning: Genome recognition, RNA encapsidation and the initiation of complex retrovirus assembly. J Gen Virology 2000; 81:1889-1899. 22. Vogt VM. Proteolytic processing and particle formation. Curr Top Microbiol Immunol 1996; 214:95-132. 23. Kucherova L, Altanerova V, Altaner C, Boris-Lawrie K. Bovine leukemia virus structural gene vectors are immunogenic and lack pathogenicity in a rabbit model. J Virol 1999; 73:8160-8166. 24. Boris-Lawrie KA, Temin HM. Recent advances in retrovirus vector technology. Curr Opin Gen Dev 1993; 3:102-109. 25. Adam MA, Ramesh N, Miller AD et al. Internal initiation of translation in retroviral vectors carrying picornavirus 5’ nontranslated regions. J Virol 1991; 65:4895-4990. 26. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39:459-467. 27. Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res 1986; 14:9381-9396. 28. Burns JC, Friedmann T, Driever W et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90:8033-8037. 29. Hopkins N. High titers of retrovirus (vesicular stomatitis virus) pseudotypes, at last. Proc Natl Acad Sci USA 1993; 90:8759-8760. 30. Miller AD. Retrovirus packaging cells. Human Gene Ther 1990; 1:5-14. 31. Temin HM. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther 1990; 1:111-123. 32. Chong H, Starkey W, Vile RG. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol 1998; 72:2663-2670.
HIV-1 Replication
13
CHAPTER 2
HIV-1 Replication Eric O. Freed
Introduction
I
n general terms, the replication cycle of lentiviruses, including HIV-1, closely resembles that of other retroviruses.1 There are, however, a number of unique aspects of HIV replication; for example, the HIVs and SIVs target receptors and coreceptors distinct from those used by other retroviruses. Lentiviruses encode a number of regulatory and accessory proteins not encoded by the genomes of the prototypical “simple” retroviruses. Of particular interest from the gene therapy perspective, lentiviruses possess the ability to productively infect some types of non-dividing cells. This chapter, while reiterating certain points discussed in Chapter 1, will attempt to focus on issues unique to HIV-1 replication. The HIV-1 genome encodes the major structural and non-structural proteins common to all replication-competent retroviruses (Fig. 1, and Chapter 1). From the 5'- to 3'-ends of the genome are found the gag (for group-specific antigen), pol (for polymerase), and env (for envelope glycoprotein) genes. The gag gene encodes a polyprotein precursor whose name, Pr55Gag , is based on its molecular weight. Pr55Gag is cleaved by the viral protease (PR) to the mature Gag proteins matrix (also known as MA or p17), capsid (CA or p24), nucleocapsid (NC or p7), and p6. Two spacer peptides, p2 and p1, are also generated upon Pr55Gag processing. The pol-encoded enzymes are initially synthesized as part of a large polyprotein precursor, Pr160GagPol, whose synthesis results from a rare frameshifting event during Pr55Gag translation. The individual pol-encoded enzymes, PR, reverse transcriptase (RT), and integrase (IN), are cleaved from Pr160GagPol by the viral PR. The envelope (Env) glycoproteins are also synthesized as a polyprotein precursor (Fig. 1). Unlike the Gag and Pol precursors, which are cleaved by the viral PR, the Env precursor, known as gp160, is processed by a cellular protease during Env trafficking to the cell surface. gp160 processing results in the generation of the surface (SU) Env glycoprotein gp120 and the transmembrane (TM) glycoprotein gp41. gp120 contains the determinants that interact with receptor and coreceptor, while gp41 not only anchors the gp120/gp41 complex in the membrane (Fig. 2), but also contains domains that are critical for catalyzing the membrane fusion reaction between viral and host lipid bilayers during virus entry. Comparison of env sequences from a large number of virus isolates revealed that gp120 is organized into five conserved regions (C1-C5) and five highly variable domains (V1-V5). The variable regions tend to be located in disulfide-linked loops. gp41 is composed of three major domains: the ectodomain (which contains determinants essential for membrane fusion), the transmembrane anchor sequence, and the cytoplasmic tail. In addition to the gag, pol, and env genes, HIV-1 also encodes a number of regulatory and accessory proteins. Tat is critical for transcription from the HIV-1 LTR and Rev plays a major Lentiviral Vector Systems for Gene Transfer, edited by Gary L. Buchschacher, Jr. ©2003 Eurekah.com.
14
Lentiviral Vector Systems for Gene Transfer
Fig. 1. Organization of the HIV-1 genome. The relative locations of the HIV-1 open reading frames gag, pol, env, vif, vpr, vpu, nef, tat, and rev are indicated. The 5' and 3' LTRs are shown, with U3, R, and U5 regions noted. The ψ indicates the position of the RNA packaging signal. The major Gag domains (MA, CA, NC, p6) and the Gag spacer peptides (p2 and p1) are shown under the gag gene. The site of Gag N-terminal myristylation is denoted as “myr”. Under the pol gene are indicated the PR, RT (p66 and p51 subdomains), and IN coding regions. The SU and TM Env glycoproteins (gp120 and gp41, respectively) are enlarged to show the position in gp120 of the major conserved (C1-C5) and variable (V1-V5) regions and in gp41 the location of the fusion peptide, the N- and C-helices, membrane-spanning domain, and the cytoplasmic tail.
role in the transport of viral RNAs from the nucleus to the cytoplasm. Vpu, Vif, Vpr and Nef have been termed “accessory” or “auxiliary” proteins to reflect the fact that they are not uniformly required for virus replication. The functions of these very interesting proteins will be discussed in more detail at the end of this chapter. HIV replication proceeds in a series of events that can be divided into two overall phases: “early” and “late” (Fig. 3).1 Although some events occur in a concerted or simultaneous fashion, the replication cycle can be viewed most simply as proceeding in an ordered, step-wise manner. In this chapter, each step in virus replication will be considered; additional information can be obtained from the more detailed reviews and primary references that are cited.
The HIV-1 Replication Cycle Virus Entry CD4 Binding Early in the AIDS epidemic it was observed that HIV specifically targets and depletes the CD4+ subset of T-lymphocytes in the peripheral blood of infected individuals. By the mid 1980s, it was well established that the CD4 molecule was the primary cell-surface receptor for SIV/HIV, making it the first retroviral receptor identified.2 Following its identification as the principal HIV receptor, numerous studies attempted to identify the domains of both CD4 and gp120 responsible for the CD4/Env interaction. The high-affinity binding site on CD4 for gp120 maps to a small segment of the N-terminal extracellular domain. The region in Env involved in CD4 binding is located primarily in the third (C3) and fourth (C4) conserved domains of gp120, although residues elsewhere in gp120 also play a role. The recently obtained
HIV-1 Replication
15
Fig. 2. Schematic representation of a mature HIV-1 particle. Positions of the major viral proteins, the lipid bilayer, and the genomic RNA are indicated. Modified from Freed, 1998 (ref. 22)
crystal structure of the gp120 “core” reveals two major domains, the “inner” and “outer” domains, connected by a “bridging sheet”.3 One of the interesting features of the gp120 structure evident from this work is that the CD4 binding site in gp120 is deeply recessed and flanked by heavily glycosylated variable regions. A number of direct gp120/CD4 contacts are resolved in this structure. As a consequence of the high affinity interaction between gp120 and CD4, these two molecules associate during their transport to the surface of infected cells in the late phase of the replication cycle.4 This intracellular Env/CD4 interaction leads to the downmodulation of CD4 from the cell surface, rendering infected cells partially resistant to further infection by HIV Env-bearing viruses. This Env-mediated “superinfection interference” is not operative against virions bearing heterologous Env glycoproteins [e.g., those of amphotropic murine leukemia virus (A-MuLV) or the vesicular stomatitis virus G glycoprotein (VSV-G)] as such pseudotyped viruses bind and enter the target cell in a CD4-independent manner.
Coreceptor Interactions After the identification of CD4 as the major HIV receptor, it was soon appreciated that CD4 was not sufficient for HIV Env-mediated membrane fusion and virus entry. This conclusion was based in part on the observation that primary virus isolates from infected individuals display variable tropism for CD4+ cells. Certain isolates, referred to as macrophage-tropic (or “M”-tropic) replicate efficiently in primary macrophage cultures, whereas other isolates, referred to as T-cell-line tropic (“T”- or “TCL”-tropic) cannot productively infect macrophages but replicate to high levels in T-cell lines. Both M- and TCL-tropic isolates replicate in activated peripheral blood mononuclear cells (PBMC). A decade-long search ultimately identified members of the G protein-coupled receptor superfamily of seven-transmembrane domain proteins as coreceptors for HIV entry. 5,6 These molecules serve as receptors for the α and β
16
Lentiviral Vector Systems for Gene Transfer
Fig. 3. Schematic representation of the HIV-1 life cycle. The major steps in the early and late stages of the replication cycle (described in detail in the text) are indicated.
chemokines. Two coreceptors appear to be predominately important in vivo: the α-chemokine receptor CXCR4 (originally designated fusin) and the β-chemokine receptor CCR5. The identification of the coreceptors largely explains the basis for the differential cell-type tropism mentioned above: T-cell lines typically express CXCR4 but not CCR5; primary lymphocytes express both CXCR4 and CCR5, and macrophages express CCR5. To reflect the importance of coreceptors in HIV biology, a system of nomenclature was developed based on coreceptor usage: strains (generally TCL-tropic) that preferentially use CXCR4 are named X4 viruses, isolates (generally M-tropic) that utilize CCR5 are denoted R5 isolates, and dual-tropic strains that utilize both CCR5 and CXCR4 are termed R5X4 isolates. The V3 loop of gp120 plays a major role in determining HIV-1 tropism; in fact, exchanging the V3 region between isolates can confer M-tropism upon TCL-tropic clones.7 The V1/ V2 region also appears to influence coreceptor usage. In addition to the V1/V2 and V3 variable loops, highly conserved regions of gp120 take part in coreceptor binding. Antibodies whose epitopes are exposed upon CD4 binding block gp120/CCR5 interaction; these epitopes lie in part within the gp120 “bridging sheet”. It has been observed that binding of gp120 to CD4 changes the conformation of gp120 such that its affinity for coreceptor is increased. This finding suggests the following series of events leading up to membrane fusion: gp120 first binds CD4; a ternary complex composed of gp120, CD4, and coreceptor then forms, and finally conformational changes in gp41 ultimately trigger membrane fusion 5-7 (Fig. 4). Interestingly, certain HIV and SIV isolates are able to bind coreceptor and infect cells in the absence of CD4.8 Thus, it appears that the gp120 in these isolates is in a constituitively “activated” conformation. The importance of coreceptors in vivo is illustrated by a number of studies indicating that genetic heterogeneity at coreceptor alleles can affect the susceptibility of an individual to HIV infection, or can alter the course of the disease following infection. The best characterized example of this phenomenon is the so-called CCR5/∆32 mutation; individuals homozygous for this mutant allele (which encodes a truncated form of the CCR5 protein) are almost
HIV-1 Replication
17
Fig. 4. Steps leading to membrane fusion induced by HIV-1 Env. Panel 1. The gp120/gp41 complex in its “resting” configuration prior to interaction with CD4 and coreceptor. Panel 2. gp120 binds CD4 and interacts with coreceptor, leading to conformational changes in both gp120 and gp41. Panel 3. The gp41 ectodomain adopts a hypothetical extended conformation; the fusion peptide at the N-terminus of gp41 inserts directly into the target cell lipid bilayer. Panel 4. The N- and C-helices of the gp41 ectodomain fold into a highly stable six-helix bundle, bringing the membranes in apposition and allowing membrane fusion to occur. Modified from Freed and Martin, ©2001 (see ref. 1).
completely resistant to HIV infection.9-11 These observations suggest that coreceptors might be effective targets for antiviral therapy.
Membrane Fusion The membrane fusion reaction that takes place between the lipid bilayers of the viral envelope and the host cell plasma membrane enables the viral core to gain access to the cytoplasm and is thus central to the infection process. As mentioned above, membrane fusion is catalyzed by the gp120/gp41 Env glycoprotein complex (Fig. 4). The role of gp120 is primarily to bind the target cell, interact with coreceptor, and induce conformational changes in gp41 that allow it to directly promote the fusion event. A number of domains in both gp120 and gp41 participate in CD4/coreceptor binding or the membrane fusion process itself. At the heart of the fusion reaction is the ectodomain of gp41; this region contains a highly hydrophobic N-terminus (the so-called “fusion peptide”) and two heptad repeat motifs, referred to as the N-helix and the C-helix (Figs. 1 and 4). Structural analyses of these two helical sequences, in the context of a gp41 ectodomain trimer, indicate that they pack in an antiparallel fashion to generate a six-helix bundle 12,13 (Fig. 4). Mutations within, or peptides derived from, these heptad repeats potently inhibit membrane fusion. It appears that the N- and C-helices undergo
Lentiviral Vector Systems for Gene Transfer
18
rearrangements following CD4/coreceptor binding that enable the N-terminal fusion peptide to insert directly into the target membrane. In many respects, this “spring-loaded” mechanism of membrane fusion closely parallels the fusion model proposed for influenza HA2.14
Post-Entry Events Following the fusion between the envelope of the incoming virus particle and the host cell plasma membrane, the viral core enters the host cytoplasm. The events that follow remain the least well understood part of the virus life cycle. In particular, the process of “uncoating”, during which the core (defined as the structure that remains after the lipid bilayer is stripped away) is converted to a complex referred to as the reverse transcription complex (RTC) and then the preintegration complex (PIC). During these steps, CA appears to be lost while at least some MA, NC, the pol-encoded enzymes RT and IN, and the accessory protein Vpr, remain associated. Because of the very high ratio of physical particles to infectious units in HIV-1 preparations (approximately 1000:1), these uncoating steps are very difficult to study; the vast majority of viral protein that enters the target cell does not lead to a productive infection. However, successful virus entry can be followed by monitoring reverse transcription and, ultimately, integration.
Reverse Transcription One of the defining features of retroviruses is their ability to convert their RNA genomes into double-stranded DNA early post-infection. This reaction is catalyzed by the RT enzyme.15 In the case of HIV-1, RT is a heterodimer of two subunits, one of which is 66 kDa (p66), the other 51 kDa (p51). These two subunits are both derived from the same region of the Pr160GagPol precursor protein; p51 is formed when the C-terminal, 15kDa RNaseH domain of p66 is removed by PR. A number of groups have crystallized the RT holoenzyme in various contexts, leaving us with a very well-defined structure. Interestingly, the p66 and p51 domains, while largely overlapping in protein sequence, adopt quite different conformations. The p66 subunit can be visualized as a right hand, with the polymerase active site within the palm, and a deep template-binding cleft formed by the palm, fingers and thumb subdomains.16 In this representation, the active site is located in the palm. Reverse transcription proceeds in a series of steps that utilize several cis-acting elements in the viral genome.15 With one interesting distinction, mentioned below, reverse transcription of the HIV-1 genome occurs by a process that is fundamentally similar to that used by other retroviruses. The steps involved in the conversion of the RNA genome to DNA are described briefly below, and are depicted in Fig. 5. 1. Reverse transcription is initiated using as a primer a molecule of tRNA that is bound to the primer binding site (pbs). DNA synthesis proceeds to the 5' end of the RNA molecule, generating a DNA/RNA hybrid. 2. The RNA portion of this hybrid is degraded by the RNaseH activity that is an inherent part of the RT holoenzyme, generating a DNA fragment known as the minus-strand strong stop DNA. 3. By using short regions of homology (the so-called “R” regions), the minus-strand strongstop DNA “jumps” from the 5' to the 3' end of the genome. This step is referred to as the first strand transfer. 4. Minus-strand synthesis occurs, using the 3' end of the minus-strand strong stop DNA as a primer. 5. Plus-strand synthesis occurs, using as primers fragments of RNA remaining from minusstrand synthesis. The primary site of priming for retroviruses takes place at a purine-rich sequence known as the polypurine tract (PPT). For HIV, priming also occurs efficiently from another site, known as the central PPT. The implications of priming at the central PPT will be discussed further in the context of nuclear import.
HIV-1 Replication
19
Fig. 5. Reverse transcription. Thin lines represent RNA; DNA is indicated as a thick line. Cis-acting elements, defined in the text, are shown. The tRNA primer is shown bound to the pbs.
6. The tRNA bound to the pbs is removed by RNaseH, thereby allowing second-strand transfer to take place. 7. Plus-strand synthesis proceeds to the end of the minus strand. For HIV, an additional termination site, referred to as the central termination signal (CTS), is located near the center of the genome. Since the CTS is 3' of the central PPT, approximately 100 nucleotides of plusstrand DNA is displaced, resulting in the formation of a DNA “flap”. It has been reported that this central flap plays a crucial role in the import of the viral PIC to the nucleus.17
20
Lentiviral Vector Systems for Gene Transfer
HIV, and other retroviruses, package two single stranded copies of their RNA genome per virion. Because reverse transcription involves “jumps” from one template to another, the RT/ template interaction is of a relatively low affinity.18 As a consequence, frequent template switches can occur; if the two RNA molecules in a particular virion are not genetically identical, this template switching will result in the generation of a novel recombinant DNA genome containing sequences derived from both parental RNAs.19 The high frequency of genetic recombination, together with the high mutation rate of HIV-1 RT (3 X 10-5 per cycle of replication20) results in HIV populations being highly heterogeneous in sequence (forming so-called “quasispecies”). As a consequence, HIV is able to rapidly evade the host immune response and develop resistance to antiviral drugs. The RT enzyme was an early target in the development of antiviral drugs. Two general classes of RT inhibitors have been developed: the nucleoside analogs [e.g., AZT (zidovudine), ddI (didanosine), ddC (zalcitabine), and 3TC (lamivudine)] and the nonnucleoside inhibitors (e.g., nevirapine and delavirdine). Because of the above-mentioned high mutation rate of RT, resistance to these compounds emerges rapidly; however, potent treatment regimens result from the combination of RT and PR inhibitors.
Nuclear Import During reverse transcription, the viral genome (RNA, then DNA) remains associated with the high molecular weight RTC. The viral DNA is eventually transported to the nucleus as part of the PIC. As mentioned above, the composition of the PIC, and the mechanism by which the PIC translocates to the nucleus, have been the subject of some debate. There appears to be widespread agreement that CA is not part of the PIC, but that at least some MA is retained. The pol-encoded enzyme IN, which of course must be present in the nucleus at the time of integration (see below), is also part of the PIC. The accessory protein Vpr and, in some studies, the Gag NC protein, are also detected in this complex. Although it was originally proposed that MA was the primary determinant of PIC nuclear import,21 certain key pieces of data supporting this model were not reproduced in subsequent studies.22 It is currently believed that Vpr plays a role in nuclear import, and some studies suggest a role for IN.23 Most recently, as alluded to above, the central DNA flap that is a product of lentiviral reverse transcription has been implicated in PIC nuclear import.17 It must be emphasized that our understanding of this process is incomplete and that further studies will be required to elucidate the role of viral, and, presumably, cellular factors in the translocation of the PIC to the nucleus. This topic will be discussed in much greater detail in Chapter 3.
Integration Following nuclear import of the viral PIC, the 32 kDa IN protein catalyzes the insertion of the linear, double-stranded viral DNA into the host cell chromosome.24 The integrated DNA, referred to as the “provirus”, behaves essentially as a cellular gene. Integration is an essential step in retrovirus replication, as IN mutants generally fail to establish spreading infections. As with reverse transcription, integration proceeds via a well-defined series of steps that are quite similar among all retroviruses. 1) The integration process begins when IN clips off several nucleotides from the 3’ termini of both strands of linear viral DNA. This reaction, known as 3'-end processing, generates a molecule of double-stranded DNA with 3’-recessed ends. 2) In the nucleus, IN makes a staggered cleavage in the cellular target DNA. The 3’ recessed ends of viral DNA formed in the 3'-end processing reaction are joined to the ends of the cleaved cellular DNA. This reaction is known as strand transfer. The integration process is completed when cellular repair enzymes fill in the gaps between the integrated viral DNA and the host target DNA.
HIV-1 Replication
21
The IN enzyme is composed of three distinct domains: an N-terminal domain that contains a zinc-finger, a central “core” sequence, and a C-terminal domain. The core contains the active site of the enzyme and bears marked structural similarity to other polynucleotidyl transferases (e.g., the bacteriophage MuA transposase and RNAse H). Three highly conserved residues, Asp64, Asp116 and Glu152 (the so-called D,D-35-E motif) are critical to IN function. It is well established that IN functions as a multimer; however, it is still not clear how many molecules of IN make up the functional holoenzyme. Recent studies suggest that not only is the viral DNA present in a large macromolecular PIC, but that the ends of the viral DNA are also organized into a multi-component complex composed of both viral and cellular proteins. These complexes at the viral DNA ends are referred to as “intasomes”.25,26 Much of what we know about retroviral integration derives from the study of in vitro integration reactions using purified IN. Despite the utility of this simplified system, the major product of such reactions using HIV-1 IN is a single end of viral DNA joined to one strand of the target, rather than the product observed in vivo in which both ends of the viral DNA are integrated. This observation highlights the importance of additional viral and perhaps cellular proteins in carrying out the integration reaction. Indeed, when PICs are purified from infected cells they are able to direct authentic and complete integration reactions in vitro. Such reactions provide a powerful tool to screen for compounds that block integration in vivo.27
Gene Expression Following integration into the host chromosome, the integrated provirus serves as the template for the synthesis of the viral RNAs that ultimately encode the full complement of structural, regulatory, and accessory proteins used to direct virus replication. In this section, we will consider the transcription of the viral RNAs, and the role of the Tat protein in RNA synthesis, and will summarize the role of Rev in the export of viral RNAs to the cytoplasm.
Transcription/Tat Function The HIV-1 LTR serves as the site of transcriptional initiation and harbors cis-acting elements required for RNA synthesis1 (Fig. 6). The LTR is composed of three regions: U3 (for unique, 3' end), R (for repeated) and U5 (for unique, 5' end). Transcription initiates at the U3/ R junction. U3 contains a variety of elements that direct the binding of RNA polymerase II (pol II) to the DNA template. A TATA element, to which transcription factor IID (TFIID) binds, is located approximately 25 nucleotides upstream of the transcription start site. Located 5' of the TATA box are three Sp1 and two NF-κB binding sites. Although mutational analyses of the HIV-1 LTR reveal that the Sp1 and NF-κB sites are variably important, depending upon the cell type, removal of all Sp1 and NF-κB sites abolishes virus replication.28 Upstream of the NF-κB sites is a domain, sometimes referred to as the “modulatory region”, which contains binding sites for several additional transcriptional factors, including LEF, Ets, and USF. The basal transcriptional activity from the HIV LTR is very low; RNA synthesis is greatly increased (by more than two logs) when the transcriptional transactivator protein Tat is present.29,30 Tat is a 101 amino acid protein encoded by a two-exon RNA; a smaller (72 amino acid) “one-exon” Tat is encoded by some isolates. Tat contains several distinct functional domains: an activation domain, which lies within the N-terminal 48 residues of the protein and which itself is comprised of an acidic domain, a Cys-rich region, and a hydrophobic core element; a highly basic RNA binding domain; and an overlapping nuclear localization signal. Much effort over the past decade has been focused on understanding the mechanism by which Tat transactivates LTR-driven gene expression. Several salient features are emphasized below: 1) Tat acts upon an RNA element, known as the transactivation response region (TAR).31 TAR, which is present at the 5' end of all viral RNAs, consists of a base-paired stem, a small
22
Lentiviral Vector Systems for Gene Transfer
Fig. 6. Schematic representation of the HIV-1 LTR. The position of binding sites for host factors (LBP-1, NFκB, LEF, Ets, USF-1, and NFAT-1) are shown at and 5' of the transcription start site. The TAR stem/ loop structure, with bulge, is represented at the 5' end of a nascent mRNA.
(trinucleotide) non-base-paired bulge, and a 6-nucleotide G-rich loop (Fig. 6). 2) Tat appears to bind to the TAR bulge. 3) It was observed a number of years ago that Tat functions poorly in rodent cells, suggesting that cellular factors play an important role in Tat activity. This prediction was borne out recently with the identification of a cellular protein that interacts, via its activation domain, with Tat.32 The protein in question is cyclin T1 (cycT1), which forms a heterodimer with a member of the cyclin-dependent kinase family (CDK9). The cycT1/CDK9 heterodimer is itself part of a large protein complex related to the Drosophila positive-transcriptional elongation factor b (P-TEF-b). Tat recruits the human P-TEFb complex to TAR, resulting in the phosphorylation of the C-terminal domain (CTD) of RNA Pol II and a dramatic stimulation of transcriptional processivity.
RNA Export/Rev Function Transcription from the HIV-1 LTR leads to the generation of a large number (more than 30) of viral RNAs.33 These fall into three major classes: 1) unspliced RNAs, which function as the mRNAs for the Gag and GagPol polyprotein precursors, and are packaged into progeny virions as genomic RNA, 2) partially spliced mRNAs, which are around 5 kb in size and encode the Env, Vif, Vpu, and Vpr proteins, and 3) small (1.7 to 2.0 kb), multiply spliced mRNAs, which are translated into Rev, Tat, and Nef. Since most cellular mRNAs are fully spliced before their transport out of the nucleus, the need for unspliced and partially spliced RNAs in the cytoplasm poses a problem for HIV. This problem has been overcome through the evolution of a novel viral protein, Rev (for “regulator of expression of viral proteins”), and a cis-acting RNA element, the Rev responsive element (RRE).34 Rev is 19 kDa (116 amino acid) phosphoprotein encoded by two exons, both of which are essential for protein function.34 Rev contains two functional domains: an Arg-rich sequence that is required for RNA binding and nuclear localization, and a hydrophobic, Leu-rich motif that mediates nuclear export. The RRE is a large (250 nucleotide), highly structured RNA element that is located in the env gene and is present in all unspliced and partially spliced HIV1 RNAs. It folds into a series of stem-loop structures emanating from a central bubble. A Rev monomer initially binds one of the stem-loops (known as stem-loop 2) and then, through cooperative protein-protein and protein-RNA interactions, multimerizes with other Rev molecules. This Rev multimer eventually coats the RRE at a stochiometry of approximately eight Rev molecules per RRE. Rev binding to the RRE results in the formation of a complex capable of interacting with the cellular nuclear export machinery. As a consequence, the RRE-containing RNA is transported, in an unspliced or partially spliced form, to the cytoplasm. Rev then shuttles back to the nucleus, using its nuclear localization signal. An additional level of
HIV-1 Replication
23
complexity is provided by the presence in HIV-1 RNAs of cis-acting elements, located within gag, pol, and env, whose presence inhibits RNA utilization in the absence of Rev.35,36 These elements likely bind cellular proteins that retain RNAs containing the elements in the nucleus. Rev counteracts this effect, allowing efficient RNA export to proceed. It is probable that the more “simple” retroviruses contain in their RNAs RRE-like sequences that interact with cellular Rev-like proteins to facilitate their transport to the cytoplasm. Indeed, such an element, referred to as the constitutive transport element (CTE) has been identified in the genome of Mason-Pfizer Monkey virus.37 By introducing the CTE in HIV-1 RNAs, the requirement for Rev and the RRE can be bypassed.
Virus Particle Production Following the synthesis of the full complement of viral proteins, the assembly process begins. The major player in virus assembly is the Gag precursor polyprotein, Pr55Gag.22,38 This protein contains determinants that target it to the plasma membrane, bind the membrane itself, promote Gag-Gag interactions, encapsidate the viral RNA genome, associate with the viral Env glycoproteins, and stimulate budding from the cell. Our understanding of virus assembly has been greatly assisted by detailed mutational analyses of all major domains of the Gag precursor, and by NMR and X-ray crystallography studies that have solved the structures of MA, the N-terminal and C-terminal domains of CA, and NC.39 It is important to note, however, that at this time we have little structural information comparing the folding of the mature Gag proteins with the corresponding regions of the precursor protein from which they are derived. Pr160GagPol is synthesized as the result of a frameshifting event during Gag translation. The use of this frameshifting strategy ensures that the Pol proteins are expressed at 5-10% the level of the Gag proteins. Pr160GagPol is packaged into virions via its Gag domain, largely using the same Gag-Gag interactions that drive Gag assembly.
Gag Membrane Binding and Targeting The assembly of lentiviruses, including HIV-1, takes place at the plasma membrane of the infected cell (Fig. 3). The MA domain of Gag, which occupies the N-terminal 131 residues of Pr55Gag, is largely responsible for targeting and binding the plasma membrane. The MA domain is cotranslationally modified at its N-terminus by myristic acid (Fig. 7); this fatty acid modification is essential for Gag membrane binding. Structural studies reveal that HIV-1 MA folds to expose a patch of highly basic residues on the face of MA predicted to juxtapose the plasma membrane. Together with the finding that mutations in these residues can impair membrane binding, this observation suggests that the positively charged face of MA interacts with the negatively charged acidic phospholipids on the inner leaflet of the plasma membrane thereby stabilizing membrane binding. Although MA contains the primary determinants of Gag membrane binding, the mature MA protein binds membrane weakly relative to Pr55Gag. By analogy with cellular proteins (such as recoverin), it has been proposed that MA undergoes a conformational transition following its cleavage from the Gag precursor.40 This conformation change, according to the model, causes a sequestration of the N-terminal myristic acid moiety and a partial loss in membrane binding ability. This so-called “myristyl switch” model could explain how MA might detach from the lipid bilayer and associate with the PIC following infection. HIV-1 Gag associates with membrane within minutes of its synthesis, and this membrane binding appears to be largely specific for the host cell plasma membrane. Although it is not fully understood how Gag specifically targets the plasma membrane in preference to more abundant intracellular membranes, MA, in particular the highly basic domain (Fig. 7), clearly plays a role in this process. Mutations within MA can re-route assembly to intracellular compartments (e.g., the ER or Golgi),41,42 and substitution of MA with a heterologous membrane
24
Lentiviral Vector Systems for Gene Transfer
Fig. 7. Functional domains of the HIV-1 Gag domains MA (A), CA (B), NC (C), and p6 (D). Details are provided in the text. Adapted from Freed, 1998 (ref. 22).
binding signal results in promiscuous targeting of virus assembly to both plasma and intracellular membranes.
RNA Encapsidation As discussed above, each retrovirus particle contains two single-stranded copies of genomic RNA. The cis-acting sequence that directs RNA encapsidation, known variously as the packaging signal, encapsidation element, or ψ-site, is typically located in the region of the RNA 5' of the gag initiation codon.43 In the case of HIV-1, the packaging signal appears to be more dispersed than in the murine and avian retroviruses and a larger region of the genome is required for efficient RNA packaging. The HIV-1 packaging signal is composed primarily of four stem-loop structures, referred to as SL1-SL4, although sequences outside this region contribute to efficient RNA encapsidation. The secondary structure of this packaging signal, rather than the actual nucleotide sequence itself, seems to be important in conferring RNA encapsidation specificity. RNAs that lack the packaging signal are not efficiently encapsidated
HIV-1 Replication
25
into virus particles. Retroviral RNAs are linked together at a sequence near the 5' end of the genome known as the dimer initiation signal (DIS). It is currently unclear to what extent RNA dimerization is required for efficient encapsidation. The specific encapsidation of retroviral RNAs into virus particles is mediated by interactions between the packaging signal and the NC domain of Gag. Nearly all retroviral NC proteins contain one or two zinc finger motifs, each of which coordinates a zinc ion. HIV-1 NC contains two zinc-finger motifs (Fig. 7) of the “CCHC” type (Cys-X2-Cys-X4-His-X4-Cys; where X denotes a variable amino acid). The zinc fingers of HIV-1 NC are flanked by highly basic sequences. NC displays both non-specific nucleic acid binding properties and specific genomic RNA binding; in general, the non-specific binding properties are conferred by the basic residues, whereas the zinc finger motifs, in conjunction with the basic residues, contribute to the specificity of the NC/RNA interaction. It has been proposed that NC first interacts, in a sequence-specific fashion, with the packaging signal (SL3 appears to be particularly important in this regard) then additional NC domains coat the viral RNA in a sequence-independent manner. In addition to its function in RNA encapsidation, NC plays a role in a variety of additional steps in the viral life cycle. In many cases these activities can be attributed to the ability of NC to function as a nucleic acid chaperone.44 This property enables NC to refold nucleic acid molecules to the most energetically favorable conformation. In general, retroviruses are able to package their own RNAs genomes, but not those of other retroviruses. The evaluation of chimeric viruses indicates, as mentioned above, that encapsidation specificity is determined by NC. In some cases, non-reciprocal packaging can be observed; for example, HIV-1 packages both HIV-1 and HIV-2 genomic RNAs, whereas HIV2 reportedly does not efficiently encapsidate HIV-1 RNA.45
Assembly Once Gag has arrived at the plasma membrane, it must engage in Gag-Gag (as well as Gag-lipid and Gag-RNA) interactions to enable the assembly of progeny virions to take place. A number of approaches, including in vitro assembly reactions, mutational analyses, virion incorporation assays, and yeast two-hybrid screens have suggested that several domains in Gag are important in mediating Gag-Gag interactions.22 These domains primarily encompass a region spanning the C-terminus of CA, the p2 spacer peptide, and the N-terminal portion of NC. The HIV-1 CA folds into two distinct structural and functional domains: an N-terminal “core” domain, and a C-terminal “dimerization” domain (Fig. 7). The C-terminal domain harbors the so-called “major homology region” which contains residues conserved among many retrovirus genera. Mutations within the C-terminal dimerization domain often cause defects in virus assembly, suggesting the involvement of this region in Gag-Gag interactions. HIV-1 CA, when expressed in vitro, can direct the assembly of tubular or spherical particles, again highlighting the role of CA in virus assembly. Mutations in NC, specifically within the highly basic residues near the N-terminus of the protein, also induce defects in virus particle production. This finding, together with the observation that CA-NC fusion proteins assemble in vitro more efficiently than does CA alone, have suggested that NC also promotes Gag-Gag interactions. Interestingly, in vitro assembly of CA-NC fusion proteins requires the presence of nucleic acid.46 This latter result suggests a model in which interactions between the Gag NC domain and RNA allow Gag molecules to align and pack. This model is consistent with mutational studies demonstrating that mutation in the basic residues within NC disrupt both Gag assembly and RNA binding.
Env Transport and Incorporation The HIV-1 Env glycoprotein is synthesized in the rough ER to generate the Env precursor protein, gp160.47 The protein is cotranslationally inserted into the lumen of the ER through
26
Lentiviral Vector Systems for Gene Transfer
the use of an N-terminal signal peptide; a stop-transfer signal is located in the gp41 portion of gp160. The gp120 domain is very heavily glycosylated, initially with high-mannose side chains which are converted to complex side chains during transport though the Golgi. In the ER, gp160 forms intramolecular disulfide bonds and undergoes oligomerization. Currently, the functional multimeric form appears to be a trimer, although dimers and tetramers can also be detected. gp160 is transported to the cell surface via the secretory pathway; during its trafficking through the Golgi it is cleaved by a host protease (furin or a furin-like enzyme) to generate the mature SU glycoprotein, gp120, and TM glycoprotein, gp41. Cleavage takes place at the C-terminus of a highly conserved Lys/Arg-X-Lys/Arg-Arg motif. gp160 processing is absolutely required to activate the fusogenic potential of the gp120/gp41 complex, presumably by allowing the exposure of the hydrophobic fusion peptide located at the N-terminus of gp41 (Fig. 1). After gp160 cleavage, gp41 anchors the Env complex in the membrane and associates non-covalently with gp120. The relatively weak nature of the gp120-gp41 interaction results in significant amounts of gp120 shedding from the surface of Env-expressing cells and virions. Env glycoprotein complexes that reach the cell surface are either rapidly internalized (through recognition by host cell machinery of an endocytosis motif in the gp41 cytoplasmic tail) or are incorporated into virus particles. Although the process by which the Env glycoproteins are incorporated into virions remains incompletely understood, a number of lines of evidence suggest that an interaction between the gp41 cytoplasmic tail and the MA domain of Gag recruits Env into virions.22 Observations that provide support for a gp41-MA interaction include: 1) mutations in both MA and the gp41 cytoplasmic tail can disrupt Env incorporation, 2) the effects of MA mutations on Env incorporation can be reversed by truncating the gp41 cytoplasmic tail, and the effects on Env incorporation of a small deletion in the gp41 cytoplasmic tail can be reversed by a single amino acid change in MA.48 3) HIV-1 Env is able to target virus budding to the basolateral surface of polarized epithelial cells, and 4) a direct gp41MA interaction has reportedly been detected in vitro. Despite these findings, the incorporation of heterologous or mutant Env glycoproteins containing short cytoplasmic tails can occur efficiently. It therefore appears that the incorporation of full-length Env, which contains an unusually long (150 amino acid) cytoplasmic tail, requires an interaction with, or at least must be sterically accommodated by MA. In contrast, heterologous Env glycoproteins containing short cytoplasmic tails are not subject to steric restrictions and can be efficiently incorporated. Interestingly, it was recently demonstrated that an Env mutant lacking the gp41 cytoplasmic tail was incorporated in a limited number of cell lines (e.g., HeLa and MT-4) but was largely excluded from virions in most other cell types.49 The cell type-dependent requirement for the gp41 cytoplasmic tail in Env incorporation suggests the involvement of host factors in the Env incorporation process. A practical ramification of HIV’s ability to incorporate heterologous Env glycoproteins is evident in the frequent use of the A-MuLV Env and VSV-G in pseudotyping studies. These glycoproteins, in particular VSV-G, are quite stable and confer markedly higher levels of infectivity than does the HIV-1 Env glycoprotein. In addition, the ability of VSV-G to confer virus infectivity in a wide range of cell types makes it particularly useful in potential gene therapy applications.
Budding The final step in the process of virus assembly and release involves the pinching off, or budding, of the virus particle from the host cell plasma membrane. While it was felt initially that budding was likely to be a spontaneous event, it has become clear that a wide range of retroviruses (and at least several other enveloped viruses) encode specific sequences that promote particle release. These sequences are collectively referred to as “late” or “L” domains to reflect their role late in virus assembly. Retroviruses encode their L domains at a variety of
HIV-1 Replication
27
positions in Gag; in the case of HIV-1, the L domain is present in p6 (Fig. 7). Deletion of p6, or mutations within a highly conserved Pro-Thr/Ser-Ala-Pro (P-T/S-A-P) motif located near the N-terminus of p6, markedly impair particle release.50,51 Examination of cells expressing p6-mutant HIV-1 clones reveals the presence of large numbers of particles attached to the plasma membrane by a thin tether, apparently unable to pinch off from the cell. Although the mechanism by which L domains stimulate virus release remains to be elucidated, evidence is increasing that these domains function by interacting with host factors. Most retroviral L domains contain the motif Pro-Pro-Pro-Tyr (P-P-P-Y), which is the consensus binding sequence for the so-called “WW” family of proteins. Indeed, direct interactions between P-P-P-Y-type L domains and WW proteins have been detected in vitro.52 One of these proteins, Nedd4, is a ubiquitin ligase. This latter observation, together with the finding that proteosome inhibitors, which disrupt ubiquitination, impair both HIV and Rous sarcoma virus release, suggests that L domains may function through the host ubiquitination pathway.53 How this would promote virus release remains an interesting question for future investigation.
Maturation During or shortly after virus release from the plasma membrane, the viral PR cleaves the Gag and GagPol polyprotein precursors to generate the mature Gag and Pol proteins (Figs. 1 and 3). Retroviral PRs are members of the family of aspartyl proteases. X-ray crystallography indicates that retroviral PRs function as dimers, with the substrate-binding site located in a cleft formed by two (identical) monomers.54 PR-mediated Gag and GagPol processing sets in motion a series of structural rearrangements that ultimately leads to virion maturation. PR cleaves each site with a differing efficiency; as a result, PR-mediated Gag and GagPol processing takes place as an ordered, stepwise cascade of cleavage reactions. The most visible outcome of HIV-1 maturation is that virion morphology is converted from doughnut-shaped (containing an electron-lucent center) to containing an electron-dense, conical core. Because of the degree and magnitude of protein rearrangements that are presumed to occur during maturation, this process can be considered as a second assembly (or re-assembly) reaction. Studies performed using cryo-EM techniques have visualized unprocessed retroviral Gag monomers in immature virions as being aligned likes spokes on a wheel, projecting inward from the membrane-associated MA domain at the N-terminus to NC at the C-terminus.55 Following cleavage, CA forms a conical shell around the RNA/protein complex within the core (Fig. 2). Numerous mutations have been reported, many of which are located within the N-terminal domain of CA, that prevent the formation of the normal conical core. Invariably, the failure of the virion to mature properly is associated with a complete loss of infectivity; core condensation thus appears to be essential during an early post-entry step of the replication cycle. Interestingly, core-like structures can assemble in vitro from a CA-NC fusion protein in the presence of RNA. These cones closely resemble the fullerenes formed by elemental carbon.56 During virus assembly, the N-terminal domain of CA binds, and ultimately packages into virions, the host protein cyclophilin A.57,58 Mutations that disrupt CA-cyclophilin A binding, or treatment of virus-infected cells with cyclosporin (which prevents cyclophilin A incorporation) result in markedly impaired virus infectivity. The incorporation of cyclophilin A into virions is HIV-1-specific, as neither HIV-2 nor SIV CA proteins bind this host factor. Although uncertainty remains regarding the role that cyclophilin A plays in stimulating infectivity, it has been suggested that this protein, which functions in the cell as a peptidyl-prolyl cis-trans isomerase, functions as a chaperone during maturation to prevent unfavorable CA aggregation.59 The absolute requirement for PR-mediated virion maturation has been applied to the treatment of HIV-infected individuals using inhibitors of PR. Although in infected patients,
28
Lentiviral Vector Systems for Gene Transfer
the use of PR inhibitors alone rapidly leads to the generation of drug-resistant variants, when combined with anti-RT inhibitors [(in so-called “triple” therapy or “highly active antiretroviral therapy” (HAART)], long-lasting, clinically significant reductions in virus loads can be achieved.
Role of the HIV Accessory Proteins in Virus Replication In addition to the proteins encoded by other replication-competent retroviruses (i.e., the products of the gag, pol, and env genes), and the regulatory proteins (Rev and Tat), lentiviruses encode several additional proteins with a variety of interesting, and in many cases poorly understood, functions.1,60 These proteins are commonly referred to as being “accessory” or “auxiliary” to reflect the observation that at least in culture, they are not essential for virus replication. However, in vivo, these proteins contribute, to varying degrees, to efficient virus spread and disease induction.
Vpu Vpu (for viral protein u) is an 81 amino acid integral membrane phosphoprotein that is unique to HIV-1; with the exception of the highly HIV-1-related SIVcpz, it is not encoded by the genomes of SIV or HIV-2 isolates. Vpu performs two major functions during HIV-1 replication: 1) it enhances the release of virus particles, and 2) promotes the degradation of CD4. Mutational inactivation of Vpu reduces by several-fold the efficiency with which virions are released from virus-expressing cells.61 This release function is independent of the p6 Gag L domain (described above). Interestingly, although divergent retroviruses, such as MuLV and visna, do not encode Vpu proteins, HIV-1 Vpu can stimulate their release as well.62 This observation suggests that the enhancement of release occurs through a general pathway that does not depend on the interaction of Vpu with specific viral factors. HIV-1 has evolved several mechanisms to downregulate cell-surface expression of the major receptor CD4. One mechanism involves intracellular trapping of CD4 by Env glycoproteins, a second operates through Nef (see below) and the third is promoted by Vpu. CD4 degradation by Vpu is mediated through the host ubiquitin/proteasome pathway.63 One outcome of Vpuinduced CD4 degradation is to liberate gp160 from Env/CD4 complexes in the ER, thereby increasing the amount of Env glycoprotein available for transport to the cell surface.
Vpr The vpr gene (for viral protein r) encodes a 14-kDa, 96 amino acid protein that is incorporated efficiently into virions. The incorporation of Vpr depends upon a specific interaction with a Leu-rich motif located near the C-terminus of p6 (Fig. 7). In addition to weakly stimulating gene expression from the HIV LTR, Vpr also induces the arrest of Vpr-expressing cells in the G2 phase of the cell cycle, and reportedly facilitates transport of the viral PIC to the nucleus of infected cells. Although it is not entirely clear why HIV would evolve a cell-cycle arrest function, a number of groups have reported that Vpr rapidly and efficiently arrests cells in G2. Indeed, it has been suggested that de novo Vpr expression is not required and that the Vpr present on incoming virions is sufficient to induce cell-cycle arrest. G2 arrest appears to result from inhibition of the p34cdc2-cyclin B kinase complex.64 It has been proposed that HIV LTR expression is increased during G2, thus perhaps providing a rationale for the evolution of this cell-cycle arrest function. Several observations have suggested that Vpr might play a role in nuclear import of the viral PIC: 1) Vpr mutation reduces virus infectivity in fully differentiated monocyte-derived macrophages, 2) Vpr is detected in PICs, and 3) Vpr, when expressed in cells, localizes to the nucleus. A variety of models have been proposed to account for the ability of Vpr to stimulate nuclear import; these will be discussed in more detail in the next chapter.
HIV-1 Replication
29
Vif Expression of Vif (for viral infectivity factor) is highly conserved among lentiviruses; it is encoded by all lentiviruses except equine infectious anemia virus. Vif mutation can cause profound defects in virus infectivity. Interestingly, the defective phenotype is cell-type dependent and is determined not by the target cell but by the virus-producing cell. Thus, certain cell lines (for example HeLa, COS, 293T, SupT1, CEM-SS and Jurkat) are “permissive” for Vif mutants; virus produced from these lines is fully infectious regardless of the target cell used. In contrast, other cell types (most notably, primary lymphocytes and macrophages) are “nonpermissive”. This cell-type specificity argues that host factors play a role in Vif function, and that the defect observed with vif defective mutants is imposed during virus assembly. Analysis of transient heterokaryons formed between permissive and non-permissive cells has indicated that the non-permissive phenotype is dominant, perhaps suggesting that Vif counteracts the effect of a cellular factor that inhibits the formation of infectious virions.65 Although the Vif-defective phenotype may be imposed during assembly, it is manifested early post-entry as a failure to efficiently reverse transcribe the viral genome. Reminiscent of observations made with certain post-entry Gag mutants, Vif(-) virions have been reported to display defects in proper core condensation. Interestingly, Vif has been detected at low levels in virus particles; however, the implications of virion incorporation for Vif function remain unclear.
Nef Although Nef was originally reported to suppress gene expression from the HIV LTR (hence the name “negative factor”) it is now clear that Nef plays an important positive role in lentiviral pathogenesis. Nef is a 27 kDa, membrane-associated phosphoprotein; like Gag, its membrane binding is dependent upon a myristic acid moiety covalently attached to the N terminus. As is the case for the other HIV accessory proteins, several primary Nef functions have been reported: 1) downregulation of CD4 and major histocompatibility class I (MHC I) molecules from the cell surface, 2) stimulation of virus infectivity in single-round assays, and 3) modulation of cellular activation pathways. As mentioned above, Nef is one of the three viral proteins (along with Env and Vpu) whose expression reduces cell-surface expression of CD4. Nef-induced CD4 downregulation is achieved by increasing the rate at which CD4 is internalized from the plasma membrane66 reportedly via Nef acting as a bridge between CD4 and adapter protein (AP) complexes in clathrin-coated pits. Nef also downregulates cell-surface expression of MHC I molecules, perhaps impairing the ability of cytotoxic T lymphocytes (CTLs) to detect and eliminate virus-expressing cells.67 Although in general the effects of Nef deletion on virus replication kinetics in culture are quite limited, it has been reported that in single-cycle assays, the presence of Nef modestly stimulates virus infectivity. Again, the Nef(-) defect is manifested by a reduction in the amount of viral DNA synthesized post-infection. It is currently unclear to what extent this enhancement of virus infectivity contributes to the requirement for Nef expression in vivo. It has been unambiguously demonstrated that Nef(-) clones of SIV display profound defects in virus replication and disease induction in infected macaques.68 The presence of nef deletions in virus isolates obtained from at least some infected individuals who progress to disease very slowly (the so-called long-term non-progressors) implies that Nef may play a similar role in maintaining high virus loads in HIV-1 infected humans. Although this requirement for Nef in vivo remains unexplained, Nef contains a highly conserved consensus binding site for Src homology region 3 (SH3) domains. Indeed, Nef has been reported to interact with a variety of Src-like kinases and affect their activities.69 The effect of such interactions on signal transduction pathways could stimulate virus replication in vivo. Nef has been detected at low levels in virus particles, where it localizes to the virion core. As is the case for Vif, the implications of these findings remain to be determined.
30
Lentiviral Vector Systems for Gene Transfer
Vpx Although the focus of this chapter is on HIV-1, it is worth noting briefly the functions of an additional protein, Vpx, that is encoded by the genomes of the HIV-2/SIVsm/SIVmac lineage of primate lentiviruses (but not by HIV-1). Vpx bears considerable sequence homology with Vpr, and, like the latter protein, is incorporated at relatively high levels into virions via an interaction with the C-terminus of Gag. Vpx appears to play a role in infection of non-dividing cells but does not induce cell-cycle arrest.70 Thus, the proposed nuclear import/cell cycle arrest functions of HIV-1 Vpr are segregated into two proteins (Vpr and Vpx) in the HIV-2/SIVsm/ SIVmac lentiviruses.
Concluding Remarks During the past 15 years, a wealth of knowledge has been acquired concerning the replication cycle of HIV-1. However, it should be clear from the above discussions that much remains to be learned before our understanding is complete. From the perspective of lentiviral vector development, the mechanism by which HIV-1 infects non-dividing cells is of particular interest. This topic will be the focus of Chapter 3.
References 1. Freed EO, Martin MA. HIVs and their replication. In: Knipe DM, Howley PM, Griffin D, Lamb RA, Roizman B, Martin MA, Straus SE, eds. Fields Virology, 4th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2001:1971-2041. 2. Bour S, Geleziunas R, Wainberg MA. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev 1995; 59:63-93. 3. Kwong PD, Wyatt R, Robinson J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659. 4. Hoxie JA, Alpers JD, Rackowski JL et al. Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science 1986; 234:1123-1127. 5. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700. 6. Doms RW, Peiper SC. Unwelcomed guests with master keys: How HIV uses chemokine receptors for cellular entry. Virology 1997; 235:179-90. 7. O’Brien WA, Koyanagi Y, Namazie A et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990; 348:69-73. 8. Endres MJ, Clapham PR, Marsh M et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87:745-756. 9. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862. 10. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377. 11. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725. 12. Chan DC, Fass D, Berger JM et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273. 13. Weissenhorn W, Dessen A, Harrison SC et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430. 14. Bullough PA, Hughson FM, Skehel JJ et al. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994; 371:37-43. 15. Telesnitsky A, Goff SP. Reverse transcription and the generation of retroviral DNA. In: Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997:121-160.
HIV-1 Replication
31
16. Arnold E, Jacobo-Molina A, Nanni RG et al. Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Nature 1992; 357:85-89. 17. Zennou V, Petit C, Guetard D et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101:173-185. 18. Temin HM. Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc Natl Acad Sci USA 1993; 90:6900-6903. 19. Pathak VK, Hu W-S. “Might as well jump!” Template switching by retroviral reverse transcriptase, defective genome formation, and recombination. Semin Virol 1997; 8:141-150. 20. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087-5094. 21. Bukrinsky MI, Haggerty S, Dempsey MP et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365:666-669. 22. Freed EO. HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 1998; 251:1-15. 23. Gallay P, Hope T, Chin D, Trono D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci USA 1997; 94:98259830. 24. Brown PO. Integration. In: J. M. Coffin, Varmus HE, eds. Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997:161-203. 25. Chen H, Wei SQ, Engelman A. Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome. J Biol Chem 1999; 274:17358-17364. 26. Wei SQ, Mizuuchi K, Craigie R. A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration. EMBO J 1997; 16:7511-7520. 27. Farnet CM, Bushman FD. HIV cDNA integration: molecular biology and inhibitor development. Aids 1996; 10:S3-11. 28. Ross EK, Buckler-White AJ, Rabson AB et al. Contribution of NF-kB and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: Distinct patterns of viral growth are determined by T-cell types. J Virol 1991; 65:4350-4358. 29. Dayton AI, Sodroski JG, Rosen CA et al. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986; 44:941-947. 30. Fisher AG, Feinberg MB, Josephs SF et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986; 320:367-371. 31. Berkhout B, Silverman RH, Jeang K-T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989; 59:273-282. 32. Wei P, Garber ME, Fang SM et al. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92:451-462. 33. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 1993; 67:6365-6378. 34. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52:491-532. 35. Maldarelli F, Martin MA, Strebel K. Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: Novel level of gene regulation. J Virol 1991; 65:5732-5743. 36. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, Haseltine WA. Intragenic cis-acting art generesponsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci USA 1988; 85:2071-2075. 37. Bray M, Prasad S, Dubay JW et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 1994; 91:1256-1260. 38. Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Coffin H, Varmus HE, eds. Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1997:263-334. 39. Turner BG, Summers MF. Structural biology of HIV. J Mol Biol 1999; 285:1-32. 40. Zhou W, Resh MD. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol 1996; 70:8540-8548.
32
Lentiviral Vector Systems for Gene Transfer
41. Facke M, Janetzko A, Shoeman RL et al. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol 1993; 67:4972-4980. 42. Freed EO, Orenstein JM, Buckler-White AJ et al. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 1994; 68:5311-5320. 43. Berkowitz R, Fisher J, Goff, SP. RNA packaging. Curr Top Microbiol Immunol 1996; 214:177-218 44. Rein A, Henderson LE, Levin JG. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: Significance for viral replication. Trends Biochem Sci 1998; 23:297-301. 45. Kaye JF, Lever AM. Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: A possible role for the p2 domain of Gag in RNA encapsidation. J Virol 1998; 72:5877-5885. 46. Campbell S, Vogt VM. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol 1995; 69:6487-6497. 47. Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995; 270:23883-23886. 48. Murakami T, Freed EO. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol 2000; 74:3548-3554. 49. Murakami T, Freed EO. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci USA 2000; 97:343-348. 50. Gottlinger HG, Dorfman T, Sodroski JG et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991; 88:3195-3199. 51. Huang M, Orenstein JM, Martin MA et al. p6Gag is required for particle production from fulllength human immunodeficiency virus type 1 molecular clones expressing protease. J Virol 1995; 69:6810-6818. 52. Garnier L, Wills JW, Verderame MF et al. WW domains and retrovirus budding. Nature 1996; 381:744-745. 53. Vogt VM. Ubiquitin in retrovirus assembly: Actor or bystander? Proc Natl Acad Sci USA 2000; 97:12945-12947. 54. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993; 62:543-585. 55. Yeager M, Wilson-Kubalek EM, Weiner SG et al. Supramolecular organization of immature and mature murine leukemia virus revealed by electron cryo-microscopy: Implications for retroviral assembly mechanisms. Proc Natl Acad Sci U S A 1998; 95:7299-7304. 56. Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI. Assembly and analysis of conical models for the HIV-1 core. Science 1999; 283:80-83. 57. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994; 372:359-362. 58. Luban J, Bossolt KL, Franke EK et al. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993; 73:1067-1078. 59. Grattinger M, Hohenberg H, Thomas D et al. In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A. Virology 1999; 257:247-260. 60. Cullen BR. HIV-1 auxiliary proteins: Making connections in a dying cell. Cell 1998; 93:685-692. 61. Strebel K, Klimkait T, Martin MA. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988; 241:1221-1223. 62. Gottlinger HG, Dorfman T, Cohen EA et al. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 1993; 90:7381-7385. 63. Margottin F, Bour SP, Durand H et al. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998; 1:565-574. 64. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995; 69:6705-6711.
HIV-1 Replication
33
65. Simon JH, Gaddis NC, Fouchier RA et al. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 1998; 4:1397-1400. 66. Aiken C, Konner J, Landau NR et al. Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994; 76:853-864. 67. Collins KL, Chen BK, Kalams SA et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391:397-401. 68. Kestler HW, III, Ringler DJ, Mori K et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65:651-62. 69. Marsh JW. The numerous effector functions of Nef. Arch Biochem Biophys 1999; 365:192-198. 70. Fletcher TM, 3rd, Brichacek B, Sharova N et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). Embo J 1996; 15:6155-6165.
CHAPTER 3
Determinants for Lentiviral Infection of Non-Dividing Cells Marie A. Vodicka
Abstract
L
entiviruses share the common characteristic of infecting non-dividing target cells, distinguishing them from the oncogenic retroviruses which only productively infect dividing cells. The search for determinants for infection of non-dividing cells has produced a number of candidates. From HIV-1, the viral proteins matrix, integrase and Vpr have all been implicated. A structural determinant, the central DNA flap, has also been implicated. The supporting evidence for each of these proposed determinants will be examined and compared to how other viruses, non-retroviruses, transport their genomes to the nucleus. With currently available data, integrase and the central DNA flap appear to be the key players, and yet the mechanism for infection of non-dividing cells remains undefined.
Introduction Because retroviruses require integration into the host cell genome to complete the viral life cycle, the virus must have a mechanism for getting its genome in proximity to the host cell chromosomes. The oncogenic retroviruses require mitosis for integration, presumably because this then allows them access to host cell chromosomes.1,2 However, one of the distinguishing features of lentiviruses is the ability to infect non-dividing cells.3 Why lentiviruses share this characteristic and how they are able to infect non-dividing cells is not well understood. Macrophages, or cells of the monocyte lineage, are major in vivo targets of all lentiviruses. Macrophages are terminally differentiated cells that are in a G0, or non-proliferating, state. From a teleological perspective, lentiviruses either have the capacity to infect non-dividing cells, and so macrophages became a major target; or because the lentiviruses need to infect macrophages to complete their life cycles, they evolved mechanisms to infect non-dividing cells. Interestingly, the primary targets for the primate lentiviruses (HIV and SIV) and FIV are activated T-cells, a rapidly dividing cell type. Yet infection of non-dividing cells is important for the life cycle and pathogenesis of these viruses. For HIV, non-dividing target cells include macrophages which have been implicated in transmission of virus between hosts, and resting T cells which have been implicated in transmission and in persistence of a viral reservoir.4 Whether proliferating or not, cells must be metabolically active; completely quiescent cells cannot complete reverse transcription and are not productively infected by HIV.5 Thus even the lentiviruses with expanded cell tropism depend on infection of non-dividing cells. The proposed determinants for HIV infection of non-dividing cells, examining the evidence for each determinant and pathway and referring to relevance of HIV results for other Lentiviral Vector Systems for Gene Transfer, edited by Gary L. Buchschacher, Jr. ©2003 Eurekah.com.
36
Lentiviral Vector Systems for Gene Transfer
lentiviruses will be presented. This list includes the viral structural protein—matrix (MA), a viral enzymatic protein—integrase (IN), a viral accessory protein—Vpr, a viral cis-acting DNA sequence—the central polypurine track (cPPT), and the host cell cytoskeleton.
Nuclear Transport Before discussing how viruses reach the nucleus, a brief overview of cellular nuclear transport will be given (Fig. 1). Bi-directional transport of molecules between the nucleus and cytoplasm of eukaryotic cells is controlled by large (approximately 125 MD), multi-protein complexes called nuclear pore complexes (NPC) that are found throughout the double layered nuclear envelope which maintain the separation of these compartments.6 The aqueous channels permit the diffusion of small molecules into and out of the nucleus, but larger molecules, usually anything greater than 50 KD or larger in diameter than 9 nm, require signal-mediated transport.7,8 However, nuclear molecules smaller than the theoretical exclusion size usually contain nuclear import signals. Nuclear import and export of proteins and RNAs are mediated by a family of nuclear transport proteins, generally termed importins (or karyopherins) and exportins (reviewed in ref. 8).9 In general, nuclear proteins contain a nuclear localization sequence (NLS) that is recognized, either directly by a member of the importin β/transportin family of transporters, or indirectly through an adapter protein which subsequently binds to the importin β for cargo transport. The most studied of these adapters is importin α, which mediates protein import via the “classical pathway”. Importin α binds to a single or bipartite stretch of basic amino acids that functions as a NLS. However, other adapter proteins have been identified which recognize different NLSs. Nuclear export works in a similar way, but with different transporter and adapter proteins.8,10 These pathways often involve the transport of RNA or RNPs from the nucleus to the cytoplasm. As for nuclear import, different nuclear export substrates use different nuclear export signals (NES) and transportins, but all pathways converge at the nuclear pore. The best characterized nuclear exporter is CRM1, which mediates nuclear export of leucine-rich NES cargo proteins by direct binding to the NES.11,12 Finally, there are some nucleocytoplasmic shuttling proteins, best exemplified by the M9 signal of hnRNP A1,13 containing overlapping import and export signals which often cannot be separated, and so are termed nuclear shuttling (NS) signals.14 Directionality of nucleocytoplasmic transport is thought to be controlled by a gradient of GTP and GDP bound forms of the GTPase, Ran.15-17 The Ran GTPase-activating protein (RanGAP) and its activators are in high concentrations in the cytoplasm while the Ran guanine nucleotide exchange factor (RanGEF) is at high concentrations in the nucleus, leading to the prediction that cytoplasmic Ran is mostly GDP loaded and nuclear Ran is mostly GTP loaded. For nuclear import, RanGTP promotes dissociation of importin β and its cargo on the nuclear side while nuclear export factors bind cargo at higher affinity in the presence of RanGTP (nuclear) and release cargo in the presence of RanGDP (cytoplasmic). This model fits currently available data to explain directionality of transport, but the mechanism for actual transit through the pore is still not understood.18
Transit of Non-Retroviral Particles One of the issues confounding analysis of retroviral infection and integration is our paucity of knowledge about viral particle composition and structure after it enters the cytoplasm of the target cell. Although the molecular details of reverse transcription and integration are well characterized (see Chapter 2), the transit of the virus core and viral genome from the site of entry at the plasma membrane to the site of integration in the host chromosomes is poorly understood for retroviruses. However, a number of diverse viruses must deliver their genomes to the nucleus to replicate, and some of these pathways are better understood (Table 1).
37
Determinants for Lentiviral Infection of Non-Dividing Cells
Table 1. Delivery of viral genomes to nucleus Virus
Genome
Structure
Transport (envelope/capsid size)
Nuclear Entry to Nucleus
Adenovirus
dsDNA
non-enveloped 90 nm
capsid in endosome & direct contact with microtubule motors; capsid disassembly during transport
capsid binds NPC, injects DNA through pore
SV40
dsDNA
non-enveloped 50 nm
capsid in endosome & soluble import factors
through NPC after capsid conformational changes
Herpes Virus dsDNA
enveloped 100 nm
capsid direct transport on microtubules by dynein
through NPC; unknown mechanism
Influenza
minusstrand RNA, segmented
enveloped 20X100 nm long rods
RNA-RNP complexes with soluble import
classical import via NPC factors
Oncogenic Retovirus
RNA, enveloped capsid 50X with DNA 100 nm cones; intermediate PIC 28 nm
PIC in cytoplasm, unknown mechanism
at mitosis; unknown mechanism
Lentivirus (HIV)
RNA, enveloped capsid 50X with DNA 100 nm cones; intermediate PIC 28 nm
PIC in cytoplasm, possible actin & microtubule cytoskeleton; soluble import factors
through NPC; mechanism unknown
Many DNA viruses transport their genomes to the intact nucleus to take advantage of host cell DNA replication factors. Some RNA viruses also transport their genomes to the nucleus, not for RNA synthesis, but to make use of host cell splicing factors. The mechanisms for transport are as varied as the viruses, but all pathways converge at the nuclear pore for entry.19 Transport of DNA is not a normal cellular function, and so viruses must adapt the normal cellular nuclear import pathway to deliver their genomes. Viral genome complexes and capsids are too large to diffuse through the cytoplasm,20 and so many of them enlist host cell cytoskeletal transport systems, particularly microtubules,21 in addition to the soluble nuclear import factors.22 Two DNA tumor viruses, SV40 and adenovirus, use different mechanisms for delivering their genomes to the nucleus. However, both remain as intact capsids throughout much of their cytoplasmic transit. The non-enveloped SV40 virion enters the cell by endocytosis and is transported through the cytoplasm in the endosome. Near the nucleus, the viral particle, having adopted a modified conformation, exits the endosome. In this partially dissociated form composed of viral structural proteins, the still recognizable viral particle enters the nucleus through the NPC, facilitated by its NLS containing proteins.23 In contrast, adenovirus capsids travel on microtubules, initially within an endocytic vesicle, but later, by direct interaction with host cell microtubule motors.24,25 The adenovirus capsid docks at the NPC and then
38
Lentiviral Vector Systems for Gene Transfer
Fig. 1. Nuclear import in the cell. The major nuclear import factors and pathways are represented schematically, beginning with NLS-substrates binding to soluble nuclear import factors (the adapter, importin α and the transporter importin β or transportin) in the cytoplasm. These complexes are docked at the nuclear pore and then translocated through the pore into the nucleus where they dissociate when RanGDP is converted to RanGTP. Import factors are recycled to the cytoplasm via nuclear export pathways and NLS substrates remain in the nucleus. The directionality is likely controlled by higher concentrations of RanGDP in the cytoplasm and higher concentrations of RanGTP in the nucleus, maintained by the Ran GTPase activating protein (RanGAP) and the Ran guanine nucleotide exchange factor (RanGEF), respectively.
dissociates as its genome is injected through the pore into the nucleoplasm.22,26 Interestingly, the dissociation of the adenovirus genome from its capsid occurs in a stepwise fashion, beginning immediately upon endocytic uptake of the virion as it enters the cell, and continuing until the genome is completely dissociated from the capsid to enter the nucleus.24 Herpes virus capsid enters the cytoplasm via direct fusion between the viral envelope and the cell plasma membrane. The released capsid is transported by dynein along microtubules to the NPC where the capsid is left and the genome with associated viral proteins enters the nucleus.27 The RNA genome of influenza virus enters the nucleus as part of ribonucleoprotein (RNP) complexes, making use of the cellular nuclear import pathways by NLSs in the protein component of the RNPs.28, 29 Thus delivery of a viral payload to the nucleus is not unique to retroviruses, but this part of the life cycle has been uniquely difficult to study for retroviruses. The capsids of the viruses described above remain largely intact, or at least as recognizable structures, throughout much of this process. Retroviral particles disassemble, and the resulting complexes for reverse transcription and integration are difficult to visualize and remain poorly defined throughout the cytoplasmic transport and nuclear entry.
Determinants for Lentiviral Infection of Non-Dividing Cells
39
Fig.2. HIV and MLV preintegration complexes and nuclear entry. Structural (black circles) and enzymatic proteins (white circles) are part of the viral core, and some remain associated with the PIC after viral entry, uncoating and reverse transcription. The structure of the PIC is not well defined, but is known to differ in composition between the lentivirus HIV (which has a partially triple stranded genome and carries the accessory protein Vpr) and the oncogenic retrovirus, MLV. HIV infects in the absence of mitosis and contains several potential determinants for nuclear entry, listed right, but MLV requires mitosis for integration and productive infection. Note, DNA flap drawn larger, out of scale, for emphasis. RT, reverse transcriptase; NC, nucleocapsid; CA, capsid; MA, matrix; IN, integrase.
Retroviral Preintegration Complexes Post-entry retroviral particles first form a reverse transcription complex (RTC), and upon completion of viral DNA synthesis from the RNA template (see Chapter 2 for details), the viral genome complex is termed a preintegration complex (PIC). Studied mostly from MLV and HIV, the strict functional definition of the PIC is to be integration competent in any of a number of in vitro integration assays. The structure and components of the retroviral PIC remain elusive. However, analysis of integration competent complexes from infected cells has provided some information on the size (estimated Stokes radius of 28 nm)30 and composition of the PIC (Fig. 2). In contrast to the viruses described above, neither capsid or nucleocapsid were found associated with the viral genome. But the matrix protein (MA), Vpr, integrase (IN), and reverse transcriptase (RT) have all been found in theses complexes,31 in addition to several cellular proteins, most notably HMGI/Y and BAF.32,33 Failure to detect a particular protein in the complex is not proof that it is absent, however, because it may be due to sensitivity of detection or loss of components during isolation. HMG and BAF proteins appear to facilitate integration itself and have not been posited for importance in transport of the complex or for infection of non-dividing cells.33-35
40
Lentiviral Vector Systems for Gene Transfer
Assays for Infection of Non-Dividing Cells HIV infection of non-dividing cells is assayed both directly and indirectly. Productive, spreading infection in a non-dividing cell type, particularly macrophages, and other terminally differentiated cells, such as neurons, is the best demonstration of infection of non-dividing cells. Failure to replicate in macrophages, however, must be contrasted with replication in a dividing cell type, usually T-cells, to demonstrate that the virus being assayed is not completely replication defective. Alternatively, single cycle assays are also used, often comparing infection of artificially growth-arrested cell cultures to their unmanipulated, proliferating counterparts. Indicator cell lines that activate a reporter gene upon expression of newly synthesized viral proteins (MAGI, GHOST)36,37 are most commonly used for these experiments, but HIV or other lentiviral derived vectors carrying reporter genes can be assayed in diverse cell types, limited only by envelope tropism. Nuclear entry of viral genomes, although not a measure of virus infectivity, is often used as an assay read-out because it is a prerequisite for viral integration. Detection of 2 LTR circles, circularized viral genomic DNA found only in the nucleus,38 by a variety of methods (PCR, Southern blot), is the most widely used of these assays. Thus, although the 2 LTR circle is a dead-end product in the viral life cycle, it is an indication that reverse transcription is complete and that the viral genome has entered the nucleus. More recently, assays to detect bona fide integration have also been developed, using Alu-PCR, a nested PCR method with primers to the LTR and to repetitive Alu-elements found throughout the human genome.39
Viral Protein Determinants for HIV-1 Infection of Non-Dividing Cells HIV MA was the first protein examined for its effects on infection of non-dividing cells. A stretch of basic residues in the amino terminus of MA (25GKKKYKLKH) was tested in a classic assay for NLS function;40 microinjection of BSA coupled to a synthetic peptide containing (25GKKKYKLKH) resulted in nuclear uptake of the conjugate.41 Substitution of the first two arginines with threonines (25GTTKYKLKH) to disrupt NLS function inhibited infection and nuclear accumulation of viral genomes (2 LTR circles) in growth arrested T-cells while leaving infectivity and nuclear entry unperturbed in proliferating T-cells.41 Further experiments demonstrated that mutations in the MA-NLS which knock-out the nuclear import function dramatically decreased HIV infection of macrophage but not dividing T-cell cultures.42-44 The hypothesis that MA promotes nuclear entry of the HIV genome complex by using the classical nuclear import pathway of the cell was supported by additional experiments. MA-GST fusions enter the nucleus in microinjection experiments.45 MA fails to enter the nucleus when the importin α/β pathway is disrupted, and manipulations interfering with MA nuclear entry also block HIV infection of macrophages.46 MA is myristoylated at its N-terminus to target the Gag polyprotein precursor to the plasma membrane during virion assembly (see Chapter 2). This would seem to contradict its NLS, and thus it was proposed that a Cterminal phosphorylation of MA regulates MA localization.44 However the role of phosphorylation in regulation of MA localization and nuclear import of the PIC remains controversial.4749 In fact, the role of N-terminal basic region of MA for promoting nuclear entry of the PIC has been called into question.50-52 Subsequent researchers were unable to demonstrate an autonomous NLS function for the proposed MA-NLS, nor were they able to demonstrate nuclear import of MA as part of a fusion protein, and the “NLS mutant” phenotype of MA was attributed to gag processing defects. Yet some researchers, having demonstrated a second MA NLS, contend that the karyophilic properties of MA are necessary and sufficient for the nuclear import of the HIV PIC and infection of non-dividing cells.53 The importance of MA is further
Determinants for Lentiviral Infection of Non-Dividing Cells
41
Fig. 3. Lentivirus genomes. Note that the accessory genes, vpr/vpx are found only in primate lentiviruses and that vif is found in all lentiviruses except EIAV (Modified from ref. 3).
42
Lentiviral Vector Systems for Gene Transfer
confounded by experiments demonstrating that MA is dispensable for HIV infection in some conditions.54 Vpr was the next HIV protein examined for its effect on infection of non-dividing cells. It had been noted that Vpr mutations decreased HIV-1 infection of macrophages.55-57 Subsequent experiments attributed this to Vpr nuclear targeting of the PIC in a partially redundant fashion with MA.43 Deletion of Vpr decreased transport of the viral genome to the nucleus (2 LTR circles) and decreased infection of macrophages.43 Again, the attenuation in infection was specific to non-proliferating cells without affecting infection of proliferating cells. Significantly, viruses with mutations deleting Vpr and disrupting the NLS of MA had a more severe phenotype than the single mutants, with a decrease in infection of macrophages and growth arrested cells. However no conventional NLS is detectable in Vpr, and Vpr mediated nuclear import was not disrupted by interference with the importin pathway.46 Vpr binds to importin α, not as an NLS substrate but through a different site on importin α from its NLS binding site.58 Additionally Vpr binds to nucleoporins, and it has been proposed that this facilitates docking of the PIC to the nuclear pore for viral genome entry.59-61 Nuclear pore targeting was shown to be necessary for Vpr to positively affect HIV infection of macrophages. Two independent signals within Vpr, one in the amino half and the other in the carboxy half of the protein, have been implicated in Vpr nuclear import,62-64 and these seem to function in the absence of additional soluble factors, usually required for nuclear import.65 Vpr has also been shown to weakly enhance nuclear uptake of NLS substrates.66 For HIV-2, the closely related protein, Vpx, is posited to perform a similar function to HIV-1 Vpr in terms of promoting macrophage infection.67,68 Vpr (or Vpx in HIV-2) is an attractive candidate as a determinant for infection of non-dividing cells on the one hand because it is part of the PIC and has clearly demonstrated nuclear import or NPC docking ability. And yet, it is a poor candidate on the other hand because it is only present in primate lentiviruses (Fig. 3). The non-primate lentiviruses infect non-dividing cells without a Vpr. Viruses lacking Vpr and MA-NLS still replicate, at reduced levels, in non-dividing cells, and so another determinant was sought. The third HIV protein implicated in nuclear entry of the PIC is the viral integrase (IN), whose enzymatic function is essential for integration of the double-stranded DNA viral genome into the chromosomes of the infected cell to form the provirus. IN also displays nuclear import function when assayed by microinjection, but unlike Vpr and like MA, IN nuclear import is blocked when the importin α/β pathway is disrupted.45 However mutations in IN to inactivate the putative NLS are replication defective—apparently integration defective, and therefore it was impossible to separate the nuclear import properties of IN from its integration function using this mutant. Recently this IN NLS (aa 211-219) has been disputed for its importance in infection of non-dividing cells and even for its NLS function. However the nuclear import abilities of IN first assayed by microinjection of GST-IN45 fusion proteins have been confirmed using green fluorescent protein-IN fusion proteins.69,70 By using truncations of these fusion proteins, another region of IN with NLS function has been identified by Malim and colleagues.71 This sequence (aa 161-173), IIGQVRDQAEHLK, does not resemble a classical NLS, but addition of this sequence confers nuclear import to a heterologous substrate. Mutagenesis of the IN NLS prevents nuclear accumulation of INfusion protein. In a viral context, the IN NLS mutant is replication defective both for dividing and non-dividing cells. However, the authors demonstrate the primary defect is nuclear entry because the enzyme is integration competent in vitro and viral infection can be complemented by addition of IN with a mutation in the catalytic site and a wild-type NLS. From this the authors infer that since IN forms dimers, one subunit provides the catalytic activity and the other provides the NLS function, thus demonstrating that IN NLS is required for all HIV infection. Based on results primarily from HIV-1 studies, IN appears the most likely candidate for a viral protein determinant for infection of non-dividing cells. However, the transfer of any of
Determinants for Lentiviral Infection of Non-Dividing Cells
43
Fig. 4. Involvement of cytoskeleton during early HIV infection. Many viruses (Table 1) depend upon host cell cytoskeletal transport systems for delivery of the viral genome to the nucleus. This possibility has only recently been investigated for HIV, and this diagram remains somewhat speculative.
these three proteins (MA, Vpr, IN) to MLV does not enable MLV to infect non-dividing cells (A. Perez, unpublished data).72 The role of MA is in dispute. Vpr has nuclear import properties, but it is not part of non-primate lentiviruses. Although Vpr may have a facilitory function, it is unlikely to be essential for HIV infection of non-dividing cells. Nuclear import functions of Vpr and MA may be important for a different stage of the life cycle because both proteins have been identified as nucleocytoplasmic shuttling proteins.63,73 IN has a demonstrable NLS, the function of which appears important for HIV infection. However, it appears essential for infection of dividing as well as non-dividing cells. How this might change our thinking about determinants for infection of non-dividing cells is discussed further in the next sections.
Viral Genome Structural Determinants The newest development in understanding HIV infection of non-dividing cells is not a protein at all, but a structural component of the HIV genome.74 All lentiviruses, including HIV, contain a central polypurine track (cPPT) that enables initiation of second plus-strand synthesis (see Chapter 2). 75,76 This results in what has been termed a central DNA flap (see Fig. 5). Recent experiments demonstrated that mutations in the HIV genome which prevent formation of this flap are replication defective. Even minor alterations to the cPPT affecting flap formation result in severe attenuation of infectivity. The authors attribute the defect to a failure of nuclear entry of the genome. This is because virus production is not affected, reverse transcription products form in the appropriate time and amount, and isolated PICs can perform in vitro integration. Thus, the defect appears to be between completion of reverse transcription and integration and, therefore, at the point of nuclear entry. Further supporting the importance of
44
Lentiviral Vector Systems for Gene Transfer
Fig. 5. Models for lentivirus (HIV) nuclear transport and entry. These models are conjectural based upon currently available data. A) Lentiviruses may require transport of the PIC through the cytoplasm to the nucleus, making use of host cell microtubule transport. Microtubule motors would perform the actual translocation, but it is unclear if motors would interact directly with viral components of the PIC or through a cellular protein. B) IN is the best viral protein candidate for HIV nuclear entry. It may facilitate viral genome entry through proposed classical NLSs or through more recently proposed functional nuclear import signal that likely operates by binding to another protein with a NLS. This other protein, designated “X”, would interact with the cellular nuclear import factors, such as importin β. Protein X could be a viral protein, such as MA, or more likely, an unidentified cellular protein. C) The DNA flap produced from the cPPT is a structural element required for HIV infection, appearing to be important for nuclear entry. D) All of the above proposed determinants may work together to promote nuclear entry of the PIC, enabling infection of non-dividing cells. In this view, the complex may be transported to the nucleus on microtubules, where soluble nuclear import factors and viral proteins, such as Vpr, dock it to the NPC. Nuclear import signals in viral and cellular proteins associated with the complex and the genome structure promote translocation of the complex through the pore, into the nucleus where it is able to integrate into the host cell genome. Note, DNA flap drawn larger, out of scale, for emphasis. PIC, preintegration complex; IN, integrase; β, importin β; NPC, nuclear pore complex.
Determinants for Lentiviral Infection of Non-Dividing Cells
45
this structure for infection of non-dividing cells is that when transferred to a HIV vector, it enhances transduction in non-dividing cells by about 10 fold.77,78 However there are problems with interpreting this central DNA flap as the determinant for nuclear entry of the genome and infection of non-dividing cells. Mutations in the cPPT affect infection of dividing as well as non-dividing cells. Therefore the defect is not specific to non-dividing cells. The authors point out that there is no direct evidence for a mitosis-dependent mechanism for lentiviral genome nuclear entry and that a failure at nuclear entry may affect dividing as well as non-dividing cells;74 this is similar to the phenotype of the newly described IN-NLS mutant above.71 Also, it is unclear if this cDNA flap is a stable structure that is preserved up to integration.79 Additionally, the cPPT is not absolutely required for infection of non-dividing cells because HIV vectors that lack the cPPT still transduce non-dividing cells.80 Perhaps the most striking feature of these studies is that they raise the possibility of a structural determinant for infection of non-dividing cells—a structure found in lentiviruses, but not in oncogenic retroviruses.
Cellular Transport Pathways and the Cytoskeleton The previous sections have focused on lentiviral nuclear entry, but not on transport through the cytoplasm. However, above it was discussed how other viruses use nuclear transport factors, and especially microtubule transport, to reach the nucleus. Unless retroviruses are significantly different from other viruses, it seems likely that the cytoskeleton plays a role in transport of retroviral particles through the cytoplasm to the nucleus (Table 1; Fig. 4). Actin is present in the HIV virion, and the integrity of the actin cytoskeleton is thought to be important for virion assembly.81,82 In analogy with entry of other viruses, integrity of the cortical actin cytoskeleton is likely important for HIV entry at the plasma membrane.21 An intact actin cytoskeleton may also be necessary for completion of reverse transcription,83 but microfilament disruption in this experiment cannot distinguish between effects at entry and early post-entry. There is also recent evidence for involvement of microtubules in HIV transport to the nucleus (Vodicka, Hope, McDonald, unpublished data). Thus HIV cytoplasmic transport may rely on microtubules as do adenovirus, herpes virus and SV40. It is unclear if an HIV protein in the PIC would bind directly to microtubule motors or if this interaction would be mediated by a cellular protein. However, considering that the lentiviral PIC is too big to diffuse through the cytoplasm and that diverse viruses use the host cell cytoskeleton, especially microtubules, to deliver their genomes to the nucleus, it is likely that lentiviral infection will also rely on cellular cytoskeletal transport (Fig. 4).
Summary and Conclusions Unfortunately, the current data leave us with no clear answer for a single, or multiple, determinant for lentiviral infection of non-dividing cells (Fig. 5). In this discussion, and in the field, it has been assumed that the mechanism is shared between all lentiviruses, but it should at least be considered that different lentiviruses may infect non-dividing cells by different mechanisms. However, embracing that assumption, the most conserved characteristics between lentiviruses that have been implicated as determinants for infecting non-dividing cells are the IN and cPPT. The recent demonstration of the importance of HIV-1 IN NLS and DNA flap may lead us to approach the question a little differently. Perhaps, as suggested by Charneau’s and Malim’s groups, lentiviruses always go through the NPC to get inside the nucleus even in dividing cells, and the previous experimental distinction between infection of dividing and non-dividing cells is misleading when searching for a determinant for infection of non-dividing cells. If so, what makes lentiviruses different from oncogenic retroviruses? There is evidence that avian sarcoma virus IN contains a functional NLS,84 and yet this oncogenic retrovirus does not infect nondividing cells. Perhaps we should look to a structural determinant, such as the DNA flap. Yet
46
Lentiviral Vector Systems for Gene Transfer
even this is not absolutely required to infect non-dividing cells. It is striking that neither HIV1 IN or the cPPT transferred to MLV confers ability to infect non-dividing cells. Most studies on lentiviral infection of non-dividing cells have focused on nuclear entry, but perhaps nuclear entry per se is not the determining factor. This suggests that nuclear entry may be necessary for infection of non-dividing cells, but some other determinant(s) may govern this process. Perhaps in analogy with infection of other viruses, the infection needs to be viewed as a whole—viral entry, uncoating and reverse transcription, transport of the PIC, nuclear entry of the genome, and integration—with each step a necessary precursor to the next. In this whole process, a hierarchy of necessary steps, lies the difference between lentiviruses and oncogenic retroviruses, and while disruption of a single step will block lentiviral infection, transfer of a single determinant will not enable oncogenic retroviral infection of non-dividing cells. The gaps between entry at the plasma membrane and nuclear entry, and between nuclear entry and integration may hold the keys to our understanding lentiviral infection of nondividing cells.
References 1. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68:510-516. 2. Roe T, Reynolds TC, Yu G et al. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993; 12:2099-2108. 3. Joag SV, Stephens EB, Narayan O. Lentiviruses. 3rd ed. Vol. 2. Philadelphia: Lippincott-Raven, 1996. 4. Zhang Z, Schuler T, Zupancic M et al. Sexual transmision and propagation of SIV and HIV inresting and activated CD4+ T cells. Science 1999; 286:1353-1357. 5. Korin YD. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol 1999; 73:6526-6532. 6. Talcott B, Moore MS. Getting across the nuclear pore complex. Trends Cell Biol 1999; 9:312-318. 7. Mataj IW, Englmeier L. Nucleocytoplsamic transport: The soluble phase. Ann Rev Biochem 1998; 67:265-306. 8. Nakielny S, Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell 1999; 99:677-690. 9. Adam SA, Gerace L. Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import. Cell 1991; 66:837-847. 10. Cullen BR. Nuclear RNA export pathways. Mol Cell Biol 2000; 20:4181-4187. 11. Wen W, Meinkoth JL, Tsien RY et al. Identificaion of a signal for rapid export of proteins from the nucleus. Cell 1995; 82:463-473. 12. Fukuda M, Asano S, Nakamura T et al. CRM1 is repsonsible for intracellular transport mediated by the nuclear export signal. Nature 1997; 390:308-311. 13. Michael WM, Choi M, Dreyfuss G. A nuclear export signal in hnRNP A1: A signal-mediated, temperature-dependent nuclear protein export pathway. Cell 1995; 83:415-422. 14. Michael WM. Nucleocytoplasmic shuttling signals: Two for the price of one. Trends Cell Biol 2000; 10:46-50. 15. Cole CN, Hammell CM. Nucleocytoplasmic transport: driving and directing transport. Curr Biol 1998; 8:R368-372. 16. Moore MS, Blobel G. The GTP-binding protein Ran/TC4 is required for protein import in to the nucleus. Nature 1993; 365:661-663. 17. Görlich D, Dabrowski M, Bischoff FR et al. A novel class of RanGTP binding proteins. J Cell Biol 1997; 138:65-80. 18. Ohno M, Fornerod M, Mattaj IW. Nucleocytoplasmic transport: the last 200 nanometers. Cell 1998; 92:327-336. 19. Izaurralde E, Kann M, Pante N et al. Viruses, mircoorganisms and scientists meet the nuclear pore. EMBO J 1999; 18:289-296.
Determinants for Lentiviral Infection of Non-Dividing Cells
47
20. Luby-Phelps K. Ctyoarchitechture and physical properits of cytoplasm: volume, visocity, diffucion, intracellullar surface area. Int Rev Cytol 2000; 192:198-221. 21. Sodeik B. Mechanisms of viral transport in the cytoplasm. Trends Microbio 2000; 8:465-472. 22. Whittaker GR, Helenius A. Nuclear import and export of viruses and virus genomes. Virology 1998; 246:1-23. 23. Greber UF, Kasamatsu H. Nuclear targeting of SV40 and adenovirus. Trends Cell Biol 1996; 6:189-195. 24. Greber UF, Willetts M, Webster P et al. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75:477-486. 25. Soumalainen M, Nakano MY, Keller S et al. Microtubule-dependent plus-and minus end-directed motilities are competing for nuclear targeting of adenovirus. J Cell Biol 1999; 144:657-672. 26. Greber UF, Soumaliainen M, Stidwill RP et al. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J 1997; 16:5998-6007. 27. Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated transport of incoming herpes implex virus 1 capsids to the nucleus. J Cell Biol 1997; 136:1007-1021. 28. O’Neill RE, Jaskunas R, Blobel G et al. Nuclear import of influenza virus RNA can be mediated by viralnucleoproteina nd transport factors requred for protein import. J Biol Chem 1995; 270:22701-22704. 29. Whittaker G, Bui M, Helenius A. The role of nuclear import and export in influenza virus infection. Trends Cell Biol 1996; 6:67-71. 30. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J Virol 1997; 71:5382-5390. 31. Farnet CM, Haseltine WA. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65:1910-1915. 32. Farnet CM, Bushman FD. HIV-1 cDNA integration: requirement of HMGI(Y) protein for function of preintegration complexes in vitro. Cell 1997; 88:483-492. 33. Li L, Farnet CM, Anderson WF et al. Modulation of activity of Moloney Murine Leukemia virus preintegration complexes by host factors in vitro. 1998; 72:2125-2131. 34. Chen H, Engelman A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc Natl Acad Sci USA 1998; 95:15270-15274. 35. Hindmarsh P, Ridky T, Reeves R et al. HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virs concerted DNA integration in vitro. J Virol 1999; 73:2994-3003. 36. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human imunodeficiency virus with a sensitive cell line on the basis of activation of an integrated betagalatosidase gene. J Virol 1992; 66:2232-2239. 37. Cecilia D, KewalRamani VN, O’Leary J et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998; 72:6988-6996. 38. Brown PO, Bowerman B, Varmus HE et al. Correct integration of retroviral DNA in vitro. Cell 1987; 49:349-365. 39. Courcoul M, Patience C, Rey F et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif-human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol 1995; 69:2068-2074. 40. Kalderon D, Roberts BL, Richardson WD et al. A short amino acid sequence able to specify nuclear localization. Cell 1984; 39:499-509. 41. Bukrinsky MI, Haggerty S, Dempsey MP et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365:666-669. 42. von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Nat Acad Sci USA 1994; 91:6992-6996. 43. Heinzinger NK, Bukrinsky MI, Haggerty SA et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci 1994; 91:7311-7315.
48
Lentiviral Vector Systems for Gene Transfer
44. Gallay P, Swingler S, Allen C et al. HIV-1 infection of nondividing cells: C-terminal tyrosine phosophorylation of the viral matrix protein is a key regulator. Cell 1995; 80:379-388. 45. Gallay P, Hope TJ, Chin D et al. HIV-1 infection of non-dividing cells through recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci, USA 1997; 94:9825-9830. 46. Gallay P, Stitt V, Mundy C et al. 1996. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 70:1027-1032. 47. Paillart JC, Gottlinger HG. Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag memrane targeting. J Virol 1999; 73:2604-2602. 48. Fouchier RAM, Malim MH. Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res 1999; 52:275-299. 49. Freed EO. Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection. Cell 1997; 88:171-173. 50. Freed EO, Englund G, Martin, MA. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol 1995; 69:3949-3954. 51. Fouchier RAM, Meyer BE, Simon JHM et al. HIV-1 infection of non-dividing cells: Evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 1997; 16:4531-4539. 52. Freed, EO. HIV-1 gag proteins: Diverse functions in the virus life cycle. Virology 1998; 251:1-15. 53. Haffar OK, Popov S, Dubrosvsky L et al. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J Mol Biol 2000; 299:359-368. 54. Reil H, Bukovsky AA, Gelderblom HR et al. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J 1998; 17:2699-2708. 55. Westervelt P, Henkel T, Trowbridge DB et al. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol 1992; 66:3925-3931. 56. Conno RI, Chen BK, Choe S et al. Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 1995; 206:935-944. 57. Ballliet JW, Kolson DL, Eiger G et al. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes, vpr, vpu, and nef: Mutational analysis of a primary HIV-1 isolate. Virology 1995; 206:935-934. 58. Popov S, Dubrovsky L, Lee MA et al. Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation. Proc Nat Acad Sci USA 1996; 93:11859-11864. 59. Vodicka MA, Koepp DM, Silver PA et al. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes & Dev 1998; 12:175-185. 60. Fouchier RA, Meyer BE, Simon JH et al. Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol 1998; 72:6004-6013. 61. Popov S, Rexach M, Blobel G et al. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998; 273:13347-13352. 62. Jenkins Y, McEntee M, Weis K et al. Characterization of HIV-1 vpr nuclear import: Analysis of signals and pathways. J Cell Biol 1998; 143:878-885. 63. Sherman MP, Noronha DE, Heusch MI et al. Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol 2001; 75:1522-1532. 64. Kamata M, Aida Y. Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization. J Virol 2000; 74:7179-7186. 65. Adam SA, Sterne Marr R, Gerace L. Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors. J Cell Biol 1990; 111:807-816. 66. Popov S, Rexach M, Zybarth G et al. Viral protein R regulates nuclear import of the HIV-1 preintegration complex. EMBO J 1998; 17:909-917. 67. Fletcher TMI, Brichacek B, Stivahtis G et al. 1996. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIVsm. EMBO J 15:6155-6165.
Determinants for Lentiviral Infection of Non-Dividing Cells
49
68. Stivahtis GL, Soares MA, Vodicka MA et al. Conservation and host-specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate evolution and biology. J Virol 1997; 71:4331-4338. 69. Tsurutani N, Kubo M, Maeda Y et al. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for effiecient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J Virol 2000; 74:4795-4806. 70. Pluymers W, Cherepanov P, Schols D et al. Nuclear localization of human immunodeficiency virus type 1 Integrase expressed as a fusion protein with green fluorescent protein. Virology 1999; 258:327-332. 71. Bouyac-Bertoia M, Dvorin JD, Fouchier RAM et al. HIV-1 Integrase requires a functional NLS. Mol Cell 2001; 7(5):1025-1035. 72. Deminie CA, Emerman M. Functional exchange of an oncoretrovirus and a lentivirus matrix protein. J Virol 1994; 68:4442-4449. 73. Dupont S, Sharova N, DeHoratius C et al. A novel nuclear export activity in HIV-1 Matrix protein required for viral replication. Nature 1999; 402:681-685. 74. Zennou V, Petit C, Guetard D et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101:173-185. 75. Charneau P, Mirambeau G, Roux P et al. HIV-1 reverse transcription a termination step at the center of the genome. J Mol Biol 1994; 241:651-662. 76. Charneau P, Alizon M, Clavel F. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol 1992; 66:2814-2820. 77. Follenzi A, Ailles LE, Bakovic S et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Gen 2000; 25:217-222. 78. Sirven A, Plfumio F, Zennou V et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000; 96:4103-4110. 79. Rumbaugh JA, Fuentes GM, Bambara RA. Processing of an HIV replication intermediate by the human DNA replication enzyme FEN1. J Biol Chem 1998; 273:28740-28745. 80. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272:263-267. 81. Rey O, Canon J, Krogstad P. HIV-1 Gag protein associates with F-actin present in microfilaments. Virology 1996; 220:530534. 82. Ott DE, Coren LV, Johnson DG et al. Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology 2000; 266:42-51. 83. Bukrinskaya A, Brichacek B, Mann A et al. Establishment of a functional human immunodeficiency virus typ 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998; 188:2113-2125. 84. Kukolj G, Jones KS, Skalka AM. Subcellular localization of avian sarcoma virus and human immunodeficiency virus type 1 integrases. J Virol 1997; 71:843-847.
CHAPTER 4
HIV-1 Vector Systems Narasimhachar Srinivasakumar
Abstract
H
uman immunodeficiency virus type 1 (HIV-1) based gene transfer systems are gaining in popularity due to their ability to transduce terminally differentiated and non-dividing cells. Oncoretroviral vectors based on Moloney murine leukemia virus (MoMLV), on the other hand, can only transduce dividing cells. The reasons for increased ability of lentivirus vectors to transduce such cells has been attributed to several of the viral proteins (integrase, matrix and Vpr) that are purported to be involved in the nuclear import of the pre-integration complex (PIC). Nuclear import is also augmented by a unique triple stranded DNA region created during reverse transcription of the incoming viral RNA in the target cell (discussed in chapter 3). This chapter deals with the rationale behind the design of human immunodeficiency virus type 1 (HIV-1) based packaging systems with an emphasis on some recent advances in the field for the creation of safe and efficient HIV-1 based vectors. The review covers trans-acting proteins and cis-sequences required for the deployment of HIV-1 vectors for gene transfer. This is a rapidly advancing field that with further refinements may soon allow the utilization of HIV-1 based and/or other lentivirus vectors in a clinical setting.
Introduction Designing a gene transfer system using HIV-1 requires an understanding of key features of the replicative cycle of the virus (see chapter 2 for details). A brief overview of HIV-1 replication is presented below emphasizing those aspects critical for the creation of an HIV-1 based packaging system. The overview is followed by a detailed description of the various components of an HIV-1 based packaging systems including the various flavors it comes in.
Regulation of Gene Expression The proviral form of HIV-1 has the prototypical structure of retroviruses with the coding regions sandwiched between two long terminal repeats (LTR). Each LTR consists of unique 3 (U3), repeat (R) and unique 5 (U5) regions. The viral enhancer and promoter elements are present in the U3 region. The HIV-1 genome encodes for at least nine proteins (Fig. 1). Transcription of vector RNA begins at the first nucleotide of R in the 5' LTR and polyadenylation (pA) occurs at the last nucleotide of R in the 3' LTR.1 Thus the genomic RNA is bounded by the r and u5 sequences at the 5' end and u3 and r sequences at the 3' end. Transcription from the 5' LTR requires the viral transcriptional activator protein Tat. Tat, unlike most transcriptional activators that contain specific DNA binding motifs, binds to a cis-element, the transacting response (or TAR) element at the 5’ end of the nascent RNA within r and enhances processivity of RNA polymerase II.2-5 This results in an abundant amount of genome-length Lentiviral Vector Systems for Gene Transfer, edited by Gary L. Buchschacher, Jr. ©2003 Eurekah.com.
52
Lentiviral Vector Systems for Gene Transfer
Fig. 1. Schematic representation of the coding regions in HIV-1 provirus (A). The coding region of the viral regulatory proteins, Tat and Rev, are each derived from two exons. The major 5' splice site is marked but other splice donor and acceptor sites are not shown. Transcription from the 5' LTR of the provirus results in single genome-length RNA (B) from which all other RNA species are derived. The full-length or unspliced mRNA is used for encapsidation into the virus particle and is also the substrate for translation into Pr55Gag and Pr160Gag-Pol precursor polyproteins (C). The viral proteins Vif, Vpr, Vpu and Env are translated from singly spliced mRNAs while Rev, Tat and Nef are translated from multiply spliced RNAs. The various subunits derived from the two precursor polyproteins are shown. Further details are provided in the text.
viral RNA to be produced in the infected cell. In the absence of Tat most transcripts suffer premature termination. The full-length message derived from the provirus is alternatively spliced to generate multiple species of mRNA. At least 30 species of mRNA have been described in HIV-1 with several slightly different mRNAs coding for the same protein.6-13 The fully spliced mRNAs encode for Rev, Tat or Nef. The unspliced message codes for Gag and Gag-Pol proteins while the singly and partially spliced messages code for envelope (Env) and the accessory proteins Vif, Vpr or Vpu. Since incompletely spliced messages are usually retained in the nucleus of eukaryotic cells, the expression of proteins derived from these messages requires that the corresponding RNAs exit the nucleus without undergoing splicing.14-17 Moreover, sequences have been identified in gag that retain the unspliced message in the nucleus.18-20 The inhibitory sequences have been referred to as cis-acting repressor sequence (CRS) elements or cis-acting inhibitory sequences (INS). The Rev protein binds to a target sequence within the env coding region called Rev-response element (RRE) to bring about nucleo-cytoplasmic transport of such messages. Rev may also play a role in the stability of the RNA and its polysomal association or translation.21,22 Studies have indicated that for Rev to bring about nucleo-cytoplasmic transport, the RNA must form a complex with the splicing machinery. Thus, an intact 5’ splice
HIV-1 Vector Systems
53
donor site in the RNA is essential for Rev to produce its effect.23 The 5’ splice donor is also used for the generation of partially spliced messages that are translated into Vif, Vpr and Vpu proteins.
Virion Assembly HIV-1 is an enveloped virus. The surface of the virus particle is decorated with the envelope (Env) glycoprotein consisting of a surface glycoprotein (gp120) and a transmembrane protein (gp41). Lining the inner aspect of the lipid envelope is the viral matrix (MA/p17) protein. The most characteristic structure of the virus is the cone shaped core composed predominantly of the capsid (p24) protein. Also present within the virion are the nucleocapsid (NC/p7) protein , and the viral enzymes consisting of the reverse transcriptase (RT), integrase (IN) and protease (PR). The internal proteins of the virion are derived for the most part from the Gag (Pr55gag) and GagPol (Pr160 gagpol) precursor polyproteins (Fig. 1). Both precursors are translated from the unspliced mRNA molecule containing the gag and pol coding sequences. The Pr160Gag-Pol is synthesized by a ribosomal frame-shifting mechanism that occurs during translation of Gag once every 10 or 20 translation events.1,24 The Gag precursor can assemble into virus-like particles in the absence of other internal proteins of the virion.25-35 The Gag-Pol precursor, while it cannot form virus particles on its own, is drawn into the assembling particle through its interaction with the Gag precursor.36-39 The enzymes present as part of the Gag-Pol precursor, PR, RT and IN, are thus incorporated into the virus particle. Vpr and Vif have also been demonstrated within the virion. Vpr is incorporated into assembling virus particle through an interaction with the p6 protein present in the C-terminus of the Gag polyprotein.40-42 Vif is incorporated into the virion via an interaction with the genomic RNA.43 The precursor polyproteins, together with two molecules of genomic RNA, accumulate beneath the portion of the plasma membrane containing the viral Env glycoprotein. A viruslike particle then pinches off from the plasma membrane. The genomic RNA is incorporated into the assembling virion via interactions between the nucleocapsid (NC) protein within Gag/ Gag-Pol proteins and the encapsidation or packaging (E/ψ) signal present in the vector RNA molecule. Following release of the virus particle, the Pr160Gag-Pol precursor is cleaved to yield the viral PR, RT and IN proteins. Proteolytic cleavage of the Gag precursor yields the MA (p17), CA (p24), NC (p7) and p6 proteins. The mature virus particle is then ready to infect target cells.
Virus Entry Following binding of the virus to the target cells via the Env glycoprotein and corresponding receptor/coreceptors on the target cell, fusion of the viral and plasma membrane of the cell ensues. This results in the deposition of the viral core into the cytoplasm. The core is stripped of the capsid protein and the genomic RNA is reverse transcribed into a double stranded cDNA. During reverse transcription, due to presence of a central polypurine tract (cPPT) and termination sequence (CTS), a unique triple-stranded DNA region consisting of the double stranded DNA and a DNA flap is created in the middle of the newly synthesized cDNA. This unique structure, by an unknown mechanism, enhances the import of the viral pre-integration complex (PIC) into nucleus of the target cell.44-46 The PIC also contains the viral IN protein, MA and Vpr proteins. These proteins may also be involved in nuclear import of the PIC although the role of the MA protein in nuclear import is controversial. The cDNA is then inserted into the chromosome of the target cell, apparently at a random location, by the viral IN protein.
HIV-1 Vector System Development The design of lentivirus packaging systems has benefited greatly from detailed studies conducted with oncoretroviral based packaging systems. However, creating a packaging or
54
Lentiviral Vector Systems for Gene Transfer
Fig. 2. A schematic representation of the components of an HIV-1 based vector system consisting of a packaging or helper construct (A), an Env expression construct (B) and a gene transfer vector (C). The various RNA species derived from each expression construct are shown. Rev is required for expression of helper and gene transfer vector RNA, both of which contain the RRE. Tat is required for expression of the gene transfer vector RNA from the viral LTR promoter. The various components (proteins and two copies of the vector RNA) assemble into a virus particle at the plasma membrane. Once budded off from the membrane, the virus is then ready to infect and transduce the gene transfer vector together with its encoded transgene into target cells.
gene transfer system using HIV-1 poses several unique challenges. This is because of the complexity of gene expression in HIV-1 (see above and chapter 2). For instance, expression of both helper and gene transfer vector RNAs require sequences that ensure the transport of the RNA molecules into the cytoplasm. To create a packaging system with HIV-1, one needs a) packaging or helper constructs that provide all necessary virion proteins to form a virus-like particle and b) a gene transfer vector that provides the RNA for encapsidation by the assembling virus particle (Fig. 2). The gene transfer vector ideally should expresses only the transgene of interest but none of the viral proteins. The helper proteins consist of HIV-1 proteins that form the internal proteins of the virion and an Env protein, either from HIV-1 or, more commonly, from a different virus, which allows the virus particle to infect target cells bearing the appropriate receptor. The basic components of an HIV-1 based packaging system are described below.
HIV-1 Vector Systems
55
Fig. 3. Cis-elements required for creation of an HIV-1 based gene transfer vector. The putative secondary structure of the E/ψ signal that encompasses the entire 5' untranslated region is depicted. Elements involved in reverse transcription and integration: primer binding site (PBS), polypurine tract (PPT),central polypurine tract and central termination sequences (cPPT/CTS) and integration (att sites) are shown. The cPPT/CTS, while not absolutely essential for the reverse transcription step in the context of lentivirus vectors, improves nuclear translocaton of the pre-integration complex (PIC) in both dividing and non-dividing cells. The left att site is derived from the u3 region present in the RNA genome while the right att site is derived from the u5 region in the RNA. The RRE is required for nucleo-cytoplasmic of the vector RNA. Several different lengths of RRE can be used. The nucleotide positions shown correspond to the extended RRE described by Mann et al.208 ψ: packaging signal. The transgene expression cassette is usually positioned between the 3' Tat/Rev splice acceptor site and the 3' LTR. Details of the cis-elements are discussed further in the text. The sequences and numbers shown are with reference to the molecular clone pNL4-3 (GenBank Accession number M19921).
Packaging or Helper Constructs Packaging constructs are designed to ensure high levels of particle production. A typical packaging plasmid (Fig. 2) contains a heterologous promoter driving the expression of the HIV-1 gag/pol coding region. The HIV-1 polyadenylation signal present in the 3' LTR is replaced with a heterologous polyadenylation signal. Also required are signals for transport of gag/pol RNA from the nucleus to the cytoplasm for efficient translation. Without a transport mechanism, no Gag and Gag-Pol expression can occur. The Rev and RRE of HIV-1 are most commonly used to provide transport functions for the gag/pol message. The RRE sequence is positioned between the 3' end of the Gag-Pol coding sequence and the polyadenylation signal. The major 5' splice donor site present upstream of gag is retained for Rev function. Expression of HIV-1 Gag and Gag-Pol from this construct requires the coexpression of Rev in trans during virus stock production. Rev can be expressed by including rev coding sequences together with the gag/pol sequences in the same packaging construct (Fig. 2) or can be provided using a separate plasmid encoding the cDNA of Rev (Fig. 7).
56
Lentiviral Vector Systems for Gene Transfer
Gene Transfer Vectors The gene transfer vector should contain, in addition to the transgene expression cassette, all cis-acting sequences required for transcription, polyadenylation, efficient nucleo-cytoplasmic transport, encapsidation, reverse transcription and integration of the vector RNA. The ideal vector lacks all viral protein coding sequences and has a capacity for large transgenes (Figs. 2 and 3). It is believed that HIV-1 vectors can accommodate a transgene expression cassette of approximately 8-11 kb in length.47,48 Recent studies have also revealed that providing cissignals that enhance nuclear import of PICs would be beneficial. The cis-elements that are required for constructing gene transfer vectors (Fig. 3) are described, as they occur from 5' to 3' in the vector, in greater detail below.
Transcription Signals Transcription of the vector RNA requires the enhancer and promoter elements in the U3 region and the R region in the 5’LTR. The R region contains the TAR element that mediates the transactivation by viral Tat protein to generate abundant amounts of genome-length RNA.
Encapsidation Signals In order for the vector RNA to be encapsidated into the assembling virus particle, the vector must contain an E/ψ signal. The entire 5' untranslated region constitutes the E/ψ region and exhibits a complex secondary structure (Fig. 3). This region consists of seven stem-loop structures. Four of these stem-loop (SL) structures encompassing the 5’ splice donor site and the 5' end of gag have been termed SL1, SL2, SL3 and SL4.49 SL1, SL3 and SL4 are involved in Gag binding while SL2 contains the 5' splice site and is not essential for encapsidation. SL1 also contains the dimer-linkage signal (DLS) in its loop. Due to its location, SL1/DLS is present in all HIV-1 RNAs, i.e., it is present in both spliced and unspliced RNAs. Deletion or mutations in SL1 or SL3 reduces encapsidation of the RNA. Combined deletion of SL1 and SL3 has a greater effect then deletion of each SL by itself. Studies have revealed that sequences upstream of the 5’ splice donor site including the lower stem of TAR and the poly A stem-loop are also essential for packaging.50-53 It should be emphasized that mutations to the E/ψ region or structures do not completely eliminate packaging but instead allow spliced RNAs to be packaged in direct relation to their intracellular concentration.51,54,55 This is of concern because most packaging systems designed to date contain a deletion within the so-called E/ψ region present in the packaging or helper plasmid with the hope that the RNA derived from the helper construct will not be copackaged with the vector RNA. The good news is that in the presence of RNA with an intact E/ψ region, this RNA is likely to be preferred over the RNA with deletions in the E/ψ region. However, it also appears that sequences outside of the E/ψ region can influence encapsidation and or dimerization. For instance, presence of foreign sequences can negatively affect encapsidation of vector RNA. Foreign sequences have also been shown to enhance dimerization of RNA. Although the encapsidation and dimerization sequences overlap, they can be functionally delinked from each other. Thus mutations to the dimer linkage site can affect infectivity without affecting encapsidation.54 Thus more careful analysis of encapsidation and dimerization of RNA present within vector particles is required to evaluate the effect of the deletions or mutations within the E/ψ region of the helper construct on its encapsidation and delivery to target cells.
gag Sequences Studies in MoMLV suggested that the encapsidation signal extends into the 5' portion of the gag.56 This appears to be true in the case of HIV-1 also. The SL4 structure of the HIV-1 encapsidation signal is present in the extreme 5' end of the gag coding region.49 While at least 40 nucleotides of gag are required for optimal packaging of the vector RNA, inclusion of
HIV-1 Vector Systems
57
additional sequence of up to 653 or even up to 1053 nucleotides improves encapsidation and/ or gene transfer.55,57,58 It is not clear how exactly these additional gag sequences influence encapsidation. Most investigators use about 350 nucleotides of gag sequence in gene transfer vectors. A frameshift or stop codon is inserted near the 5’end taking care not to disrupt the structure of SL4 packaging element to ensure that no significant length of Gag peptide is synthesized in the transduced target cell.59
Nucleo-Cytoplasmic Transport Signals Just as for the expression of helper proteins, the transport of full-length vector RNA also requires Rev and RRE. Likewise, an intact 5’ splice donor site is required for Rev to function with the RRE.23 The gag coding region harbors so-called inhibitory sequences (CIS/CRS) that retain the RNA in the nucleus.19,20,60 Since gene transfer vectors lack most of the coding regions of HIV-1, the requirement for transport signals is a bit puzzling. Consistent with this, it appears that if one eliminates almost all of the gag region with the exception of the 5’ 40 nucleotides, one can then create a vector lacking the RRE and containing a mutation in the 5’ major splice donor site. Such a vector has nearly 50% of the titer of wild-type vector.61
Transgene Expression Cassette All gene transfer vectors contain, by definition, a transgene expression cassette. This cassette is usually positioned between the RRE and the 3' LTR. The transgene expression cassette usually contains promoter-enhancer elements from a heterologous virus or from a cellular promoter. Some of the more popular promoters evaluated in HIV-1 vectors are human and simian cytomegalovirus immediate early promoters, simian virus 40 early promoter , phosphoglycerate kinase promoter and the elongation factor, EF1α promoter.59,62-65 HIV-1 vectors that express the transgene under control of the viral LTR promoter have also been described.63,64 In this case, it is necessary to express the viral Tat protein together with the transgene of interest. The choice of the promoter is dictated by the target cell for gene transfer since the same promoter and enhancer elements may work with differing efficiencies in different cell types.63,65,66
Polyadenylation Signal The polyadenylation (pA) signal for the vector RNA is derived from the 3' LTR and the core AATAAA sequence in HIV-1 is present within the R region. Several ‘enhancers’ of pA have been identified in the upstream U3 region using artificial constructs.67-69 It appears that most of the U3 sequence can be deleted without compromising titer which in turn suggests that the effect of these pA enhancers are not profound in the context of HIV-1 vectors.70,71 This aspect is discussed in greater detail under self-inactivating (SIN) vectors
Sequences Involved in Reverse-Transcription and Integration The key elements required for reverse-transcription of viral RNA into a double-stranded DNA molecule are the primer binding site, the repeat (R) regions and the polypurine tract (Chapter 2). In addition to these signals, sequences recognized by the integrase present at the 5' end of U3 and 3' end of U5 (att sites) are required to effect integration of the reverse-transcribed product into the target cell chromosome. Unique to lentiviruses is the presence of a central polypurine tract (cPPT) and central termination sequence (CTS) within pol.44 During reverse transcription, these sequences, allow for the formation of a unique triple-stranded DNA molecule in this portion of the HIV-1 reverse-transcribed product. This triple-stranded DNA region or DNA-flap appears to enhance the entry of HIV PIC into the nucleus of both dividing and non-dividing cells.45,46 Thus, most recent modifications to HIV-1 vectors include the cPPT and CTS.
58
Lentiviral Vector Systems for Gene Transfer
Envelope Expression Construct The final component of an HIV-1 based packaging system is the Env expression construct. The HIV-1 virus particle is quite promiscuous in that it can be pseudotyped with Env proteins derived from many different viruses. One study compared several Env proteins from rhabodviruses (G glycoprotein of rabies, Mokola and vesicular stomatitis virus), MoMLV (4070A Env), HIV-1 and human foamy virus.72 All the different Env proteins could be used to pseudotype HIV to varying degrees with the Rhabdovirus Envs and MoMLV Env pseudotyped vectors exhibiting the highest titers. The VSV-G pseudotyped vectors are the most widely used because such vectors are quite stable under high centrifugation forces and can be readily concentrated by ultracentrifugation.73 In contrast to VSV-G, the amphotropic MoMLV Env pseudotyped vectors cannot be concentrated by ultracentrifugation without loss of titer. Some Env proteins cannot be used to pseudotype HIV-1 vectors. One example of this is the gibbon ape leukemia virus (GALV) Env. This Env is of interest because previous studies showed that the GALV Env allows enhanced gene transfer of MoMLV vectors into hematopoietic stem cells.74 The incompatibility in GALV ENV that prevents pseudotyping of HIV-1 appears to reside in the cytoplasmic domain of the protein because partial or complete substitution of the cytoplasmic tail of GALV Env with that of MoMLV Env allows more efficient pseudotyping of HIV-1 vectors.75 Another Env protein of interest is derived from the spleen necrosis virus (SNV). Vectors pseudotyped with this Env protein cannot infect human cells but can infect canine cells. In a series of elegant experiments 76-80 Dornburg’s group has shown that modification of SNV Env with an appropriate single-chain antibody of known specificity allows one to target SNV based vectors to specific cell types bearing unique markers, such as the CD34 antigen on hematopoietic stem cells, transferrin receptor present on liver cells or Her2neu antigen present on many human cells. The SNV Env can be used to pseudotype HIV-1 vectors but suffers from the drawback that the resultant vector titers are not very impressive and concentration of vector particles by ultracentrifugation is not feasible without a significant drop in titer (Srinivasakumar et al., unpublished observations). Ultrafiltration of vector particles is an alternative approach for concentration of vector particles bearing Envs that are sensitive to high g-forces. Unfortunately, ultrafiltration of vectors pseudotyped with amphotropic Env or SNV Env appears to enrich for inhibitors of virus binding and/or entry.81,82 This results in a paradoxical decrease in virus titer at lower dilutions that nullifies the effect of concentration. The inhibitors are suspected to be high molecular weight sulfated proteoglycans such as chondroitin sulfate.83-86 In contrast to these observations, other investigators have reported that ultrafiltration actually removes inhibitors.77,87 If methods can be devised for efficient removal of these inhibitors, these other Env proteins can then be used for pseudotyping lentivirus vectors to provide a different host-range for gene transfer ex vivo or in vivo.
Accessory and Regulatory Proteins and Gene Transfer Rev The requirement of Rev and RRE for expression of packaging and gene transfer vector RNAs has been discussed above.
Tat Tat is not required for expression of viral helper proteins but is required for the expression of the gene transfer vector RNA (see above). Tat is, therefore, coexpressed along with the other helper plasmids for production of virus stocks. The Tat protein is encoded in two exons. However recent experiments have shown that only the first coding exon of Tat is sufficient for production of vector stocks for gene transfer.63,88 Tat has also been implicated in causation of
HIV-1 Vector Systems
59
immune modulation, aberrant cytokine expression and induction of Kaposi’s sarcoma.89-104 It is therefore felt that Tat should be excluded from packaging systems if possible. The requirement for Tat can be obviated by making gene transfer vectors Tat-independent (see below).
Vif, Vpr and Vpu Early versions of packaging plasmids encoded most viral structural and regulatory proteins with the exception of the Env glycoprotein.59,72,105,106 This was probably because the viral accessory proteins Vif, Vpr and Vpu appeared to play important roles in the replicative cycle of HIV-1 and it was not clear if deletion of these proteins would affect gene transfer in any way. Vif has been shown to increase infectivity of virions produced in certain human T-cell lines.107,108 Vif appears to affect events after binding and fusion, either during uncoating or during RT.109 Vif exerts its effect in the producer cell. Producer cells can be classified as permissive or non permissive. In permissive cells (e.g., 293), both Vif(-) and Vif(+) constructs can be used to produce virus stocks that are equally infectious for T cells. In contrast, in non permissive cells (e.g., H9 and peripheral blood mononuclear cells) the virions produced with Vif(-) constructs are relatively less infectious than those produced with Vif(+) constructs. Vpu is a 16-kilodalton phosphoprotein that has been shown to increase virion export in human cells such as HeLa or Jurkat but not in cell lines of simian origin (e.g., Cos).110,111 In this function, it resembles the p6 protein present at the C-terminus of the Gag precursor that is also involved in virion export112 but differs from Vpu in that it demonstrates its activity in simian cells and not in human cells.111 Other functions of Vpu include down modulation of cell surface expression of CD4 and major histocompatibility complex class I molecules.113,114 Vpr is another protein with pleiotropic effects. It can cause cells to arrest in G2 phase of the cell cycle.115-117 This effect has been linked to a modest increase in transcriptional output from the viral LTR promoter.118 Vpr has also been shown to be essential for importation of PIC into the nucleus of macrophages.119-122 Vpr is recruited into the virus particle via its interaction with the p6 region of the Gag molecule.40-42 One possible disadvantage of Vpr is that when concentrated stocks of HIV-1 vector stocks are used in gene transfer experiments, Vpr delivered by the virus particles can result in apoptosis of target cells.123-125 So the advantages of using Vpr for nuclear import of PICs in some types of cells must be weighed against its propensity to cause apoptosis. In spite of these known functions of Vif, Vpr and Vpu, it appears that one can safely eliminate these proteins for preparation of high-titer virus stocks in 293T cells for transduction of many cell types. Recent reports indicate, however, that accessory proteins may be necessary for getting optimal levels of gene transfer into certain types of cells such as lymphocytes.126 A more careful evaluation for the requirement of accessory proteins for transduction of different cell types appears to be therefore warranted.
Nef The Nef protein is synthesized early after infection together with Tat and Rev and has pleiotropic effects. Nef has been shown to down modulate cell-surface expression of CD4 by inducing endocytosis, resulting in the degradation of this molecule in lysosomes.127-130 Coexpression of Nef during virus stock production increases efficiency of gene transfer into target cells.131-134 This has been attributed in part to its positive effect on increasing the efficiency of reverse transcription during viral entry.134,135 Fortunately, this effect of Nef is restricted to certain types of Env proteins used for pseudotyping virus. For instance, Nef increases infectivity of virions pseudotyped with HIV-1 or amphotropic MoMLV Env proteins but not those pseudotyped with VSV-G or Ebola virus Env proteinss.132,136,137 Thus Nef is not required for vectors pseudotyped with Env proteins that effect low pH mediated fusion and entry of viruses. Nef can, therefore, be eliminated from packaging systems that employ VSV-G
60
Lentiviral Vector Systems for Gene Transfer
Fig. 4. Schematic representation of simple gene transfer vector systems based on HIV-1. In A, a transgene expression cassette consisting of a heterologous promoter driving a marker or therapeutic gene is inserted into the env coding region and thus inactivates it. To produce infectious virus one needs to complement the above construct with a separate expression construct for Env (B). The transduced target cell not only expresses the transgene but also all other viral proteins with the exception of Env. A replication competent gene transfer vector is shown in C. The transgene in this vector is positioned within Nef and is expressed from a spliced mRNA. The expression of the transgene is, therefore, under control of the viral LTR promoter. The vector produces all viral proteins with the exception of Nef.
to pseudotype vectors. This is a fortunate occurrence, because experiments in transgenic mice have revealed that expression of HIV-1 Nef in lymphocytes and macrophages leads to a profound immune defect.138 Due to these negative connotations, it may be prudent to remove Nef from HIV-based packaging systems unless it is required for increasing the efficiency of gene transfer with some Env proteins.
Evolution of HIV-1 Vector and Packaging Systems Early HIV-1 Vector Systems The simplest HIV-1-based gene transfer systems contained not only the transgene expression cassette but also encoded for most of the internal proteins of HIV-1. The transgene expression cassette was usually located within the env coding region. To produce infectious virus with such constructs, one only needs to complement with an Env glycoprotein expression construct during virus stock production (Fig. 4 A).139,140 In a variation of the above theme (Fig. 4 B), HIV-1 vectors that contain the transgene within the nef coding region have been described.141,142 In this configuration, the virus encodes for all transacting viral protein including Env (with the exception of Nef ) as well as the transgene. Thus, this vector is replication competent. Clearly, the coexpression of viral proteins together with the transgene make these packaging systems less than ideal for use in gene therapy applications. However, such vectors are useful for studying the biology of the virus.141,142
HIV-1 Vector Systems
61
Fig. 5. Schematic representation of an HIV-1 vector system 59 consisting of a first generation packaging plasmid (A), gene transfer vector (B) and an Env expression construct (C). The packaging plasmid encodes for all HIV-1 proteins with the exception of the Env protein. The 5' LTR is replaced with a heterologous promoter and the 3’LTR is replaced with a heterologous poly A (pA) signal. A deletion is engineered into the ψ region (∆ψ). The gene transfer vector does not express any of the viral proteins and contains all cissequences for packaging, reverse transcription and integration (Fig. 2). It contains a transgene expression cassette containing a therapeutic or marker gene under control of a heterologous internal promoter. An Env expression construct (C) is provided for pseudotyping the vector to allow infection of target cells containing the appropriate receptor to which the Env protein can bind.
First Generation Packaging System Subsequent vector systems contained three components: a first generation packaging plasmid, an Env protein expressing plasmid and a gene transfer vector59 (Fig. 5). The packaging plasmids were simple modifications of the HIV-1 proviral genome. The 5’LTR was replaced with heterologous viral promoter/enhancer elements. A deletion within the E/ψ region present between the 5’ major splice donor site and the beginning of Gag coding sequence was engineered to prevent encapsidation of the RNA derived from the helper plasmid. The downstream promoter was replaced with a heterologous poly A signal. The env coding sequence was interrupted by a mutation but still retained the RRE. Such a helper construct expresses all viral proteins, including Tat and Rev with the exception of the viral Env. A separate Env expression construct was provided by cotransfection during virus stock production. Typically a VSV-G expressing envelope construct was provided to allow concentration of vector stocks by ultracentrifugation. The gene transfer vector contained the 5' LTR and the entire 5' untranslated region including about 350 nucleotides of Gag coding sequences. The vector also contained the RRE and the 3' LTR. The transgene expression cassette was positioned between the RRE and the 3' LTR. The transgene expression cassette typically used the cytomegalovirus immediate early promoter and enhancer elements to drive a green fluorescent protein gene or firefly luciferase gene or β-galactosidase gene.
62
Lentiviral Vector Systems for Gene Transfer
Fig. 6. Schematic representation of a second generation HIV-1 packaging system,72,106,143,144 along with a vector and Env-expressing construct. This is similar to the first generation packaging system (Fig. 5) but for the elimination of the viral accessory proteins Vif, Vpr , Vpu and Nef.
Second Generation Packaging System Many of the HIV-1 accessory and regulatory proteins have been implicated in the pathogenesis of acquired immune deficiency syndrome (AIDS) or have other untoward effects (see above). The second generation packaging systems were, therefore, designed not to express Vif, Vpr or Vpu but in other respects are identical to the first generation packaging system described above72,106,143,144 (Fig. 6). Virus stocks produced with such a minimal packaging system have been found to be effective in transducing most target cells in vitro and in vivo. It is not clear if this observation will hold true for transduction of all cell types.126
Third Generation Packaging System The major concern in the use of lentivirus based packaging systems is the possibility of generation of a replication competent HIV-1 or novel retrovirus during virus stock production or following gene transfer and transplantation of the tissue back in the host. The recombination between helper and vector constructs can occur at the level of input plasmid DNA within the virus producer cell or by recombination of helper and vector RNA molecules copackaged within the same virus particle. One approach to reduce this possibility is to decrease the homology between the helper and gene transfer vector. Another approach is to segregate gag/pol and rev coding sequences in separate plasmids.145 Such a packaging system uses four plasmids for the creation of vector stocks instead of the usual three (Fig. 7). The first plasmid contains gag/pol coding region together with the RRE. The second plasmid encodes for Rev cDNA to allow expression of gag/pol from the first plasmid. The third plasmid is the gene transfer vector while the fourth is the Env expression construct. Use of this type of packaging system necessitates co-evolution of the gene transfer vector, since otherwise one would also require a fifth construct to express Tat. The requirement for Tat by the gene transfer vector can be eliminated by using a Tat-independent vector in which the HIV-1 U3 in the 5' LTR is replaced with enhancer and promoter elements derived from either
HIV-1 Vector Systems
63
Fig. 7. Schematic representation of a third generation HIV-1 packaging system.145 This is a minimal HIV1 packaging system that consists of three helper plasmids: a Gag/Gag-Pol expression construct (A), a Rev expression construct (D) and Env construct (C) and a gene transfer vector. The expression of Gag/Gag-Pol and the gene transfer vector RNAs requires the coexpression of Rev. Rev is produced using a separate expression construct (D). The requirement for Tat for production of large amounts of gene-transfer vector RNA is obviated by using a Tat-independent vector (B) in which the 5’LTR is replaced with a chimeric promoter consisting of heterologus promoter/enhancer elements substituting the corresponding viral elements (see also Fig. 10).
Rous sarcoma virus or from cytomegalovirus immediate early promoter (see below). The use of four plasmids instead of the three and the elimination of Tat increases the safety of the system by further decreasing the probability of recombination between the various helper plasmids and the gene transfer vector to recreate a replication competent virus.
Recent Modifications to the Packaging System Packaging Systems Using Alternative RNA Transport Elements The constitutive transport element (CTE) is a small structured RNA element in MasonPfizer monkey virus (MPMV) that performs a similar function as Rev and RRE in HIV-1 i.e., the transport of unspliced message from the nucleus to the cytoplasm.146,147 Experiments have shown that the CTE can substitute for the function of Rev and RRE in HIV-1 provirus as well in packaging and gene transfer vectors, albeit to varying efficiencies.63,88,106,133,148-152 The use
64
Lentiviral Vector Systems for Gene Transfer
Fig. 8. Design of packaging systems based on the type of RNA-transport elements used in packaging and gene transfer vectors.88 In the RRE/Rev-based packaging system (A) expression of RNA from both helper plasmid and gene transfer vector is regulated by Rev and RRE. Rev coexpression is required for expression of the helper and vector RNAs. In the CTE-based system (B), helper and vector RNA expression is regulated by the MPMV-CTE. This is a Rev-independent packaging system i.e., no Rev coexpression is required for production of vector stocks. In the combination packaging systems (C), the helper plasmid is regulated by CTE while the gene transfer vector is controlled by RRE and Rev. An alternative scenario in which the helper plasmid is regulated by RRE and Rev while the gene transfer vector is controlled by CTE is not shown. Rev coexpression is required for production of vector stocks in this system. Possible sites of recombination between helper and vector constructs in the three types of packaging systems are shown using bi-directional arrows. Note that in C, the two constructs share homology only in the gag region. This design may be safer than other packaging systems for production of vector stocks. For clarity, constructs expressing Env, accessory and regulatory proteins are not depicted. Adapted from: Srinivasakumar N, Schuening FG. J Virology 1999; 73: 9589-9598.
of CTE gives reasonable titers in some studies63,88,133,150,151 while other studies have reported lower titers.106,149 The reason for these differences between the different studies is not yet clear. There are two regions of homology between the helper and gene transfer vector constructs. One is at the 5’ end of gag and the other is the shared RRE or CTE towards the 3’ end of the helper construct and the same element present within the gene transfer vector. Depending on the RNA transport element being used, one can design three types of packaging systems for production of HIV-1 vector stocks88 (Fig. 8) . The traditional or classical HIV-1 packaging system uses the RRE and Rev for the expression of both helper and gene transfer vector RNAs. The second packaging system uses the MPMV-CTE for expression of helper and gene transfer vector RNAs. A possible utility of a CTE-based Rev-independent HIV-1 packaging system is for the delivery of dominant negative forms of Rev into HIV-1 susceptible cells.133,150,151 In a
HIV-1 Vector Systems
65
Fig. 9. Trans-lentiviral packaging system.155 In this packaging system, the proteins encoded in the gag and pol coding regions are segregated in two different expression plasmids. One plasmid encodes for the Gag and Gag-Protease (A) while a separate construct encodes for a Vpr-RT-IN fusion protein (B). The Vpr-RT-IN is expressed using the LTR and RRE from HIV-2. This is based on the observation that Tat and Rev proteins of HIV-1, encoded in the Gag-Pro expression construct, can also function in the context of HIV-2 LTR and RRE-2. The gene transfer vector (C) and an Env expression construct (D) are the other components of the packaging system required for the production of vector stocks.
Rev-RRE based system, the coexpression of a dominant negative Rev as part of the gene transfer vector would be inhibitory for vector stock production. The third kind of packaging system is called the combination or reciprocal packaging system and utilizes the Rev and RRE for expression of one component of the packaging system and the CTE for the other component.88,151 Using dissimilar transport elements for the expression of the helper plasmid and the gene transfer vector RNAs in the combination packaging system may render the packaging system safer by reducing the chance of replication competent retrovirus (RCR) formation. Packaging System Using Codon-Optimized Helper Construct As an alternative approach to decreasing the homology at the gag end of the helper and gene transfer vector constructs, some investigators have constructed a helper plasmid containing a ‘humanized’ gag coding sequence.153 Interestingly, this not only reduces the homology in the gag region due to the silent mutations introduced, it also renders gag expression Revindependent. Elimination of homology at the gag end and at the 3’ end by removal of RRE in the helper plasmid in most probability makes this packaging system one of the safer systems
66
Lentiviral Vector Systems for Gene Transfer
described to date. On the other hand, a non-homologous recombination between the helper and gene transfer vector involving the gag region can result in a recombinant that may be able to express the Gag protein in target cells even in the absence of Rev. One can envisage the use of such codon optimized packaging system for the delivery of antisense RNA expression cassettes targeted to the gag and/or env coding regions of HIV-1. It may be possible to use this system to deliver dominant negative Rev into target cells providing that the inhibitory effect of dominant negative Rev on vector RNA transport in the producer cell can be overcome using the CTE or other modifications to vector backbone. Vector System Using Combination of Two Different Lentiviruses Another approach for decreasing homology between the components of a lentivirus packaging system is to use a helper construct derived from SIV to package an HIV-1 gene transfer vector.154 Currently, such packaging systems are still in their infancy and need to be developed further. For instance, the titer of this system is about an order of magnitude less than that obtainable with an Rev-RRE based HIV-1 packaging system. However such novel systems have great potential because of other benefits. For example, the Vpr of HIV-1 can increase efficiency of infection of macrophages. But Vpr of HIV-1 has the disadvantage of producing cell-cycle arrest and/or apoptosis of target cells when large amounts of protein are delivered via virus particles. In SIV, these functions of HIV-1 Vpr are segregated between two different proteins, the SIV Vpr and Vpx.1 The SIV Vpx, like HIV-1 Vpr, can augment nuclear import of PICS but without the apoptotic or cell-cycle arrest phenotype. This latter function is relegated to the SIV Vpr protein. Thus one can create an SIV based helper plasmid that encodes for Gag, Gag-Pol and Vpx but not Vpr and use this for generating HIV-1 vector stocks. The alternative system containing HIV-1 packaging construct and SIV based gene transfer vector has also been described.62 The latter packaging system does not have some of the advantages of the former, namely the use of SIV Vpx instead of HIV-1 Vpr. Packaging System Using Separate Helper Plasmids for Expression of Gag and Pol Coding Regions A recent novel modification to the packaging system involves a clever approach to separate gag and pol coding regions.155 In this novel packaging system (Fig. 9), gag/protease is expressed using one construct. The other enzymes of the Gag-Pol precursor, namely RT and IN are expressed as a Vpr-RT-IN fusion protein using a separate plasmid construct. The Vpr-RT-IN fusion protein is drawn into the assembling virus particle through its interaction with the p6 domain of the Gag precursor (see Virus Assembly above). Thus the internal proteins of virus particle are derived from two separate plasmid expression constructs. The use of separate plasmids for gag and pol proteins provide a higher margin of safety and has been shown to predictably reduce the frequency of recombination between the packaging plasmids and gene transfer vector.
Modifications to Gene Transfer Vector to Improve Safety and Efficacy Modifications have been engineered into gene transfer vectors not only to improve safety but also to enhance gene expression. Figure 10 shows various modifications to lentivirus vectors to improve efficacy and safety. Self-Inactivating HIV-1 Vectors Due to the nature of reverse-transcription, the promoter/enhancer elements present within the 3’ u3 of the viral genomic RNA is duplicated and positioned in both LTRs of the provirus. Thus promoter disabling mutations engineered into the U3 region of the 3’ LTR will be transferred to the 5’ LTR during reverse-transcription. Such vectors, after integration into the target cells, will not be able to generate full-length vector RNA and are called self-inactivating (SIN)
HIV-1 Vector Systems
67
Fig. 10. Modifications to HIV-1 gene transfer vector to improve safety and efficacy. Details are provided in the text. Adapted from Srinivasakumar N. Packaging cell system for lentivirus vectors. In: Morgan J, ed. Gene Therapy Protocols, 2nd ed. © 2001, Humana Press.
vectors. SIN vectors were first described for MoMLV and SNV vectors.156,157 These studies revealed that mutations in U3 frequently resulted in lower vector titers; this observation was explained by the requirement of some of the sequences in this region for efficient polyadenylation of vector RNA. In HIV-1, the core pA signal (AAUAAA) is present within the ‘R’ region. Sequences in the U3 region have been identified in HIV-1 that also modulate the efficiency of poly adenylation.67,69,158 The most important of these sequences is present between the TATA box and the R region and is about 20 bp in length. In contrast to what has been observed with MoMLV vectors, it appears that most of the U3 region of the 3’ LTR ,with the exception of the poly A ‘enhancer’ described above and the attachment (att) sequence at the 5’end of U3 recognized by viral IN, can be safely deleted without compromising vector titer.70,71 Such a deletion ensures that transcription from the 5’ LTR promoter is efficiently suppressed following reverse transcription and integration into the target cell chromosome. Another advantage of using vectors with deletions in the U3 region is the enhanced transgene expression noticed from some internal promoters in such vectors.65,71,159 This is probably due to a decrease in promoter competition between the viral LTR and the internal promoter.160 Tat-Independent HIV-1 Vectors Tat is not required for expression of helper proteins but is essential for obtaining high levels of transcription from the viral LTR promoter of the gene transfer vector. Several studies have shown that titers are lower if Tat is not provided during virus stock production.133,145,149 To overcome this, hybrid promoters that use enhancer elements from other viruses such as cytomegalovirus immediate early promoter and Rous sarcoma virus LTR, instead of those present in the U3 of HIV-1, have been created.145, 149 These vectors appear to be nearly as efficient in terms of vector titer as the original Tat-dependent vectors that contained the wild type HIV-1 LTR. Although there are reports showing that Tat, in addition to its effect on transcription from the viral LTR, can also effect the efficiency of reverse transcription,161 studies using HIV1 vectors have not revealed this requirement.145,149 Despite the observation that the requirement for Tat can be overcome by using hybrid promoters, it may not be possible to entirely remove the TAR element due to the presence of sequences essential to ensure optimal
68
Lentiviral Vector Systems for Gene Transfer
packaging of vector RNA.53,162 Moreover, the R region, including TAR, is essential for reversetranscription. Rev-Independent HIV-1 Vectors The CTE from MPMV can substitute for Rev and RRE function in proviral clones, packaging plasmids and in gene transfer vectors (see above). To create a Rev-independent gene transfer vector, this small RNA element of about ~200 bp is usually inserted between the transgene expression cassette and the 3' LTR63,88,133,150,151,163-165 (Fig. 10). If the CTE is placed further upstream, say in place of the RRE, its function seems to be compromised. Some investigators have hypothesized that the CTE needs to be as close as possible to the pA signal (< 200 nucleotides) to exert its effect.165 A Rev-independent vector is ideal for transducing transdominant Rev-encoding transgenes into HIV-1 susceptible cells.133,150 The drawback of this vector is that recombination with the helper construct involving the gag/pol region could allow Rev-RRE independent expression of Gag-Pol proteins in the transduced target cells. Minimal Gene Transfer Vectors The two important reasons for attempting to create a minimal gene transfer vector are: 1) to decrease regions of homology between the gene transfer vector and packaging plasmid and 2) to increase the payload carrying capacity of the vector. It is believed that it may be possible to accommodate between 8 and 11 kb size of foreign sequence within an HIV-1 vector.47,48 Therefore, the smaller the size of the vector backbone, the larger the size of the insert that it can accommodate. One of the smallest vectors described to date 61 has about 550 bp of the 9.7 kb of the HIV-1 provirus genome. This vector contains the 5’LTR and the entire 5' untranslated region upstream of gag and about 40 nucleotides (nt) of gag. The 5' major splice donor site in the 5' untranslated region is mutated. The vector lacks the RRE and contains deletions in U3 and U5 regions of the 3’LTR. The pA functions in the U5 region is restored using the bovine growth hormone pA signal. This vector has approximately 50% of the titer of the wild-type vector. Insertion of the cPPT and CTS sequence in this vector (~170 nt) will probably improve the titer obtained with this minimal vector without significantly affecting the payload capacity. Most vectors used to date, in contrast, contain the 5’ splice donor, an extended gag (350 to 500 nt), the cPPT and the RRE since the addition of these features usually provides higher vector titers. Vectors with Woodchuck Post-Transcriptional Regulatory Element (WPRE) for Enhanced Transgene Expression An element with Rev and RRE like properties is the woodchuck post-transcriptional regulatory element (WPRE).166 While the WPRE can substitute for Rev and RRE function in a reporter construct that is widely used for assessing transport of intron containing messages, it is not known if this sequence can substitute for Rev and RRE in the context of gene transfer vectors or HIV-1 packaging constructs. Interestingly, experiments have revealed that addition of the 600 bp WPRE in retroviral and lentiviral vectors downstream of the transgene can increase expression by 5-8 fold 65,167(Fig. 10). This element may be of use to improve expression from weak promoters that may not function at optimal levels in some target cells.
Clinical Applications of HIV-1 Vectors The application of lentivirus vectors for the treatment of many genetic and infectious diseases is discussed in Chapter 9. Two recent publications showcase the utility of these vectors for treatment of β-thalassemia in mice168 and for prevention of neurodegeration in a primate model of parkinson’s disease.169 A possible intriguing application of HIV-1 vectors is for the treatment of AIDS caused by HIV-1. The HIV-1 vector can be considered to be a defective
HIV-1 Vector Systems
69
interfering (DI) virus. HIV-1 vectors can interfere with the replication of wild-type virus by several mechanisms. One mechanism is by competing and sequestering viral regulatory proteins170 and the other is by competing with wild-type RNA for encapsidation into the assembling virus particle.171 The presence of the vector in cells was found to interfere with the spread of the wild-type virus in culture. During the spread of the wild-type virus, the vector sequences are also likely to be mobilized to other cells where they can be expected to continue to exert their interfering phenotype. HIV-1 vectors can also be harnessed to deliver dominant negative proteins or RNA into HIV-1 susceptible cells. The trick to using HIV-1 vectors for delivering interfering proteins or antisense RNAs is to design packaging systems that will not be affected by expression of these anti-HIV therapeutics in the vector producing cells. Even with packaging systems currently in use, it should be possible to deliver antisense RNAs directed against the HIV-1 env region since most packaging systems use Env from a heterologous virus for production of vector stocks. Likewise one may be able to use gag antisense molecules in packaging systems using codonoptimized helper constructs as long as the antisense sequence does not overlap the gag portion still present in the gene transfer vector. Finally, one can use a Rev-independent packaging system where nucleo-cytoplasmic transport and expression of both helper and gene transfer vector RNAs is regulated by MPMV-CTE to deliver interfering Rev into HIV-1 susceptible cells.63,88,133,150,151 It is debatable if the use of HIV-1 based vectors for delivery of some of these therapeutic genes has any advantages over using an unrelated lentivirus (discussed elsewhere in this book) to achieve some of the same goals. A novel approach to exploit interactions between the wild-type virus and vector sequence has been suggested.58 This approach consists of expressing dominant negative proteins or antigenic epitopes of common infectious agents such as the hemagglutinin epitope in the HIV-1 vectors under control of the viral LTR promoter. When a wild-type virus infects the cell, Tat produced from the incoming virus, transactivates the vector leading to the synthesis of dominant-negative protein or antigen. Cytotoxic T- cells directed against expressed antigen on HIV1 infected cells, if present, would then be expected to clear the antigen bearing cells. Alternatively, the dominant negative protein would be expected to interfere with replication of HIV-1 in that cell.
Anticipated Developments in HIV-1 Based Packaging Systems and Possible Confounding Factors Long-Term and Cell-Type Specific Gene Expression The gene-expression in target cells transduced with MoMLV is subject to silencing as a result of methylation of vector DNA and/or deacetylation of histones in the promoter region.172-175 These modifications to DNA or histones can alter the chromatin structure resulting in gradual obtundation of gene expression. Studies in the case of HIV-1 vectors, on the other hand, seem to indicate that gene expression can persist for at least for six months or more in certain tissues such as neurons, muscle and liver cells.59,143,176,177 A recent study indicates that in embryonal stem cells, differentiation leads to rapid loss of gene expression in the context of MoMLV vectors but is only partially obtunded in the case of lentiviral vectors.178 Clearly, modifications to gene transfer vectors that can provide long-term gene expression is necessary to effect a permanent cure for many diseases. Such modifications to HIV-1 vectors could involve the introduction of boundary elements or insulators to improve long-term gene expression in target cells and thereby prevent gradual shut-down of transgene expression.179-181 Currently, most HIV-1 vectors express transgenes under control of strong viral promoters or constitutively active cellular promoters such as the phosphoglycerate kinase promoter or the
70
Lentiviral Vector Systems for Gene Transfer
human elongation factor EF1 α promoter. But in many situations it may be preferable to express physiological amounts of the transgene and/or express the transgene in only the tissue of interest i.e., expression that is regulated in a tissue/cell specific manner. One excellent example of this is a recent report using a lentivirus vector for erythroid-specific expression of human β-globin.168 In this vector the β-globin gene was expressed using the β-globin promoter together with the upstream regulatory regions consisting of DNAse I hypersensitive sites that are known to confer erythroid-specificity of gene expression. The entire transgene expression cassette was inserted in an inverse orientation to that of the vector. Such an orientation allowed the retention of splicing signals within the expression cassette leading to significantly higher levels of transgene expression than that observed with other vectors. Because the transgene expression was restricted to erythroid cells, there was no negative impact on vector titer due to an antisense effect in the producer cell. This vector provided therapeutic levels of β-globin expression in thallasemic mice. Reports such as this auger well for the development of lentivirus vectors containing cell-type specific promoters for expression of transgenes. Other modifications to HIV-1 vectors will be in the use of regulatable promoters that can be turned on or off using small molecules such as tetracycline,182 Rapamycin, estradiol or RU486.183-191 The drawback of the latter approach is that one will have to coexpress the protein that is required for gene regulation (e.g., tetracycline regulated transactivator) along with the transgene. It is not clear how these regulators will affect functioning of the cell or whether expression of these proteins will lead to immune-mediated elimination of the transduced cells. Such vectors will eventually allow precise control of transgene expression in vivo. Precise control of transgene expression may be of particular importance in the nervous system where overexpression of neurotransmitters could lead to neurological effects.169
Site-Specific Integration Due to the random nature of integration, lentiviruses have the some of the same disadvantages as other retroviruses, such as the possibility of either inactivating cellular genes (e.g., tumor suppressor genes) or activating or overexpression of other genes (e.g., oncogenes). Inadvertent activation of cellular genes, including oncogenes, can be avoided by using later generation of self-inactivating vectors which are devoid of promoter and enhancer elements in the viral 3’ LTR (see above). Alternatively, it may be possible to overcome the drawback of random integration by redirecting PICs to specific regions of the host chromosome by fusing sequence specific DNA-binding domains to the viral integrase.192,193
Packaging Cell Lines Most investigators currently use a transient transfection approach to produce vector stocks. A drawback of this procedure is that there may be a significant degree of rearrangement of the input DNAs. This can lead to contamination of vector stocks with defective vector genomes. To produce ‘clean’ vector stocks it may be preferable to derive well-characterized packaging cell lines. The major hurdle for the creation of packaging cell lines appears to be the toxicity of certain viral proteins. For instance, Vpr causes cells to arrest in G2 phase of the cell cycle115,116,194 and, therefore, would not be conducive for producing cell lines that express high levels of this protein. Likewise, the viral protease has been shown to also cleave cellular proteins, which could interfere with the establishment of cell lines that stably express viral Gag-Pol proteins.195-197 VSV-G protein expression is also toxic to cells. Although cell lines that constitutively express viral packaging proteins have been described,133,198,199 more recent approaches to create lentivirus packaging cell lines resort to the use of inducible or regulatable promoters to overcome potential toxic effects of viral proteins.105,200 Availability of second generation packaging cell lines using advanced packaging and gene transfer vectors201will enable the eventual testing of HIV1 vectors in a clinical setting.
HIV-1 Vector Systems
71
Immune Response to Transgene Encoded Products One of the biggest hurdles to gene therapy may not be vector related issues, most of which will likely be solved, but the possible elimination of transduced cells if the expressed transgene is perceived as foreign by the host. Thus successful gene therapy will also involve use of therapeutic strategies that can overcome this hurdle. This could involve the coexpression of viral protein derived from HIV-1 or other viruses that are known to interfere with antigen presentation. Examples of proteins with such activities include Nef141 and/or Tat202,203 of HIV-1.
Safety Issues Safety issues for the deployment of HIV-1 vectors for gene therapy in humans are discussed further in Chapter 8. Some aspects of vector safety are elaborated upon here. Recombination between helper and gene transfer vector molecules can occur at the level of input DNAs in the producer cells or can occur during reverse transcription as consequence of copackaging of vector and helper RNAs or vector and cellular RNAs in the same virus particle. One favored site of recombination between RNA molecules during reverse-transcription appears to be in the poly A tract of the helper RNA and the sequences upstream of the 3' U3 and PPT in the gene transfer vector.155 The upstream recombination appears to occur, as anticipated, in the gag region, which results in the joining of the 5’LTR and packaging sequence of the gene transfer vector with the gag ORF of the helper plasmid. Whatever the mechanism of recombination, the consequence is the transduction of molecules into the target cells that may have an intact open reading frames for one or more viral proteins such as GagPol and/or Tat. Can these cells, harboring gag/pol sequences, produce viral proteins? Will this lead to an immune response in the transplant recipient against the proteins expressed by the recombinant vector? In other words, will the person be rendered HIV positive as deduced from antibody assays? Another concern is that the reverse-transcription of the vector RNA is error prone. It is likely that some of the vector genomes introduced into target cells will contain deleterious mutations. These mutations (e.g., deletions, insertions or duplications) can lead to inactivation of the transgene or synthesis of aberrant or nonfunctional proteins. What is the effect of introducing these altered DNA sequences into target cells? Finally, vector genomes can interact with wild-type HIV and possibly with endogenous retroviral sequences or elements. What are the consequences of the interactions between vector and wild-type HIV-1 or endogenous retroviruses? Will this lead to the mobilization of vector or host-sequences from one cell to another? Can novel viruses emerge as a result of recombination between vector and wildtype sequences or endogenous retroviral sequences? The answers to many of these questions can only be ascertained by vigorous and careful evaluation of the vectors in large animals. Preliminary studies from some investigators appear to indicate that HIV-1 based vectors are safe in primates.204 But more careful studies are clearly needed. How does one evaluate the safety of lentivirus vector stocks? The Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) recommends that 5% of each vector supernatant lot and 108 or 1% of the end of production cells (which ever is less) be tested for RCR for MoMLV vectors.205 There is, at present, no agreement on what standards to apply for lentivirus vectors, particularly those based on HIV-1. It would need to equal, if not exceed, those standards designed to detect RCRs in MoMLV vector stocks. Also, there are no agreed upon assays to detect RCRs in HIV-1 vector stocks. The methods commonly used are: 1. Infection of target cells (including phytohemagglutinin-stimulated human peripheral blood mononuclear cells) with vector stocks and assaying supernatant periodically for HIV-1 p24 over a two to four week culture period.204,206 2. Infection of indicator cell lines harboring lacz gene (Magi-cell assay)207 or puromycin resistance gene under control of HIV-1 LTR.155
Lentiviral Vector Systems for Gene Transfer
72
3. Marker mobilization assays.155 The first method (assay for p24) can only detect replication competent HIV while the latter two (infection of indicator cell lines and marker mobilization) can detect partial recombinants. The Magi-cell assay requires the recombinant to synthesize the HIV-1 Tat protein and thereby turn on lacz expression from the HIV-1 LTR. Marker mobilization detects recombinants that can synthesize Gag-Pol , Tat, Rev and Env. The last method can be modified to detect partial recombinants that can synthesize Gag-Pol after appropriate modifications to the assay.155 Once the safety concerns are addressed, then the first steps towards deploying HIV-1 vectors for clinical use can be taken.
Conclusions There has been tremendous progress in the development of HIV-1 based vectors in the last five years in terms of their safety and efficacy to deliver genes to a wide variety of tissues both in vitro and in vivo. It is a vector system that shows great promise. However, the stigma associated with HIV-1 based vectors, the lack of standardized assays for detection of recombinant replication competent HIV-1 emerging during virus stock production and the risk of immune-mediated rejection of cells bearing a foreign transgene by the host are significant hurdles that need to be addressed before clinical trials using HIV-1 vectors can be undertaken.
Acknowledgements I wish to offer my apologies to those authors whose work was not cited due to an oversight or because of space considerations. I wish to thank Gary Buchschacher, Jr. for his immense patience, support and constructive criticisms during the writing of this chapter. I was supported by grants from the American Foundation for AIDS Research and the National Institutes of Health for my research studies cited in this chapter.
References 1. Coffin J.M., Stephen HH, Varmus HE. Retroviruses: CSHL; 1997. 2. Feinberg MB, Baltimore D, Frankel AD. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 1991; 88(9):4045-4049. 3. Gaynor RB. Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol Immunol 1995; 193:51-77. 4. Jeang KT, Xiao H, Rich EA. Multifaceted Activities of the HIV-1 Transactivator of Transcription, Tat. J Biol Chem 1999; 274(41):28837-28840. 5. Jones KA. Taking a new TAK on tat transactivation [comment]. Genes Dev 1997; 11(20):2593-2599. 6. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 1993; 67(11):6365-6378. 7. Arrigo SJ, Weitsman S, Zack JA et al. Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol 1990; 64(9):4585-4588. 8. Guatelli JC, Gingeras TR, Richman DD. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells. J Virol 1990; 64(9):4093-4098. 9. Muesing MA, Smith DH, Cabradilla CD et al. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985; 313(6002):450-458. 10. Robert-Guroff M, Popovic M, Gartner S et al. Structure and expression of tat-, rev-, and nefspecific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol 1990; 64(7):3391-3398. 11. Schwartz S, Felber BK, Benko DM et al. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol 1990; 64(6):2519-2529. 12. Schwartz S, Felber BK, Fenyo EM et al. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol 1990; 64(11):5448-5456. 13. Schwartz S, Felber BK, Pavlakis GN. Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology 1991; 183(2):677-686.
HIV-1 Vector Systems
73
14. Fornerod M, Ohno M, Yoshida M et al. CRM1 is an export receptor for leucine-rich nuclear export signals [see comments]. Cell 1997; 90(6):1051-1060. 15. Hammarskjold ML, Heimer J, Hammarskjold B et al. Regulation of human immunodeficiency virus env expression by the rev gene product. J Virol 1989; 63(5):1959-1966. 16. Malim MH, Hauber J, Le SY et al. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338(6212):254-257. 17. Malim MH, Tiley LS, McCarn DF et al. HIV-1 structural gene expression requires binding of the Rev trans- activator to its RNA target sequence. Cell 1990; 60(4):675-683. 18. Salahuddin SZ, Nakamura S, Biberfeld P et al. Angiogenic properties of Kaposi’s sarcoma-derived cells after long-term culture in vitro. Science 1988; 242(4877):430-433. 19. Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992; 66(1):150-159. 20. Schwartz S, Campbell M, Nasioulas G et al. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992; 66(12):7176-7182. 21. Arrigo SJ, Chen IS. Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev 1991; 5(5):808-819. 22. Butsch M, Hull S, Wang Y et al. The 5' RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production. J Virol 1999; 73(6):4847-4855. 23. Lu XB, Heimer J, Rekosh D et al. U1 small nuclear RNA plays a direct role in the formation of a rev- regulated human immunodeficiency virus env mRNA that remains unspliced. Proc Natl Acad Sci USA 1990; 87(19):7598-7602. 24. Wills JW, Craven RC. Form, function, and use of retroviral gag proteins [editorial]. Aids 1991; 5(6):639-654. 25. Smith AJ, Cho MI, Hammarskjold ML et al. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol 1990; 64(6):2743-2750. 26. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag viruslike particles from recombinant baculovirus-infected insect cells. Cell 1989; 59(1):103-112. 27. Delchambre M, Gheysen D, Thines D et al. The GAG precursor of simian immunodeficiency virus assembles into virus- like particles. Embo J 1989; 8(9):2653-2660. 28. Jacobs E, Gheysen D, Thines D et al. The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane. Gene 1989; 79(1):71-81. 29. Karacostas V, Wolffe EJ, Nagashima K et al. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 1993; 193(2):661-671. 30. Karacostas V, Nagashima K, Gonda MA et al. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci USA 1989; 86(22):8964-8967. 31. Hu SL, Travis BM, Garrigues J et al. Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 1990; 179(1):321-329. 32. Shioda T, Shibuta H. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 1990; 175(1):139-148. 33. Haffar O, Garrigues J, Travis B et al. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990; 64(6):2653-2659. 34. Mergener K, Facke M, Welker R et al. Analysis of HIV particle formation using transient expression of subviral constructs in mammaliancells. Virology 1992; 186(1):25-39. 35. Bryant M, Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1990; 87(2):523-527. 36. Smith AJ, Srinivasakumar N, Hammarskjold ML et al. Requirements for incorporation of Pr160gagpol rom human immunodeficiency virus type 1 into virus-like particles. J Virol 1993; 67(4):2266-2275.
74
Lentiviral Vector Systems for Gene Transfer
37. Srinivasakumar N, Hammarskjold ML, Rekosh D. Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag- Pol precursor incorporation. J Virol 1995; 69(10):6106-6114. 38. Wang CT, Stegeman-Olsen J, Zhang Y et al. Assembly of HIV GAG-B-galactosidase fusion proteins into virus particles. Virology 1994; 200(2):524-534. 39. Park J, Morrow CD. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol 1992; 66(11):6304-6313. 40. Paxton W, Connor RI, Landau NR. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993; 67(12):7229-7237. 41. Selig L, Pages J, Tanchou V et al. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of vpr and vpx proteins from primate lentiviruses [In Process Citation]. J Virol 1999; 73(1):592-600. 42. Muller B, Tessmer U, Schubert U et al. Human immunodeficiency virus type 1 vpr protein is incorporated into the virion in significantly smaller amounts than gag and Is phosphorylated in infected cells [In Process Citation]. J Virol 2000; 74(20):9727-9731. 43. Khan MA, Aberham C, Kao S et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol 2001; 75(16):7252-7265. 44. Charneau P, Mirambeau G, Roux P et al. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241(5):651-662. 45. Follenzi A, Ailles LE, Bakovic S et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25(2):217-222. 46. Zennou V, Petit C, Guetard D et al. HIV-1 genome nuclear import is mediated by a centralDNA flap. Cell 2000; 101(2):173-185. 47. Trono D, Baltimore D. A human cell factor is essential for HIV-1 Rev action. Embo J 1990; 9(12):4155-4160. 48. Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature 1997; 389(6648):239242. 49. Clever J, Sassetti C, Parslow TG. RNA secondary structure and binding sites for gaggene products in the 5' packaging signal of human immunodeficiency virus type 1. J Virol 1995; 69(4):2101-2109. 50. Das AT, Klaver B, Klasens BI et al. Aconserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J Virol 1997; 71(3):2346-2356. 51. McBride MS, Panganiban AT. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures [published erratum appears in J Virol 1997 Jan;71(1):858]. J Virol 1996; 70(5):2963-2973. 52. McBride MS, Panganiban AT. Position dependence of functional hairpins important for human immunodeficiency virus type 1 RNA encapsidation in vivo. J Virol 1997; 71(3):2050-2058. 53. Helga-Maria C, Hammarskjold ML, Rekosh D. An intact TAR element and cytoplasmic localization are necessary for efficient packaging of human immunodeficiency virus type 1 genomic RNA. J Virol 1999; 73(5):4127-4135. 54. Clever JL, Parslow TG. Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol 1997; 71(5):3407-3414. 55. Luban J, Goff SP. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol 1994; 68(6):3784-3793. 56. Bender MA, Palmer TD, Gelinas RE et al. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J Virol 1987; 61(5):1639-1646. 57. Parolin C, Dorfman T, Palu G et al. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol 1994; 68(6):3888-3895. 58. Buchschacher GJ, Panganiban AT. Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 1992; 66(5):2731-2739. 59. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259):263-267.
HIV-1 Vector Systems
75
60. Nasioulas G, Zolotukhin AS, Tabernero C et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994; 68(5):2986-2993. 61. Cui Y, Iwakuma T, Chang LJ. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 1999; 73(7):6171-6176. 62. Rizvi TA, Panganiban AT. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol 1993; 67(5):2681-2688. 63. Srinivasakumar N, Schuening FG. Novel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene-transfer vectors for high-level transgene expression. J Virol 2000; 74:6659-6668. 64. Parolin P, Taddeo B, Palu G et al. Use of cis- and trans-Acting regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology 1996; 222:415-422. 65. Salmon P, Kindler V, Ducrey O et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors [In Process Citation ] Blood 2000; 96(10):3392-3398. 66. Miyoshi H, Takahashi M, Gage FH et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997; 94(19):10319-10323. 67. DeZazzo JD, Kilpatrick JE, Imperiale MJ. Involvement of long terminal repeat U3 sequences overlapping the transcription control region in human immunodeficiency virus type 1 mRNA 3' end formation. Mol Cell Biol 1991; 11(3):1624-1630. 68. DeZazzo JD, Scott JM, Imperiale MJ. Relative roles of signals upstrea of AAUAAA and promoter proximity in regulation of human immunodeficiency virus type 1 mRNA 3' end formation. Mol Cell Biol 1992; 12(12):5555-5562. 69. Valsamakis A, Zeichner S, Carswell S et al. The human immunodeficiency virus type 1 polyadenylylation signal: a 3' long terminal repeat element upstream of the AAUAAA necessary for efficient polyadenylylation. Proc Natl Acad Sci USA 1991; 88(6):2108-2112. 70. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999; 261(1):120-132. 71. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72(12):9873-9880. 72. Mochizuki H, Schwartz JP, Tanaka K et al. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol 1998; 72(11):8873-8883. 73. Yee JK, Miyanohara A, LaPorte P et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91(20):9564-9568. 74. Kiem HP, McSweeney PA, Bruno B et al. Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus-pseudotype retroviral vector. Gene Ther 1999; 6(6):966-972. 75. Stitz J, Buchholz CJ, Engelstadter M et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000; 273(1):16-20. 76. Chu TH, Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 1995; 69(4):2659-2663. 77. Chu TH, Dornburg R. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 1997; 71(1):720-725. 78. Jiang A, Chu TH, Nocken F et al. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol 1998; 72(12):10148-10156. 79. Martinez I, Dornburg R. Mapping of receptor binding domains in the envelope protein of spleen necrosis virus. J Virol 1995; 69(7):4339-4346. 80. Martinez I, Dornburg R. Mutational analysis of the envelope protein of spleen necrosis virus. J Virol 1996; 70(9):6036-6043. 81. Naviaux RK, Costanzi E, Haas M et al. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996; 70(8):5701-5705. 82. Srinivasakumar N et al. (unpublished observations).
76
Lentiviral Vector Systems for Gene Transfer
83. Batra RK, Olsen JC, Hoganson DK et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997; 272(18):11736-11743. 84. Le Doux JM, Morgan JR, Snow RG et al. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1996; 70(9):6468-6473. 85. Le Doux JM, Morgan JR, Yarmush ML. Removal of proteoglycans increases efficiency of retroviral gene transfer. Biotechnol Bioeng 1998; 58(1):23-34. 86. Le Doux JM, Morgan JR, Yarmush ML. Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol Prog 1999; 15(3):397-406. 87. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 2000; 7(11):910-913. 88. Srinivasakumar N, Schuening F. A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery. J Virol 1999; 73:9589-9598. 89. Albini A, Fontanini G, Masiello Let al. Angiogenic potential in vivo by Kaposi’s sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. Aids 1994; 8(9):1237-1244. 90. Albini A, Barillari G, Benelli R et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995; 92(11):4838-4842. 91. Albini A, Benelli R, Presta M et al. HIV-tat protein is a heparin-binding angiogenic growthfactor. Oncogene 1996; 12(2):289-297. 92. Ensoli B, Barillari G, Salahuddin SZ et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature 1990; 345(6270):84-86. 93. Ensoli B, Barillari G, Buonaguro L et al. Molecular mechanisms in the pathogenesis of AIDSassociated aposi’s sarcoma. Adv Exp Med Biol 1991; 303:27-38. 94. Ensoli B, Buonaguro L, Barillari G et al. Release, uptake, and effects of extracellular human immunoeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67(1):277287. 95. Ensoli B, Gendelman R, Markham P et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma. Nature 1994; 371(6499):674-680. 96. Chirmule N, Than S, Khan SA et al. Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J Virol 1995; 69(1):492-498. 97. Ott M, Emiliani S, Van Lint C et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275(505):1481-1485. 98. Ott M, Lovett JL, Mueller L et al. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J Immunol 1998; 160(6):2872-2880. 99. Puri RK, Leland P, Aggarwal BB. Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits intrleukin 2 and interleukin 2 receptor expression in a human CD4+ T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 1995; 11(1):31-40. 100. Rautonen N, Rautonen J, MartinNL et al. HIV-1 Tat induces cytokine synthesis by uninfected mononuclear cells [letter]. Aids 1994; 8(10):1504-1506. 101. Reinhold D, Wrenger S, Bank U et al. CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Immunobiology 1996; 195(1):119-128. 102. Subramanyam M, Gutheil WG, Bachovchin WW et al. Mechanism of HIV-1 Tat induced inhibition f antigen-specific T cell responsiveness. J Immunol 1993; 150(6):2544-2553. 103. Vacca A, Farina M, Maroder M et al. Human immunodeficiency virus type-1 tat enhances interlekin2 promoter activity through synergism with phorbol ester and calcium-mediated activation of the NF-AT cis-regulatory motif. Biochem Biophys Res Commun 1994; 205(1):467-474. 104. Verhoef K, Bauer M, Meyerhans A et al. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. AIDS Res Hum Retroviruses 1998; 14(17):1553-1559. 105. Kaul M, Yu H, Ron Y et al. Regulated lentiviral packaging cell line devoid of most viral cis- acting sequences. Virology 1998; 249(1):167-174. 106. Gasmi M, Glynn J, Jin MJ et al. Requirements for efficient production and transduction of human immunodeficiency vius type 1-based vectors. J Virol 1999; 73(3):1828-1834.
HIV-1 Vector Systems
77
107. Madani N, Kabat D. Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol 2000; 74(13):5982-5987. 108. Simon JH, Miller DL, Fouchier RA et al. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and crossspecies transmission. Embo J 1998; 17(5):1259-1267. 109. von Schwedler U, Song J, Aiken C et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67(8):4945-4955. 110. Strebel K, Klimkait T, Maldarelli F et al. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 1989; 63(9):3784-3791. 111. Schwartz MD, Geraghty RJ, Panganiban AT. HIV-1 particle release mediated by Vpu is distinct from that mediated by p6. Virology 1996; 224(1):302-309. 112. Gottlinger HG, Dorfman T, Sodroski JG et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991;88(8):3195-3199. 113. Kerkau T, Bacik I, Bennink JR et al. The human immunodeficiency virustype 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997; 185(7):1295-1305. 114. Willey RL, Maldarelli F, Martin MA et al. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992; 66(12):7193-7200. 115. Bartz SR, Rogel ME, Emerman M. Human immunodficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996; 70(4):2324-2331. 116. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995; 69(2):882-888. 117. Re F, Braaten D, Franke EK et al. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995; 69(11):6859-6864. 118. Goh WC, Rogel ME, Kinsey CM et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 1998; 4(1):65-71. 119. Heinzinger NK, Bukinsky MI, Haggerty SA et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91(15):7311-7315. 120.Popov S, Rexach M, Zybarth G et al. Viral protein R regulates nuclear import of the HIV-1 preintegration complex. Embo J 1998; 17(4):909-917. 121. Popov S, Rexach M, Ratner L et al. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998; 273(21):13347-13352. 122. Vodicka MA, Koepp DM, Silver PA et al. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998; 2(2):175-185. 123. Stewart SA, Poon B, Jowett JB et al. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle rrest. J Virol 1997; 71(7):5579-5592. 124. Stewart SA, Poon B, Jowett JB et al. Lentiviral delivery of HIV-1 Vpr protein induces apoptosi in transformed cells. Proc Natl Acad Sci USA 1999; 96(21):12039-12043. 125. Stewart SA, Poon B, Song JY et al. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000; 74(7):3105-3111. 126. Chinnasamy D, Chinnasamy N, Enriquez MJ et al. Lentiviral-mediated gene transfer into human lymphocytes: role f HIV-1 accessory proteins. Blood 2000; 96(4):1309-1316. 127. Anderson SJ, Lenburg M, Landau NR et al. The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human immunodeficiency virus type 1 Nef [published erratum appears in J Virol 1994 Jul; 68(7):4705]. J Virol 1994; 68(5):3092-3101. 128. Aiken C, Konner J, Landau NR et al. Nef induces CD4 endoctosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994; 76(5):853-864. 129. Garcia JV, Miller AD. Downregulation of cell surface CD4 by nef. Res Virol 1992; 143(1):52-55. 130. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350(6318):508-511. 131. Luo T, Livingston RA, Garcia JV. Infectivity enhancement by human immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase. J Virol 1997; 71(12):9524-9530.
78
Lentiviral Vector Systems for Gene Transfer
132. Luo T, Douglas JL, Livingston RL et al. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 1998; 241(2):224-233. 133. Srinivasakumar N, Chazal N, Helga-Maria C et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997; 71(8):5841-5848. 134. Schwrtz O, Marechal V, Danos O et al. Human immunodeficiency virus tpe 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 1995; 69(7):4053-4059. 135. Aiken C, Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995; 69(8):5048-5056. 136. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71(8):5871-5877. 137. Chazal N, Singer G, Aiken C et al. Human Immunodeficiency Virus Type 1 Particles Pseudotyped with Envelope Proteins That Fuse at Low pH No Longer Require Nef or Optimal Infectivity. J Virol 2001; 75(8):4014-4018. 138. Hanna Z Kay DG, Rebai N et al. Nef harbors a major determinant of pathogenicity for an AIDSlike disease induced by HIV-1 in transgenic mice. Cell 1998; 95(2):163-175. 139. Delwart EL, Buchschacher GL, Jr., Freed EO et al. Analysis of HIV-1 envelope mutants and pseudotyping of replication- defective HIV-1 vectors by genetic complementation. AIDS Res Hum Retroviruses 1992; 8(9):1669-1677. 140. Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector foranalysis of virus infectivity. J Virol 1990; 64(11):5270-5276. 141. Collins KL, Chen BK, Kalams SA et al. HIV-1 Nef protin protects infected primary cells against killing by cytotoxic lymphocytes. Nature 1998; 391(6665):397-401. 142. Chen BK, Feinberg MB, Baltimore D. The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J Virol 1997; 71(7):5495-5504. 143. Kafri T, Blomer U, Peerson DA et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17(3):314-317. 144. Zufferey R, Nagy D, Mandel RJ et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15(9):871-875. 145. Dull T, Zufferey R, Kelly M et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72(11):8463-8471. 146. Ernst RK, Bray M, Rekosh D et al. A structured retroviral RNA element that mediates nucleocytoplasmic export of intron-containing RNA. Mol Cell Biol 1997; 17(1):135-144. 147. Ernst RK, Bray M, Rekosh D et al. Secondary structure and mutational analysis of the MasonPfizer monkey virus RNA constitutive transport element. Rna 1997; 3(2):210-222. 148. Bray M, Prasad S, Dubay JW et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev- independent. Proc Natl Acad Sci USA 1994; 91(4):1256-1260. 149. Kim VN, Mitrophanous K, Kingsman SM et al. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72(1):811-816. 150. Mautino MR, Ramsey WJ, Reiser J et al. Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. Hum Gene Ther 2000;11(6):895-908. 151. Mautino MR, Keiser N, Morgan RA. Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther 2000; 7(16):1421-1424. 152. Zolotukhin AS, Valentin A, Pavlakis GN et al. Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J Virol 1994; 68(2):7944-7952. 153. Kotsopoulou E, Kim VN, Kingsman AJ et al. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74(10):4839-4852. 154. White SM, Renda M, Nam NY et al. Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol 1999; 73(4):2832-2840.
HIV-1 Vector Systems
79
155. Wu X, Wakefield JK, Liu H et al. Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2000; 2(1:47-55. 156. Dougherty JP, Temin HM. A promoterlessretroviral vector indicates that there are sequences in U3 required for 3' RNA processing. Proc Natl Acad Sci USA 1987; 84(5):1197-1201. 157. Yu SF, von Ruden T, Kantoff PW et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986;83(10):3194-3198. 158. DeZazzo JD, Imperiale MJ. Sequences upstream of AAUAAA influence poly(A) site selection in a complex transcription unit. Mol Cell Biol 1989; 9(11):4951-4961. 159. Kung SK, An DS, Chen IS. A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes. J Virol 2000; 74(8):3668-3681. 160. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39(3 Pt 2):449-467. 161. Harrich D, Ulich C, Garcia-Martinez LF et al. Tat is required for efficient HIV-1 reverse transcription. Embo J 1997;16(6):1224-1235. 162. McBride MS, Schwartz MD, Panganiban AT. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation. J Virol 1997;71(6):4544-4554. 163. Rizvi TA, Schmidt RD, Lew KA et al. Rev/RRE-independent Mason-Pfizer monkey virus constitutive trasport element-dependent propagation of SIVmac239 vectors using a single round of replication assay. Virology 1996;222(2):457-463. 164. Rizvi TA, Lew KA, Murphy EC, Jr. et al. Role of Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE) in the propagation of MPMV vectors by genetic complementation using homologous/heterologous env genes. Virology 1996; 224(2):517-532. 165. Rizvi TA, Schmidt RD, Lew KA. Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE) functions in a position-dependent manner. Virology 1997; 236(1):118-129. 166. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72(6):5085-5092. 167. Zufferey R, Donello JE, Trono D et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73(4):2886-2892. 168. May C, Rivella S, Callegari J et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406(6791):82-86. 169. Kordower JH, Emborg ME, Bloch J et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 2000; 290(5492):767-773. 170. Corbeau P, Wong-Staal F. Anti-HIV effects of HIV vectors. Virology 1998; 243(2):268-274. 171. Bukovsky AA, Song JP, Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild- type virus in transduced cells. J Virol 1999; 73(8):7087-7092. 172. Lorincz MC, Schubeler D, Goeke SC et al. Dynamic analysis of proviral induction and De Novo methylation: implications for a histone deacetylase-independet, methylation ensity- dependent mechanism of transcriptional repression. Mol Cell Biol 2000; 20(3):842-850. 173. Cherry SR, Biniszkiewicz D, van Parijs L et al. Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol Cell Biol 2000; 20(20):7419-7426. 174. Chen WY, Townes TM. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc Natl Acad Sci USA 2000;97(1):377-382. 175. Chen WY, Bailey EC, McCune SL et al. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 1997; 94(11):5798-5803. 176. Naldini L, Blomer U, Gage FH et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93(21):11382-11388. 177. Blomer U, Naldini L, Kafri T et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71(9):6641-6649. 178. Hamaguchi I, Woods NB, Panagopoulos I et al. Lentivirus vector gene expression during ES cellderived hematopoietic development in vitro. J Virol 2000; 74(22):10778-10784.
80
Lentiviral Vector Systems for Gene Transfer
179. Agarwal M, Austin TW, Morel F et al. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol 1998; 72(5):3720-3728. 180. Auten J, Agarwal M, Chen J et al. Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther 1999; 10(8):1389-1399. 181. Dang Q, Auten J, Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J Virol 2000; 74(6):2671-2678. 182. Kafri T, van Praag H, Gage FH et al. Lentiviral vectors: regulated gene expression. Mol Ther 2000; 1(6):516-521. 183. Shockett PE, Schatz DG. Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci USA 1996; 93(11):5173-5176. 184. Deuschle U, Meyer WK, Thiesen HJ. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 1995; 15(4):1907-1914. 185. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 1996; 93(11):5185-5190. 186. Paulus W, Baur I, Boyce FM et al. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996; 70(1):62-67. 187. Rivera VM, Clackson T, Natesan S et al. A humanized system for pharmacologic control of gene expression [see comments]. Nat Med 1996; 2(9):1028-1032. 188. Spencer DM, Wandless TJ, Schreiber SL et al. Controlling signal transduction with synthetic ligands [see comments]. Science 1993; 262(5136):1019-1024. 189. Braselmann S, Graninger P, Busslinger M. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci USA 1993; 90(5):16571661. 190. Wang Y, O’Malley BW, Jr., Tsai SY et al. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994; 91(17):8180-8184. 191. Whelan J, Miller N. Generation of estrogen receptor mutants with altered ligand specificity for use in establishing a regulatable gene expression system. J Steroid Biochem Mol Biol 1996; 58(1):3-12. 192. Bushman FD. Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences. Proc Natl Acad Sci USA 1994; 91(20):9233-9237. 193. Goulaouic H, Chow SA. Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J Virol 1996; 70(1):37-46. 194. Re F, Luban J. HIV-1 Vpr: G2 cell cycle arrest, macrophages and nuclear transport. Prog Cell Cycle Res 1997; 3:21-27. 195. Krausslich HG, Ochsenbauer C, Traenckner AM et al. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 1993; 192(2):605-617. 196. Shoeman RL Honer B, Stoller TJ et al. Cleavage of the intermediate filament subunit protein vimentin by HIV-1 protease: utilization of a novel cleavage site and identification of higher order polymers of pepstatin A. Adv Exp Med Biol 1991; 306:533-537. 197. Shoeman RL, Mothes , Honer B et al. Effect of human immunodeficiency virustype 1 protease on the intermediate filament subunit protein vimentin: cleavage, in vitro assembly and altered distribution of filaments in vivo following micrinjection of protease. Acta Histochem Suppl 1991; 41:129141. 198. Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV- 1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996; 93(24):14070-14075. 199. Corbeau P, Kraus G, Wong-Staal F. Transduction of human macrophages using a stable HIV-1/ HIV-2-derived gene delivery system. Gene Ther 1998; 5(1):99-104. 200. Kafri T, van Praag H, Ouyang L et al. A packaging cell line for lentivirus vectors. J Virol 1999; 73(1):576-84. 201. Xu K, Ma H, McCown TJ et al. Geneation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3(1):97-104.
HIV-1 Vector Systems
81
202. Howcroft TK, Strebel K, Martin MA et a. Reprssion of MHC class I gene promoter activity by two-exon Tat of HIV. Science 1993; 260(5112):1320-1322. 203. Kanazawa S, Okamoto T, Peterlin BM. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection [In Process Citation]. Immunity 2000; 12(1):61-70. 204. An DS, Wersto RP, Agricola BA et al. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD3(+) cells. J Virol 2000; 74(3):1286-1295. 205. Wilson CA, Ng TH, Miller AE. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroiral vectors. Hum Gene Ther 1997; 8(7):869-874. 206. Haas DL, Case SS, Crooks GM et al. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2000; 2(1):71-80. 207. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992; 66(4):2232-2239. 208. Mann DA, Mikaelian I, Zemmel RW et al. A molecular rheostat. Co-operative rev bindng to stem I of the rev- response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 1994; 241(2):193-207.
CHAPTER 5
HIV-2 and SIV Vector Systems James R. Gilbert and Flossie Wong-Staal
Abstract
L
entiviral vectors have received much attention in recent years due to their ability to efficiently transduce non-dividing cells. Of the lentiviruses HIV-2 and SIV offer several unique benefits as the basis for lentiviral vector design. HIV-1, HIV-2 and SIV remain the only known primate lentiviruses, and consequently are among the most extensively studied viruses known. Substantial effort has been devoted towards identifying the pathogenic determinants of the primate lentiviruses and towards understanding their replication within primates. Of the primate lentiviruses, the pathogenicity and rates of transmission of HIV-2 and SIV fall far below that of HIV-1, potentially providing vectors based upon HIV-2/SIV with a greater degree of biosafety. Last, and perhaps most importantly, HIV-2 and SIV are viruses which may be studied within non-human primate models susceptible to AIDS-like disease, making vectors based upon these viruses accessible to substantial preclinical evaluation. We approach this Chapter presenting information regarding the basic biology of HIV-2 and SIV and conclude by pointing to how unique features of HIV-2 and SIV are well suited to vector design, hoping to leave the reader with a greater appreciation of the potential these viruses offer within the field of gene transfer applications.
Introduction Replication-defective retroviral vectors have traditionally been a preferred vehicle for gene transfer due to their ability to permanently integrate within the chromosome and establish stable gene expression within transduced populations. Further, the “simple” retroviral genome and its replication cycle have been extensively characterized enabling investigators to refine retroviral vectors and reduce the risk of an immune response against transduced cells by eliminating all non-essential viral elements. The absence of non-essential viral elements is likely to be a necessary feature within vectors in order to achieve sustained in vivo gene expression. Clinical use of simple retroviral vectors has been severely limited, however, due to their inability to efficiently transduce the quiescent and post-mitotic cells which are among the most desirable targets for gene therapy. The general basis for this limitation has been elucidated. Integration of the “simple” retroviral genome first requires mitotic dissolution of the nuclear membrane in order to provide the retroviral pre-integration complex (PIC) with access to cellular chromatin.1-3 Thus, in the absence of cell division retroviral infection is blocked prior to integration. Lentiviruses, in contrast, efficiently infect non-dividing cells during the normal course of their replication. As discussed in detail in Chapter 3, the lentiviral capacity to infect nondividing cells may result from a direct interaction between the viral PIC and cellular nuclear Lentiviral Vector Systems for Gene Transfer, edited by Gary L. Buchschacher, Jr. ©2003 Eurekah.com.
84
Lentiviral Vector Systems for Gene Transfer
import machinery, resulting in transportation of the lentiviral PIC across the nuclear envelope where integration of proviral DNA may occur.4 Viral components within the PIC which contribute to nuclear import may include the viral Gag matrix, integrase, and Vpr or Vpx, although the latter accessory gene products are reported to use non-classical import pathways.59 The extent to which each of these components contributes to nuclear import is incompletely defined, although their cumulative effect provides the primate lentiviruses with a functional redundancy that helps insure the completion of an essential step in its replication cycle. Initially, the potential benefits lentiviruses were thought to offer in gene transfer inspired many investigators to develop vectors and stable packaging lines based upon HIV-1. These initial studies confirmed that transduction of non-dividing cells by lentiviral vectors was feasible, although the titers which were obtained fell significantly below a clinically useful range.1012 This problem was in part addressed in work presented by Naldini et al describing the development of a replication-defective HIV-1 vector pseudotyped with VSV-G.13 The vector was shown to retain the lentivirus-specific ability to infect non-dividing cells, and achieved efficient gene delivery both in vitro and by direct injection into the adult rat brain in vivo. Since these findings, a flurry of effort has been devoted to the design and characterization of lentiviral vectors. Of the lentiviruses considered for vector design, two promising candidates are HIV-2 and SIV. HIV-2 and SIV, being primate lentiviruses, are among the most thoroughly studied and well characterized lentiviruses currently known. Extensive biological characterization of HIV2/SIV and long term prospective studies of associated disease provide a substantial body of information to draw upon in order to assess vector behavior within a patient. This contrasts with the non-primate lentiviruses about which far less is known in terms of basic biology or their potential behavior within primates. Like all lentiviruses, both efficiently transduce a variety of non-dividing cell types. HIV-2 and SIV, however, possess features making them uniquely well suited to vector development. Among these features are a diminished pathogenic potential when compared to HIV-1, an amenability to study in primate models, and separation of the accessory gene product-associated cell cycle arrest and nuclear import functions. Each of these characteristics offer potential advantages over other lentiviral vectors and will be discussed in detail. Our goal in this Chapter is to present current information addressing the basic biology, viral dynamics and genome organization of HIV-2/SIV as this information pertains to vector development. Because basic lentiviral replication and the design of HIV-1 vectors are discussed elsewhere within this volume, we focus in this Chapter upon areas in which the primate lentiviruses contrast with one another. Despite a variety of similarities among the primate lentiviruses, distinctions do exist. We approach this Chapter intending to address these distinctions, concluding with sections addressing the development of HIV-2/SIV vectors and potential future modifications which might be introduced to improve these vectors.
Classification and Distribution Although a human virus, HIV-2 displays greater sequence homology with SIV than HIV1. Sequence relatedness between HIV-2 and SIV is approximately 75%, whereas both viruses display less than 50% homology to HIV-1.14,15 Based upon genetic diversity, six distinct subtypes (A-F) of HIV-2 have been classified.16,17 All are found predominantly within West African countries, although infrequent cases are reported in the Americas, Europe and India. The majority of isolates characterized to date belong to subtype A, isolates of which have been obtained from diverse regions across West Africa. Subtype B predominates in Ghana and Cote d’ Ivoire and constitutes the majority of HIV-2 isolates falling outside of subtype A. Rare isolates of subtypes C-F have been described in Sierra Leone and Liberia. To date, subtypes CF have been isolated only from asymptomatic individuals, whereas the bulk of HIV-2 associated cases of AIDS which have been reported are caused by subtype A. It is tempting to speculate that this may reflect a differential virulence among the viral subtypes. Unfortunately, the
HIV-2 and SIV Vectors
85
infrequent isolation of subtypes C-F and the absence of long-term prospective studies comparing subtype-specific differences makes it impossible to evaluate the statistical significance of these observations. Nomenclature for the SIV subtypes is based upon the primate species from which prototypic viral strains representative of the subtype was isolated. Five distinct lentiviruses have been obtained from non-human primates native to Africa, including chimpanzees (SIVCPZ), sooty mangabees (SIVSM), african green monkeys (SIVAGM), mandrills (SIVMND), and sykes (SIVSYK). Each of the subtypes is endemic to the primate species for which it was named and shows no evidence of disease causation within its natural host.18 Other designations commonly encountered in the literature include SIVMAC, SIVMNE and SIVSTM, named for SIV strains isolated at primate research centers from rhesus macaques, nemestrina macaques and stump-tailed macaques, respectively. Each of these viral strains causes a fatal AIDSlike disease in macaques. Due to the absence of evidence for SIV infection of macaques in their native Asian habitat and given the close genetic relatedness of these viral strains to SIVSM, it is thought that SIV is not a virus endogenous to this species. Macaques are instead thought to have become inadvertently infected by experimental inoculation with fluids obtained from other primate species, or by co-housing of macaques with other species in research facilities. Extensive genetic diversity is found within all of the HIV-2/SIV subtypes. As with all lentiviruses, the principal driving force to diversification is the viral mutation rate, although viral strains postulated to have arisen by means of recombination between distinct viral subtypes within the same individual have been reported. Phylogenetic analysis of the HIV and SIV pol sequences indicates SIVAGM, SIVMND and SIVSYK belong to discrete lineages. HIV-1 clusters with SIVCPZ in a separate lineage, whereas HIV-2 clusters with SIVSM. Despite substantial sequence variation within the lentiviral subtypes, each of these lineages are roughly equidistant and show approximately 40% divergence from one another. These observations have led some investigators to speculate HIV-1 and HIV-2 may have originated through zoonotic transmission from non-human primates to humans.
Pathology and Viral Replication Viral Transmission The basic biology of HIV-2 and SIV, in some ways, closely resembles that of HIV-1. All three of the primate lentiviruses display common routes of transmission, cellular tropisms, long and variable incubation periods, viral replication kinetics and persistence of replication despite strong humoral and cellular immune response within the host.19 Each spreads through exchange of bodily fluids including blood, blood products, saliva, semen, vaginal secretions and milk. Trans-placental transmission of HIV/SIV can occur, although perinatal transmission of HIV-2 occurs far less efficiently than for HIV-1.20 Initial infection is mediated by binding of the viral surface glycoprotein gp120 to a cellular CD4 molecule which serves as the primary receptor for all of the primate lentiviruses.21,22 Early attempts to determine if expression of the CD4 receptor was sufficient to confer susceptibility to infection to non-permisive cell types found that, although CD4 facilitates viral binding at the cell surface, it is insufficient to permit viral fusion with the cell membrane. Further, primary viral isolates display variable tropism for CD4+ lymphocytes. Together, these findings implied the necessary existence of other cellular co-factors mediating viral binding and cell fusion. After substantial effort, the chemokine receptors CCR5 and CXCR4 were identified as the principal lentiviral co-receptors.23,24 Several studies have since shown that the CD4-glycoprotein complex, formed by viral binding to the CD4+ molecule, interacts with its chemokine coreceptor to initiate the fusion process. Conversely, viral entry
86
Lentiviral Vector Systems for Gene Transfer
may be inhibited in the presence of RANTES, MIP-1α and MIP-1β, the ligands for CCR5, or SDF-1, the ligand for CXCR4, depending upon the biological phenotype of the viral strain.
Viral Phenotype and Coreceptor Use The biological phenotype of primate lentiviruses, though, evolves during the course of infection. Forces driving this change include the viruses intrinsically rapid mutation rate and immunological pressures selecting for under-represented members of the lentiviral quasi-species found within the individual at any given moment. As discussed in Chapter 2, two general viral phenotypes have been described: macrophage tropic (M-tropic) and T lymphotropic (Ttropic). Of the two principal chemokine receptors, CCR5 functions as the predominant coreceptor for M-tropic HIV-1 strains, whereas CXCR4 functions as the predominant coreceptor for T-tropic HIV-1 strains. Unlike HIV-1 and HIV-2, it should be noted that SIV uses CCR5 but not CXCR4 at all stages of infection.25 Since the initial discovery that CCR5 and CXCR4 act as the principal lentiviral coreceptors, however, at least 14 alternate lentiviral coreceptors have been identified. In the natural progression of HIV-1 infection, a discrete series of events relating viral phenotype and chemokine receptor usage to disease prognosis has been defined. Generally, initial infection by the primate lentiviruses occurs by means of M-tropic viral strains. Supporting this claim is the fact that individuals homozygous for the CCR5∆32/∆32 allele are highly resistant to HIV-1 infection. Longitudinal studies of HIV-1 infection, however, report a shift towards principal usage of the CXCR4 coreceptor and more promiscuous use of alternate coreceptors late in the course of disease progression. Principal use of CXCR4 and/or promiscuous use of alternate coreceptors by HIV-1 directly relates to the appearance of syncytiuminducing (SI) T-tropic strains and correlates poorly with disease prognosis and survival.26 In stark contrast, many primary isolates and molecular clones of HIV-2/SIV use alternate coreceptors with efficiencies comparable to CCR5 or CXCR4.27-29 Based upon data acquired using cell-free infectivity assays, some strains of HIV-2 appear capable of using alternate chemokine receptors even in the absence of CD4. Of note, broad coreceptor usage in HIV-2, unlike HIV-1, shows no correlation what-so-ever with syncytium-inducing capabilities. For HIV-1, promiscuous coreceptor usage has been hypothesized to either contribute to or to reflect enhanced cytopathicity. This does not hold true for HIV-2, for which disease progression is substantially slower despite promiscuous coreceptor usage at all stages of infection.
Viral Pathology Although HIV-2 and SIV are far less pathogenic than HIV-1, they display common elements during the acute phase of infection.18,19 Primary infection is followed by a burst of viral replication and an acute illness characterized by mononucleosis-like symptoms. Within 2 months of infection, a significant decline in CD4+ T lymphocyte levels is detected in the peripheral blood. Typically, CD4+ lymphocyte levels rebound, although rarely to pre-infection levels. Specific antiviral responses involving both the humoral and cellular arms of the immune system are detected approximately 1 month after infection. With the mounting of an immune response, the infected individual generally enters an asymptomatic phase during